Patent Application
20230183743
Hearing loss can be conductive (arising from the ear canal or middle ear), sensorineural (arising from the inner ear or auditory nerve), or mixed. Most forms of nonsyndromic deafness are associated with permanent hearing loss caused by damage to structures in the inner ear (sensorineural deafness), although some forms may involve changes in the middle ear (conductive hearing loss). The great majority of human sensorineural hearing loss is caused by abnormalities in the hair cells of the organ of Corti in the cochlea (poor hair cell function). The hair cells may be abnormal at birth, or may be damaged during the lifetime of an individual (e.g., as a result of noise trauma or infection).
The present disclosure provides the recognition that diseases or conditions associated with hearing loss can be treated via, e.g., the replacement or addition of certain gene products. The present disclosure further provides that gene products involved in the development, function, and/or maintenance of inner ear cells can be useful for treatment of diseases or conditions associated with hair cell and/or supporting cell loss. The present disclosure thus provides for the administration of compositions that result in expression of gene products involved in the development, function, and/or maintenance of inner ear cells including supporting cells and hair cell, and/or the use of such compositions in the treatment of hearing loss, or diseases or conditions associated with hearing loss. In some embodiments, a gene product can be encoded by a gap junction beta-2 (GJB2) gene (the GJB2 gene encodes connexin 26 protein) or a characteristic portion thereof. In some embodiments, a gene product can be connexin 26 protein (encoded by a GJB2 gene) or a characteristic portion thereof.
The present disclosure further provides that AAV particles can be useful for administration of compositions that result in expression of gene products involved in the development, function, and/or maintenance of inner ear cells, and/or the treatment of hearing loss, or diseases or conditions associated with hearing loss. As described herein, AAV particles comprise (i) a AAV polynucleotide construct (e.g., a recombinant AAV (rAAV) polynucleotide construct), and (ii) a capsid comprising capsid proteins. In some embodiments, an AAV polynucleotide construct comprises a GJB2 gene or a characteristic portion thereof.
The present disclosure further provides compositions comprising polynucleotide constructs comprising a GJB2 gene or a characteristic portion thereof. In some embodiments, a construct may further include regulatory elements operably attached to a coding sequence. In certain embodiments, included regulatory elements facilitate tissue specific expression at physiologically suitable levels.
Also provided herein are methods of administering constructs and compositions described herein. In certain embodiments, administration involves surgical intervention and the delivery of rAAV particles comprising therapeutic constructs. In certain embodiments AAV particles may be delivered to the inner ear of a subject in need thereof by surgical introduction through the round window membrane. In some embodiments, efficacy of an intervention is determined through established tests, and measurements are compared to known control measurements.
The scope of the present disclosure is defined by the claims appended hereto and is not limited by certain embodiments described herein. Those skilled in the art, reading the present specification, will be aware of various modifications that may be equivalent to such described embodiments, or otherwise within the scope of the claims. In general, terms used herein are in accordance with their understood meaning in the art, unless clearly indicated otherwise. Explicit definitions of certain terms are provided below; meanings of these and other terms in particular instances throughout this specification will be clear to those skilled in the art from context.
Use of ordinal terms such as “first,” “second,” “third,” etc., in the claims to modify a claim element does not by itself connote any priority, precedence, or order of one claim element over another or the temporal order in which acts of a method are performed, but are used merely as labels to distinguish one claim element having a certain name from another element having a same name (but for use of the ordinal term) to distinguish the claim elements.
The articles “a” and “an,” as used herein, should be understood to include the plural referents unless clearly indicated to the contrary. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. In some embodiments, exactly one member of a group is present in, employed in, or otherwise relevant to a given product or process. In some embodiments, more than one, or all group members are present in, employed in, or otherwise relevant to a given product or process. It is to be understood that the present disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the listed claims is introduced into another claim dependent on the same base claim (or, as relevant, any other claim) unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise. Where elements are presented as lists (e.g., in Markush group or similar format), it is to be understood that each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should be understood that, in general, where embodiments or aspects are referred to as “comprising” particular elements, features, etc., certain embodiments or aspects “consist,” or “consist essentially of,” such elements, features, etc. For purposes of simplicity, those embodiments have not in every case been specifically set forth in so many words herein. It should also be understood that any embodiment or aspect can be explicitly excluded from the claims, regardless of whether the specific exclusion is recited in the specification.
Throughout the specification, whenever a polynucleotide or polypeptide is represented by a sequence of letters (e.g., A, C, G, and T, which denote adenosine, cytidine, guanosine, and thymidine, respectively in the case of a polynucleotide), such polynucleotides or polypeptides are presented in 5′ to 3′ or N-terminus to C-terminus order, from left to right.
Administration: As used herein, the term “administration” typically refers to administration of a composition to a subject or system to achieve delivery of an agent to a subject or system. In some embodiments, an agent is, or is included in, a composition; in some embodiments, an agent is generated through metabolism of a composition or one or more components thereof. Those of ordinary skill in the art will be aware of a variety of routes that may, in appropriate circumstances, be utilized for administration to a subject, for example a human. For example, in some embodiments, administration may be systematic or local. In some embodiments, a systematic administration can be intravenous. In some embodiments, administration can be local. Local administration can involve delivery to cochlear perilymph via, e.g., injection through a round-window membrane or into scala-tympani, a scala-media injection through endolymph, perilymph and/or endolymph following canalostomy. In some embodiments, administration may involve only a single dose. In some embodiments, administration may involve application of a fixed number of doses. In some embodiments, administration may involve dosing that is intermittent (e.g., a plurality of doses separated in time) and/or periodic (e.g., individual doses separated by a common period of time) dosing. In some embodiments, administration may involve continuous dosing (e.g., perfusion) for at least a selected period of time.
Allele: As used herein, the term “allele” refers to one of two or more existing genetic variants of a specific polymorphic genomic locus.
Amelioration: As used herein, the term “amelioration” refers to prevention, reduction or palliation of a state, or improvement of a state of a subject. Amelioration may include, but does not require, complete recovery or complete prevention of a disease, disorder or condition.
Amino acid: In its broadest sense, as used herein, the term “amino acid” refers to any compound and/or substance that can be incorporated into a polypeptide chain, e.g., through formation of one or more peptide bonds. In some embodiments, an amino acid has a general structure, e.g., H2N—C(H)(R)—COOH. In some embodiments, an amino acid is a naturally-occurring amino acid. In some embodiments, an amino acid is a non-natural amino acid; in some embodiments, an amino acid is a D-amino acid; in some embodiments, an amino acid is an L-amino acid. “Standard amino acid” refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides. “Nonstandard amino acid” refers to any amino acid, other than standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source. In some embodiments, an amino acid, including a carboxy- and/or amino-terminal amino acid in a polypeptide, can contain a structural modification as compared with general structure as shown above. For example, in some embodiments, an amino acid may be modified by methylation, amidation, acetylation, pegylation, glycosylation, phosphorylation, and/or substitution (e.g., of an amino group, a carboxylic acid group, one or more protons, and/or a hydroxyl group) as compared with a general structure. In some embodiments, such modification may, for example, alter circulating half-life of a polypeptide containing a modified amino acid as compared with one containing an otherwise identical unmodified amino acid. In some embodiments, such modification does not significantly alter a relevant activity of a polypeptide containing a modified amino acid, as compared with one containing an otherwise identical unmodified amino acid.
Approximately or About: As used herein, the terms “approximately” or “about” may be applied to one or more values of interest, including a value that is similar to a stated reference value. In some embodiments, the term “approximately” or “about” refers to a range of values that fall within ±10% (greater than or less than) of a stated reference value unless otherwise stated or otherwise evident from context (except where such number would exceed 100% of a possible value). For example, in some embodiments, the term “approximately” or “about” may encompass a range of values that within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of a reference value.
Associated: As used herein, the term “associated” describes two events or entities as “associated” with one another, if the presence, level and/or form of one is correlated with that of the other. For example, a particular entity (e.g., polypeptide, genetic signature, metabolite, microbe, etc.) is considered to be associated with a particular disease, disorder, or condition, if its presence, level and/or form correlates with incidence of and/or susceptibility to the disease, disorder, or condition (e.g., across a relevant population). In some embodiments, two or more entities are physically “associated” with one another if they interact, directly or indirectly, so that they are and/or remain in physical proximity with one another. In some embodiments, two or more entities that are physically associated with one another are covalently linked to one another; in some embodiments, two or more entities that are physically associated with one another are not covalently linked to one another but are non-covalently associated, for example by means of hydrogen bonds, van der Waals interaction, hydrophobic interactions, magnetism, and combinations thereof.
Biologically active: As used herein, the term “biologically active” refers to an observable biological effect or result achieved by an agent or entity of interest. For example, in some embodiments, a specific binding interaction is a biological activity. In some embodiments, modulation (e.g., induction, enhancement, or inhibition) of a biological pathway or event is a biological activity. In some embodiments, presence or extent of a biological activity is assessed through detection of a direct or indirect product produced by a biological pathway or event of interest.
Cell Selective Promoter: As used herein, the term “cell selective promoter” refers to a promoter that is predominately active in certain cell types (e.g., transcription of a specific gene occurs only within cells expressing transcription regulatory and/or control proteins that bind to the tissue-specific promoter). In some aspects, an inner ear supporting cell selective promoter is a promoter that is predominately active in one or more supporting cells of the inner ear.
Characteristic portion: As used herein, the term “characteristic portion,” in the broadest sense, refers to a portion of a substance whose presence (or absence) correlates with presence (or absence) of a particular feature, attribute, or activity of the substance. In some embodiments, a characteristic portion of a substance is a portion that is found in a given substance and in related substances that share a particular feature, attribute or activity, but not in those that do not share the particular feature, attribute or activity. In some embodiments, a characteristic portion shares at least one functional characteristic with the intact substance. For example, in some embodiments, a “characteristic portion” of a protein or polypeptide is one that contains a continuous stretch of amino acids, or a collection of continuous stretches of amino acids, that together are characteristic of a protein or polypeptide. In some embodiments, each such continuous stretch generally contains at least 2, 5, 10, 15, 20, 50, or more amino acids. In general, a characteristic portion of a substance (e.g., of a protein, antibody, etc.) is one that, in addition to a sequence and/or structural identity specified above, shares at least one functional characteristic with the relevant intact substance. In some embodiments, a characteristic portion may be biologically active.
Characteristic sequence: As used herein, the term “characteristic sequence” is a sequence that is found in all members of a family of polypeptides or nucleic acids, and therefore can be used by those of ordinary skill in the art to define members of the family.
Characteristic sequence element: As used herein, the phrase “characteristic sequence element” refers to a sequence element found in a polymer (e.g., in a polypeptide or nucleic acid) that represents a characteristic portion of that polymer. In some embodiments, presence of a characteristic sequence element correlates with presence or level of a particular activity or property of a polymer. In some embodiments, presence (or absence) of a characteristic sequence element defines a particular polymer as a member (or not a member) of a particular family or group of such polymers. A characteristic sequence element typically comprises at least two monomers (e.g., amino acids or nucleotides). In some embodiments, a characteristic sequence element includes at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, or more monomers (e.g., contiguously linked monomers). In some embodiments, a characteristic sequence element includes at least first and second stretches of contiguous monomers spaced apart by one or more spacer regions whose length may or may not vary across polymers that share a sequence element.
Combination therapy: As used herein, the term “combination therapy” refers to those situations in which a subject is simultaneously exposed to two or more therapeutic regimens (e.g., two or more therapeutic agents). In some embodiments, two or more agents may be administered simultaneously. In some embodiments, two or more agents may be administered sequentially. In some embodiments, two or more agents may be administered in overlapping dosing regimens.
Comparable: As used herein, the term “comparable” refers to two or more agents, entities, situations, sets of conditions, subjects, populations, etc., that may not be identical to one another but that are sufficiently similar to permit comparison therebetween so that one skilled in the art will appreciate that conclusions may reasonably be drawn based on differences or similarities observed. In some embodiments, comparable sets of agents, entities, situations, sets of conditions, subjects, populations, etc. are characterized by a plurality of substantially identical features and one or a small number of varied features. Those of ordinary skill in the art will understand, in context, what degree of identity is required in any given circumstance for two or more such agents, entities, situations, sets of conditions, subjects, populations, etc. to be considered comparable. For example, those of ordinary skill in the art will appreciate that sets of agents, entities, situations, sets of conditions, subjects, populations, etc. are comparable to one another when characterized by a sufficient number and type of substantially identical features to warrant a reasonable conclusion that differences in results obtained or phenomena observed under or with different sets of circumstances, stimuli, agents, entities, situations, sets of conditions, subjects, populations, etc. are caused by or indicative of the variation in those features that are varied.
Construct: As used herein, the term “construct” refers to a composition including a polynucleotide capable of carrying at least one heterologous polynucleotide. In some embodiments, a construct can be a plasmid, a transposon, a cosmid, an artificial chromosome (e.g., a human artificial chromosome (HAC), a yeast artificial chromosome (YAC), a bacterial artificial chromosome (BAC), or a P1-derived artificial chromosome (PAC)) or a viral construct, and any Gateway® plasmids. A construct can, e.g., include sufficient cis-acting elements for expression; other elements for expression can be supplied by the host primate cell or in an in vitro expression system. A construct may include any genetic element (e.g., a plasmid, a transposon, a cosmid, an artificial chromosome, or a viral construct, etc.) that is capable of replicating when associated with proper control elements. Thus, in some embodiments, “construct” may include a cloning and/or expression construct and/or a viral construct (e.g., an adeno-associated virus (AAV) construct, an adenovirus construct, a lentivirus construct, or a retrovirus construct).
Conservative: As used herein, the term “conservative” refers to instances describing a conservative amino acid substitution, including a substitution of an amino acid residue by another amino acid residue having a side chain R group with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change functional properties of interest of a protein, for example, ability of a receptor to bind to a ligand. Examples of groups of amino acids that have side chains with similar chemical properties include: aliphatic side chains such as glycine (Gly, G), alanine (Ala, A), valine (Val, V), leucine (Leu, L), and isoleucine (Ile, I); aliphatic-hydroxyl side chains such as serine (Ser, S) and threonine (Thr, T); amide-containing side chains such as asparagine (Asn, N) and glutamine (Gln, Q); aromatic side chains such as phenylalanine (Phe, F), tyrosine (Tyr, Y), and tryptophan (Trp, W); basic side chains such as lysine (Lys, K), arginine (Arg, R), and histidine (His, H); acidic side chains such as aspartic acid (Asp, D) and glutamic acid (Glu, E); and sulfur-containing side chains such as cysteine (Cys, C) and methionine (Met, M). Conservative amino acids substitution groups include, for example, valine/leucine/soleucine (Val/Leu/Ile, V/UI), phenylalanine/tyrosine (Phe/Tyr, F/Y), lysine/arginine (Lys/Arg, K/R), alanine/valine (Ala/Val, A/V), glutamate/aspartate (Glu/Asp, E/D), and asparagine/glutamine (Asn/Gln, N/Q). In some embodiments, a conservative amino acid substitution can be a substitution of any native residue in a protein with alanine, as used in, for example, alanine scanning mutagenesis. In some embodiments, a conservative substitution is made that has a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al., 1992, Science 256:1443-1445, which is incorporated herein by reference in its entirety. In some embodiments, a substitution is a moderately conservative substitution wherein the substitution has a nonnegative value in the PAM250 log-likelihood matrix. One skilled in the art would appreciate that a change (e.g., substitution, addition, deletion, etc.) of amino acids that are not conserved between the same protein from different species is less likely to have an effect on the function of a protein and therefore, these amino acids should be selected for mutation. Amino acids that are conserved between the same protein from different species should not be changed (e.g., deleted, added, substituted, etc.), as these mutations are more likely to result in a change in function of a protein.
Control: As used herein, the term “control” refers to the art-understood meaning of a “control” being a standard against which results are compared. Typically, controls are used to augment integrity in experiments by isolating variables in order to make a conclusion about such variables. In some embodiments, a control is a reaction or assay that is performed simultaneously with a test reaction or assay to provide a comparator. For example, in one experiment, a “test” (i.e., a variable being tested) is applied. In a second experiment, a “control,” the variable being tested is not applied. In some embodiments, a control is a historical control (e.g., of a test or assay performed previously, or an amount or result that is previously known). In some embodiments, a control is or comprises a printed or otherwise saved record. In some embodiments, a control is a positive control. In some embodiments, a control is a negative control.
Determining, measuring, evaluating, assessing, assaying and analyzing: As used herein, the terms “determining,” “measuring,” “evaluating,” “assessing,” “assaying,” and “analyzing” may be used interchangeably to refer to any form of measurement, and include determining if an element is present or not. These terms include both quantitative and/or qualitative determinations. Assaying may be relative or absolute. For example, in some embodiments, “Assaying for the presence of” can be determining an amount of something present and/or determining whether or not it is present or absent.
Engineered: In general, as used herein, the term “engineered” refers to an aspect of having been manipulated by the hand of man. For example, a cell or organism is considered to be “engineered” if it has been manipulated so that its genetic information is altered (e.g., new genetic material not previously present has been introduced, for example by transformation, mating, somatic hybridization, transfection, transduction, or other mechanism, or previously present genetic material is altered or removed, for example by substitution or deletion mutation, or by mating protocols). As is common practice and is understood by those in the art, progeny of an engineered polynucleotide or cell are typically still referred to as “engineered” even though the actual manipulation was performed on a prior entity.
Excipient: As used herein, the term “excipient” refers to an inactive (e.g., non-therapeutic) agent that may be included in a pharmaceutical composition, for example to provide or contribute to a desired consistency or stabilizing effect. In some embodiments, suitable pharmaceutical excipients may include, for example, starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
Expression: As used herein, the term “expression” of a nucleic acid sequence refers to generation of any gene product (e.g., transcript, e.g., mRNA, e.g., polypeptide, etc.) from a nucleic acid sequence. In some embodiments, a gene product can be a transcript. In some embodiments, a gene product can be a polypeptide. In some embodiments, expression of a nucleic acid sequence involves one or more of the following: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, 5′ cap formation, and/or 3′ end formation); (3) translation of an RNA into a polypeptide or protein; and/or (4) post-translational modification of a polypeptide or protein.
Flanked: As used herein, the term “flanked” refers to a position relative to ends of a reference item. More specifically, in referring to reference nucleic acid sequence(s), “flanked” refers to having sequences upstream and downstream of the reference nucleic acid sequence(s). In some aspects, a flanked referenced nucleic acid sequence has a first sequence or series of nucleotide residues positioned adjacent to the 5′ end of the referenced nucleic acid and a second sequence or series of nucleotide residues positioned adjacent to the 3′ end of the referenced nucleic acid. In some aspects, the upstream and/or downstream flanking sequences are immediately adjacent to the referenced nucleic acid sequence. In some aspects, there are intervening nucleic acids between the upstream and/or downstream flanking sequences and the referenced nucleic acid sequence.
Functional: As used herein, the term “functional” describes something that exists in a form in which it exhibits a property and/or activity by which it is characterized. For example, in some aspects, a “functional” biological molecule is a biological molecule in a form in which it exhibits a property and/or activity by which it is characterized. In some such aspects, a functional biological molecule is characterized relative to another biological molecule which is non-functional in that the “non-functional” version does not exhibit the same or equivalent property and/or activity as the “functional” molecule. A biological molecule may have one function, two functions (i.e., bifunctional) or many functions (i.e., multifunctional).
Gene: As used herein, the term “gene” refers to a DNA sequence in a chromosome that codes for a gene product (e.g., an RNA product, e.g., a polypeptide product). In some embodiments, a gene includes coding sequence (i.e., sequence that encodes a particular product). In some embodiments, a gene includes non-coding sequence. In some particular embodiments, a gene may include both coding (e.g., exonic) and non-coding (e.g., intronic) sequence. In some embodiments, a gene may include one or more regulatory sequences (e.g., promoters, enhancers, etc.) and/or intron sequences that, for example, may control or impact one or more aspects of gene expression (e.g., cell-type-specific expression, inducible expression, etc.). As used herein, the term “gene” generally refers to a portion of a nucleic acid that encodes a polypeptide or fragment thereof, the term may optionally encompass regulatory sequences, as will be clear from context to those of ordinary skill in the art. This definition is not intended to exclude application of the term “gene” to non-protein-coding expression units but rather to clarify that, in most cases, the term as used in this document refers to a polypeptide-coding nucleic acid. In some embodiments, a gene may encode a polypeptide, but that polypeptide may not be functional, e.g., a gene variant may encode a polypeptide that does not function in the same way, or at all, relative to the wild-type gene. In some embodiments, a gene may encode a transcript which, in some embodiments, may be toxic beyond a threshold level. In some embodiments, a gene may encode a polypeptide, but that polypeptide may not be functional and/or may be toxic beyond a threshold level.
Hearing loss: As used herein, the term “hearing loss” may be used to a partial or total inability of a living organism to hear. In some embodiments, hearing loss may be acquired. In some embodiments, hearing loss may be hereditary. In some embodiments, hearing loss may be genetic. In some embodiments, hearing loss may be as a result of disease or trauma (e.g., physical trauma, treatment with one or more agents resulting in hearing loss, etc.). In some embodiments, hearing loss may be due to one or more known genetic causes and/or syndromes. In some embodiments, hearing loss may be of unknown etiology. In some embodiments, hearing loss may or may not be mitigated by use of hearing aids or other treatments.
Heterologous: As used herein, the term “heterologous” may be used in reference to one or more regions of a particular molecule as compared to another region and/or another molecule. In some embodiments, heterologous polypeptide domains, refers to the fact that polypeptide domains do not naturally occur together (e.g., in the same polypeptide). For example, in fusion proteins generated by the hand of man, a polypeptide domain from one polypeptide may be fused to a polypeptide domain from a different polypeptide. In such a fusion protein, two polypeptide domains would be considered “heterologous” with respect to each other, as they do not naturally occur together.
Identity: As used herein, the term “identity” refers to overall relatedness between polymeric molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be “substantially identical” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. Calculation of percent identity of two nucleic acid or polypeptide sequences, for example, can be performed by aligning two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In some embodiments, a length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of length of a reference sequence; nucleotides at corresponding positions are then compared. When a position in the first sequence is occupied by the same residue (e.g., nucleotide or amino acid) as a corresponding position in the second sequence, then the two molecules (i.e., first and second) are identical at that position. Percent identity between two sequences is a function of the number of identical positions shared by the two sequences being compared, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. Comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, percent identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4: 11-17, which is herein incorporated by reference in its entirety), which has been incorporated into the ALIGN program (version 2.0). In some embodiments, nucleic acid sequence comparisons made with the ALIGN program use a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
Inhibitory nucleic acid: As used herein, the term “inhibitory nucleic acid” refers to a nucleic acid sequence that hybridizes specifically to a target gene, including target DNA or RNA (e.g., a target mRNA (e.g., a connexin gene product, e.g., a connexin mRNA, e.g., GJB2 mRNA)). Thereby, in some embodiments, an inhibitory nucleic acid inhibits expression and/or activity of a target gene. In some embodiments, an inhibitory nucleic acid is a short interfering RNA (siRNA), a short hairpin RNA (shRNA), a microRNA (miRNA), an antisense oligonucleotide, a guide RNA (gRNA), or a ribozyme. In some embodiments, an inhibitory nucleic acid is between about 10 nucleotides to about 30 nucleotides in length (e.g., about 10 nucleotides to about 28 nucleotides, about 10 nucleotides to about 26 nucleotides, about 10 nucleotides to about 24 nucleotides, about 10 nucleotides to about 22 nucleotides, about 10 nucleotides to about 20 nucleotides, about 10 nucleotides to about 18 nucleotides, about 10 nucleotides to about 16 nucleotides, about 10 nucleotides to about 14 nucleotides, about 10 nucleotides to about 12 nucleotides, about 12 nucleotides to about 30 nucleotides, about 12 nucleotides to about 28 nucleotides, about 12 nucleotides to about 26 nucleotides, about 12 nucleotides to about 24 nucleotides, about 12 nucleotides to about 22 nucleotides, about 12 nucleotides to about 20 nucleotides, about 12 nucleotides to about 18 nucleotides, about 12 nucleotides to about 16 nucleotides, about 12 nucleotides to about 14 nucleotides, about 16 nucleotides to about 30 nucleotides, about 16 nucleotides to about 28 nucleotides, about 16 nucleotides to about 26 nucleotides, about 16 nucleotides to about 24 nucleotides, about 16 nucleotides to about 22 nucleotides, about 16 nucleotides to about 20 nucleotides, about 16 nucleotides to about 18 nucleotides, about 18 nucleotides to about 30 nucleotides, about 18 nucleotides to about 28 nucleotides, about 18 nucleotides to about 26 nucleotides, about 18 nucleotides to about 24 nucleotides, about 18 nucleotides to about 22 nucleotides, about 18 nucleotides to about 20 nucleotides, about 20 nucleotides to about 30 nucleotides, about 20 nucleotides to about 28 nucleotides, about 20 nucleotides to about 26 nucleotides, about 20 nucleotides to about 24 nucleotides, about 20 nucleotides to about 22 nucleotides, about 22 nucleotides to about 30 nucleotides, about 22 nucleotides to about 28 nucleotides, about 22 nucleotides to about 26 nucleotides, about 22 nucleotides to about 24 nucleotides, about 24 nucleotides to about 30 nucleotides, about 24 nucleotides to about 28 nucleotides, about 24 nucleotides to about 26 nucleotides, about 26 nucleotides to about 30 nucleotides, about 26 nucleotides to about 28 nucleotides, about 28 nucleotides to about 30 nucleotides, or 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides). In some embodiments, an inhibitory nucleic acid is an inhibitory RNA that targets GJB2. In some such embodiments, an inhibitory GJB2 RNA hybridizes specifically to a target on an RNA molecule comprising GJB2. In some such embodiments, a GJB2 inhibitory RNA includes, e.g., an inhibitory nucleic acid is a short interfering RNA (siRNA), a short hairpin RNA (shRNA), a microRNA (miRNA), an antisense oligonucleotide, a guide RNA (gRNA), or a ribozyme. In some embodiments, hybridizing of an inhibitory GJB2 RNA reduces expression of a GJB2 gene product. Exemplary inhibitory RNA sequences suitable for GJB2 inhibition are provided herein.
Improve, increase, enhance, inhibit or reduce: As used herein, the terms “improve,” “increase,” “enhance,” “inhibit,” “reduce,” or grammatical equivalents thereof, indicate values that are relative to a baseline or other reference measurement. In some embodiments, a value is statistically significantly difference that a baseline or other reference measurement. In some embodiments, an appropriate reference measurement may be or comprise a measurement in a particular system (e.g., in a single individual) under otherwise comparable conditions absent presence of (e.g., prior to and/or after) a particular agent or treatment, or in presence of an appropriate comparable reference agent. In some embodiments, an appropriate reference measurement may be or comprise a measurement in comparable system known or expected to respond in a particular way, in presence of the relevant agent or treatment. In some embodiments, an appropriate reference is a negative reference; in some embodiments, an appropriate reference is a positive reference.
Knockdown: As used herein, the term “knockdown” refers to a decrease in expression of one or more gene products. In some embodiments, an inhibitory nucleic acid achieve knockdown. In some embodiments, a genome editing system described herein achieves knockdown.
Knockout: As used herein, the term “knockout” refers to ablation of expression of one or more gene products. In some embodiments, a genome editing system described herein achieve knockout.
microRNA: As used herein, the term “microRNA” or “miRNA” refer to a class of biomolecules involved in control of gene expression. A mature miRNA is typically an 18-25 nucleotide non-coding RNA that regulates expression of an mRNA including sequences complementary to the miRNA. These small RNA molecules are known to control gene expression by regulating the stability and/or translation of mRNAs. In some aspects, a miRNAs binds to the 3′ UTR of target mRNAs and suppress translation. MiRNAs can also bind to target mRNAs and mediate gene silencing through the RNAi pathway. MiRNAs can also regulate gene expression by causing chromatin condensation.
In some aspects, a microRNA is between about 10 nucleotides to about 30 nucleotides in length (e.g., about 10 nucleotides to about 28 nucleotides, about 10 nucleotides to about 26 nucleotides, about 10 nucleotides to about 24 nucleotides, about 10 nucleotides to about 22 nucleotides, about 10 nucleotides to about 20 nucleotides, about 10 nucleotides to about 18 nucleotides, about 10 nucleotides to about 16 nucleotides, about 10 nucleotides to about 14 nucleotides, about 10 nucleotides to about 12 nucleotides, about 12 nucleotides to about 30 nucleotides, about 12 nucleotides to about 28 nucleotides, about 12 nucleotides to about 26 nucleotides, about 12 nucleotides to about 24 nucleotides, about 12 nucleotides to about 22 nucleotides, about 12 nucleotides to about 20 nucleotides, about 12 nucleotides to about 18 nucleotides, about 12 nucleotides to about 16 nucleotides, about 12 nucleotides to about 14 nucleotides, about 16 nucleotides to about 30 nucleotides, about 16 nucleotides to about 28 nucleotides, about 16 nucleotides to about 26 nucleotides, about 16 nucleotides to about 24 nucleotides, about 16 nucleotides to about 22 nucleotides, about 16 nucleotides to about 20 nucleotides, about 16 nucleotides to about 18 nucleotides, about 18 nucleotides to about 30 nucleotides, about 18 nucleotides to about 28 nucleotides, about 18 nucleotides to about 26 nucleotides, about 18 nucleotides to about 24 nucleotides, about 18 nucleotides to about 22 nucleotides, about 18 nucleotides to about 20 nucleotides, about 20 nucleotides to about 30 nucleotides, about 20 nucleotides to about 28 nucleotides, about 20 nucleotides to about 26 nucleotides, about 20 nucleotides to about 24 nucleotides, about 20 nucleotides to about 22 nucleotides, about 22 nucleotides to about 30 nucleotides, about 22 nucleotides to about 28 nucleotides, about 22 nucleotides to about 26 nucleotides, about 22 nucleotides to about 24 nucleotides, about 24 nucleotides to about 30 nucleotides, about 24 nucleotides to about 28 nucleotides, about 24 nucleotides to about 26 nucleotides, about 26 nucleotides to about 30 nucleotides, about 26 nucleotides to about 28 nucleotides, about 28 nucleotides to about 30 nucleotides, or 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides).
microRNA regulatory target site: As used herein, the term “microRNA regulatory target site” or “miRTS” refers to a sequence that directly interacts with a miRNA on the mRNA transcript. Often, the miRTS is present in the 3′ untranslated region (UTR) of the mRNA, but it may also be present in the coding sequence, or in the 5′ UTR. miRTS are not necessarily perfect complements to miRNAs, usually having only a few bases of complementarity to the miRNA, and often containing one or more mismatches. The miRTS may be any sequence capable of being bound by a miRNA sufficiently that the translation of a gene to which the miRTS is operably linked is repressed by a miRNA silencing mechanism such as the RNA-induced silencing complex (RISC). In some aspects, inclusion of a miRTS into a nucleic acid construct comprising a polynucleotide (e.g., a therapeutic polynucleotide) can result in degradation of the therapeutic polynucleotide after transcription. In some aspects, inclusion of a miRTS into a nucleic acid construct comprising a polynucleotide (e.g., a therapeutic polynucleotide) can result in decreased expression of the therapeutic polynucleotide in cells expressing the miRNA.
Nucleic acid: As used herein, the term “nucleic acid”, in its broadest sense, refers to any compound and/or substance that is or can be incorporated into an oligonucleotide chain. In some embodiments, a nucleic acid is a compound and/or substance that is or can be incorporated into an oligonucleotide chain via a phosphodiester linkage. As will be clear from context, in some embodiments, “nucleic acid” refers to an individual nucleic acid residue (e.g., a nucleotide and/or nucleoside); in some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising individual nucleic acid residues. In some embodiments, a “nucleic acid” is or comprises RNA; in some embodiments, a “nucleic acid” is or comprises DNA. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleic acid residues. In some embodiments, a nucleic acid is, comprises, or consists of one or more nucleic acid analogs. In some embodiments, a nucleic acid analog differs from a nucleic acid in that it does not utilize a phosphodiester backbone. Alternatively or additionally, in some embodiments, a nucleic acid has one or more phosphorothioate and/or 5′-N-phosphoramidite linkages rather than phosphodiester bonds. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxy guanosine, and deoxycytidine). In some embodiments, a nucleic acid is, comprises, or consists of one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, 2-thiocytidine, methylated bases, intercalated bases, and combinations thereof). In some embodiments, a nucleic acid comprises one or more modified sugars (e.g., 2′-fluororibose, ribose, 2′-deoxyribose, arabinose, and hexose) as compared with those in natural nucleic acids. In some embodiments, a nucleic acid has a nucleotide sequence that encodes a functional gene product such as an RNA or protein. In some embodiments, a nucleic acid includes one or more introns. In some embodiments, nucleic acids are prepared by one or more of isolation from a natural source, enzymatic synthesis by polymerization based on a complementary template (in vivo or in vitro), reproduction in a recombinant cell or system, and chemical synthesis. In some embodiments, a nucleic acid is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000 or more residues long. In some embodiments, a nucleic acid is partly or wholly single stranded; in some embodiments, a nucleic acid is partly or wholly double stranded. In some embodiments, a nucleic acid has a nucleotide sequence comprising at least one element that encodes, or is complementary to a sequence that encodes, a polypeptide. In some embodiments, a nucleic acid has enzymatic activity.
Operably linked: As used herein, refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control element “operably linked” to a functional element is associated in such a way that expression and/or activity of the functional element is achieved under conditions compatible with the control element. In some embodiments, “operably linked” control elements are contiguous (e.g., covalently linked) with coding elements of interest; in some embodiments, control elements act in trans to or otherwise at a from the functional element of interest. In some embodiments, “operably linked” refers to functional linkage between a regulatory sequence and a heterologous nucleic acid sequence resulting in expression of the latter. For example, a first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. In some embodiments, for example, a functional linkage may include transcriptional control. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences can be contiguous with each other and, e.g., where necessary to join two protein coding regions, are in the same reading frame.
Pharmaceutical composition: As used herein, the term “pharmaceutical composition” refers to a composition in which an active agent is formulated together with one or more pharmaceutically acceptable carriers. In some embodiments, an active agent is present in unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, a pharmaceutical composition may be specially formulated for administration in solid or liquid form, including those adapted for, e.g., administration, for example, an injectable formulation that is, e.g., an aqueous or non-aqueous solution or suspension or a liquid drop designed to be administered into an ear canal. In some embodiments, a pharmaceutical composition may be formulated for administration via injection either in a particular organ or compartment, e.g., directly into an ear, or systemic, e.g., intravenously. In some embodiments, a formulation may be or comprise drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes, capsules, powders, etc. In some embodiments, an active agent may be or comprise an isolated, purified, or pure compound.
Pharmaceutically acceptable: As used herein, the term “pharmaceutically acceptable” which, for example, may be used in reference to a carrier, diluent, or excipient used to formulate a pharmaceutical composition as disclosed herein, means that a carrier, diluent, or excipient is compatible with other ingredients of a composition and not deleterious to a recipient thereof.
Pharmaceutically acceptable carrier: As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting a subject compound from one organ, or portion of a body, to another organ, or portion of a body. Each carrier must be is “acceptable” in the sense of being compatible with other ingredients of a formulation and not injurious to a patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffered solutions; polyesters, polycarbonates and/or polyanhydrides; and other non-toxic compatible substances employed in pharmaceutical formulations.
Polyadenylation: As used herein, “polyadenylation” refers to the covalent linkage of a polyadenylyl moiety, or its modified variant, to a messenger RNA molecule. In eukaryotic organisms, most messenger RNA (mRNA) molecules are polyadenylated at the 3′ end. In some embodiments, a 3′ poly(A) tail is a long sequence of adenine nucleotides (e.g., 50, 60, 70, 100, 200, 500, 1000, 2000, 3000, 4000, or 5000) added to the pre-mRNA through the action of an enzyme, polyadenylate polymerase. In higher eukaryotes, a poly(A) tail can be added onto transcripts that contain a specific sequence, the polyadenylation signal or “poly(A) sequence.” A poly(A) tail and proteins bound to it aid in protecting mRNA from degradation by exonucleases. Polyadenylation can be affect transcription termination, export of the mRNA from the nucleus, and translation. Typically, polyadenylation occurs in the nucleus immediately after transcription of DNA into RNA, but additionally can also occur later in the cytoplasm. After transcription has been terminated, the mRNA chain can be cleaved through the action of an endonuclease complex associated with RNA polymerase. The cleavage site can be characterized by the presence of the base sequence AAUAAA near the cleavage site. After mRNA has been cleaved, adenosine residues can be added to the free 3′ end at the cleavage site. As used herein, a “poly(A) sequence” is a sequence that triggers the endonuclease cleavage of an mRNA and the additional of a series of adenosines to the 3′ end of the cleaved mRNA.
Polypeptide: As used herein, the term “polypeptide” refers to any polymeric chain of residues (e.g., amino acids) that are typically linked by peptide bonds. In some embodiments, a polypeptide has an amino acid sequence that occurs in nature. In some embodiments, a polypeptide has an amino acid sequence that does not occur in nature. In some embodiments, a polypeptide has an amino acid sequence that is engineered in that it is designed and/or produced through action of the hand of man. In some embodiments, a polypeptide may comprise or consist of natural amino acids, non-natural amino acids, or both. In some embodiments, a polypeptide may include one or more pendant groups or other modifications, e.g., modifying or attached to one or more amino acid side chains, at a polypeptide's N-terminus, at a polypeptide's C-terminus, or any combination thereof. In some embodiments, such pendant groups or modifications may be acetylation, amidation, lipidation, methylation, pegylation, etc., including combinations thereof. In some embodiments, polypeptides may contain L-amino acids, D-amino acids, or both and may contain any of a variety of amino acid modifications or analogs known in the art. In some embodiments, useful modifications may be or include, e.g., terminal acetylation, amidation, methylation, etc. In some embodiments, a protein may comprise natural amino acids, non-natural amino acids, synthetic amino acids, and combinations thereof. The term “peptide” is generally used to refer to a polypeptide having a length of less than about 100 amino acids, less than about 50 amino acids, less than 20 amino acids, or less than 10 amino acids. In some embodiments, a protein is antibodies, antibody fragments, biologically active portions thereof, and/or characteristic portions thereof.
Polynucleotide: As used herein, the term “polynucleotide” refers to any polymeric chain of nucleic acids. In some embodiments, a polynucleotide is or comprises RNA; in some embodiments, a polynucleotide is or comprises DNA. In some embodiments, a polynucleotide is, comprises, or consists of one or more natural nucleic acid residues. In some embodiments, a polynucleotide is, comprises, or consists of one or more nucleic acid analogs. In some embodiments, a polynucleotide analog differs from a nucleic acid in that it does not utilize a phosphodiester backbone. Alternatively or additionally, in some embodiments, a polynucleotide has one or more phosphorothioate and/or 5′-N-phosphoramidite linkages rather than phosphodiester bonds. In some embodiments, a polynucleotide is, comprises, or consists of one or more natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxy guanosine, and deoxycytidine). In some embodiments, a polynucleotide is, comprises, or consists of one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, 2-thiocytidine, methylated bases, intercalated bases, and combinations thereof). In some embodiments, a polynucleotide comprises one or more modified sugars (e.g., 2′-fluororibose, ribose, 2′-deoxyribose, arabinose, and hexose) as compared with those in natural nucleic acids. In some embodiments, a polynucleotide has a nucleotide sequence that encodes a functional gene product such as an RNA or protein. In some embodiments, a polynucleotide includes one or more introns. In some embodiments, a polynucleotide is prepared by one or more of isolation from a natural source, enzymatic synthesis by polymerization based on a complementary template (in vivo or in vitro), reproduction in a recombinant cell or system, and chemical synthesis. In some embodiments, a polynucleotide is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000 or more residues long. In some embodiments, a polynucleotide is partly or wholly single stranded; in some embodiments, a polynucleotide is partly or wholly double stranded. In some embodiments, a polynucleotide has a nucleotide sequence comprising at least one element that encodes, or is the complement of a sequence that encodes, a polypeptide. In some embodiments, a polynucleotide has enzymatic activity.
Promoter: As used herein, the term “promoter” refers to a nucleic acid sequence that functions to control the transcription of one or more coding sequences (e.g., a gene or transgene, e.g., encoding a therapeutic polypeptide), located upstream with respect to the direction of transcription of the transcription initiation site of the coding sequence. In some aspects, the promoter is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites or other DNA sequence (e.g., a transcription factor binding site, a repressor and/or activator protein binding site, or other sequences of nucleotides that act directly or indirectly to regulate the amount of transcription from the promoter). In some aspects, the promoter can comprise a naturally occurring promoter sequence, a functional fragment thereof, or a mutant of the naturally occurring promoter sequence or a functional fragment thereof.
Protein: As used herein, the term “protein” refers to a polypeptide (i.e., a string of at least two amino acids linked to one another by peptide bonds). Proteins may include moieties other than amino acids (e.g., may be glycoproteins, proteoglycans, etc.) and/or may be otherwise processed or modified. Those of ordinary skill in the art will appreciate that a “protein” can be a complete polypeptide chain as produced by a cell (with or without a signal sequence), or can be a characteristic portion thereof. Those of ordinary skill will appreciate that a protein can sometimes include more than one polypeptide chain, for example linked by one or more disulfide bonds or associated by other means.
Recombinant: As used herein, the term “recombinant” is intended to refer to polypeptides that are designed, engineered, prepared, expressed, created, manufactured, and/or or isolated by recombinant means, such as polypeptides expressed using a recombinant expression construct transfected into a host cell; polypeptides isolated from a recombinant, combinatorial human polypeptide library; polypeptides isolated from an animal (e.g., a mouse, rabbit, sheep, fish, etc.) that is transgenic for or otherwise has been manipulated to express a gene or genes, or gene components that encode and/or direct expression of the polypeptide or one or more component(s), portion(s), element(s), or domain(s) thereof, and/or polypeptides prepared, expressed, created or isolated by any other means that involves splicing or ligating selected nucleic acid sequence elements to one another, chemically synthesizing selected sequence elements, and/or otherwise generating a nucleic acid that encodes and/or directs expression of a polypeptide or one or more component(s), portion(s), element(s), or domain(s) thereof. In some embodiments, one or more of such selected sequence elements is found in nature. In some embodiments, one or more of such selected sequence elements is designed in silico. In some embodiments, one or more such selected sequence elements results from mutagenesis (e.g., in vivo or in vitro) of a known sequence element, e.g., from a natural or synthetic source such as, for example, in the germline of a source organism of interest (e.g., of a human, a mouse, etc).
Reference: As used herein, the term “reference” describes a standard or control relative to which a comparison is performed. For example, in some embodiments, an agent, animal, individual, population, sample, sequence or value of interest is compared with a reference or control agent, animal, individual, population, sample, sequence or value. In some embodiments, a reference or control is tested and/or determined substantially simultaneously with the testing or determination of interest. In some embodiments, a reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as would be understood by those skilled in the art, a reference or control is determined or characterized under comparable conditions or circumstances to those under assessment. Those skilled in the art will appreciate when sufficient similarities are present to justify reliance on and/or comparison to a particular possible reference or control. In some embodiments, a reference is a negative control reference; in some embodiments, a reference is a positive control reference.
Regulatory Element: As used herein, the term “regulatory element” or “regulatory sequence” refers to non-coding regions of DNA that regulate, in some way, expression of one or more particular genes. In some embodiments, such genes are apposed or “in the neighborhood” of a given regulatory element. In some embodiments, such genes are located quite far from a given regulatory element. In some embodiments, a regulatory element impairs or enhances transcription of one or more genes. In some embodiments, a regulatory element may be located in cis to a gene being regulated. In some embodiments, a regulatory element may be located in trans to a gene being regulated. For example, in some embodiments, a regulatory sequence refers to a nucleic acid sequence which is regulates expression of a gene product operably linked to a regulatory sequence. In some such embodiments, this sequence may be an enhancer sequence and other regulatory elements which regulate expression of a gene product.
Sample: As used herein, the term “sample” typically refers to an aliquot of material obtained or derived from a source of interest. In some embodiments, a source of interest is a biological or environmental source. In some embodiments, a source of interest may be or comprise a cell or an organism, such as a microbe (e.g., virus), a plant, or an animal (e.g., a human). In some embodiments, a source of interest is or comprises biological tissue or fluid. In some embodiments, a biological tissue or fluid may be or comprise amniotic fluid, aqueous humor, ascites, bile, bone marrow, blood, breast milk, cerebrospinal fluid, cerumen, chyle, chime, ejaculate, endolymph, exudate, feces, gastric acid, gastric juice, lymph, mucus, pericardial fluid, perilymph, peritoneal fluid, pleural fluid, pus, rheum, saliva, sebum, semen, serum, smegma, sputum, synovial fluid, sweat, tears, urine, vaginal secretions, vitreous humour, vomit, and/or combinations or component(s) thereof. In some embodiments, a biological fluid may be or comprise an intracellular fluid, an extracellular fluid, an intravascular fluid (blood plasma), an interstitial fluid, a lymphatic fluid, and/or a transcellular fluid. In some embodiments, a biological fluid may be or comprise a plant exudate. In some embodiments, a biological tissue or sample may be obtained, for example, by aspirate, biopsy (e.g., fine needle or tissue biopsy), swab (e.g., oral, nasal, skin, or vaginal swab), scraping, surgery, washing or lavage (e.g., bronchioalveolar, ductal, nasal, ocular, oral, uterine, vaginal, or other washing or lavage). In some embodiments, a biological sample is or comprises cells obtained from an individual. In some embodiments, a sample is a “primary sample” obtained directly from a source of interest by any appropriate means. In some embodiments, as will be clear from context, the term “sample” refers to a preparation that is obtained by processing (e.g., by removing one or more components of and/or by adding one or more agents to) a primary sample. For example, filtering using a semi-permeable membrane. Such a “processed sample” may comprise, for example nucleic acids or proteins extracted from a sample or obtained by subjecting a primary sample to one or more techniques such as amplification or reverse transcription of nucleic acid, isolation and/or purification of certain components, etc.
Selective expression: As used herein, the term “selective expression” or “selectively expresses” refers to expression of a coding sequence, gene, transgene, or polynucleotide (e.g., a therapeutic polynucleotide) of interest predominately in certain specific cell types (e.g., inner ear cells, e.g., inner ear supporting cells).
Subject: As used herein, the term “subject” refers an organism, typically a mammal (e.g., a human, in some embodiments including prenatal human forms). In some embodiments, a subject is suffering from a relevant disease, disorder or condition. In some embodiments, a subject is susceptible to a disease, disorder, or condition. In some embodiments, a subject displays one or more symptoms or characteristics of a disease, disorder or condition. In some embodiments, a subject does not display any symptom or characteristic of a disease, disorder, or condition. In some embodiments, a subject is someone with one or more features characteristic of susceptibility to or risk of a disease, disorder, or condition. In some embodiments, a subject is a patient. In some embodiments, a subject is an individual to whom diagnosis and/or therapy is and/or has been administered.
Substantially: As used herein, the term “substantially” refers to a qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the art will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term “substantially” is therefore used herein to capture a potential lack of completeness inherent in many biological and chemical phenomena.
Supporting cell: As used herein, the term “support cell,” “supporting cell,” “inner ear support cell,” or “inner ear supporting cell” refers to cells of the inner ear that maintain the structure of the inner ear and maintain the environment of the sensory epithelium of the inner ear. In some aspects, inner ear supporting cells include, but are not limited to, inner phalangeal cells/border cells (IPhC), inner pillar cells (IPC), outer pillar cells (OPC), Deiters' cells rows 1 and 2 (DC1/2), Deiters' cells row 3 (DC3), Hensen's cells (Hec), Claudius cells/outer sulcus cells (CC/OSC), interdental cells (Idc), inner sulcus cells (ISC), Kolliker's organ cells (KO), greater ridge epithelial ridge cells (GER) (including lateral greater epithelial ridge cells (LGER)), and OC90+ cells (OC90), fibroblasts, and other cells of the lateral wall.
Treatment: As used herein, the term “treatment” (also “treat” or “treating”) refers to any administration of a therapy that partially or completely alleviates, ameliorates, eliminates, reverses, relieves, inhibits, delays onset of, reduces severity of, and/or reduces incidence of one or more symptoms, features, and/or causes of a particular disease, disorder, and/or condition. In some embodiments, such treatment may be of a subject who does not exhibit signs of the relevant disease, disorder and/or condition and/or of a subject who exhibits only early signs of the disease, disorder, and/or condition. Alternatively, or additionally, such treatment may be of a subject who exhibits one or more established signs of the relevant disease, disorder and/or condition. In some embodiments, treatment may be of a subject who has been diagnosed as suffering from the relevant disease, disorder, and/or condition. In some embodiments, treatment may be of a subject known to have one or more susceptibility factors that are statistically correlated with increased risk of development of a given disease, disorder, and/or condition.
Variant: As used herein, the term “variant” refers to a version of something, e.g., a gene sequence, that is different, in some way, from another version. To determine if something is a variant, a reference version is typically chosen and a variant is different relative to that reference version. In some embodiments, a variant can have the same or a different (e.g., increased or decreased) level of activity or functionality than a wild type sequence. For example, in some embodiments, a variant can have improved functionality as compared to a wild-type sequence if it is, e.g., codon-optimized to resist degradation, e.g., by an inhibitory nucleic acid, e.g., miRNA. Such a variant is referred to herein as a gain-of-function variant. In some embodiments, a variant has a reduction or elimination in activity or functionality or a change in activity that results in a negative outcome (e.g., increased electrical activity resulting in chronic depolarization that leads to cell death). Such a variant is referred to herein as a loss-of-function variant. For example, in some embodiments, a GJB2 gene sequence is a wild-type sequence, which encodes a functional protein and exists in a majority of members of species with genomes containing the GJB2 gene. In some such embodiments, a gain-of-function variant can be a gene sequence of GJB2 that contains one or more nucleotide differences relative to a wild-type GJB2 gene sequence. In some embodiments, a gain-of-function variant is a codon-optimized sequence which encodes a transcript or polypeptide that may have improved properties (e.g., less susceptibility to degradation, e.g., less susceptibility to miRNA mediated degradation) than its corresponding wild type (e.g., non-codon optimized) version. In some embodiments, a loss-of-function variant has one or more changes that result in a transcript or polypeptide that is defective in some way (e.g., decreased function, non-functioning) relative to the wild type transcript and/or polypeptide. For example, in some embodiments, a mutation in a GJB2 sequence results in a non-functional or otherwise defective connexin 26 (Cx26) protein.
Generally, an ear can be described as including: an outer ear, middle ear, inner ear, hearing (acoustic) nerve, and auditory system (which processes sound as it travels from the ear to the brain). In addition to detecting sound, ears also help to maintain balance. Thus, in some embodiments, disorders of the inner ear can cause hearing loss, tinnitus, vertigo, imbalance, or combinations thereof.
Hearing loss can be the result of genetic factors, environmental factors, or a combination of genetic and environmental factors. About half of all people who have tinnitus—phantom noises in their auditory system (ringing, buzzing, chirping, humming, or beating)—also have an over-sensitivity to/reduced tolerance for certain sound frequency and volume ranges, known as hyperacusis (also spelled hyperacousis). A variety of nonsyndromic and syndromic-related hearing losses will be known to those of skill in the art (e.g., DFNB1 and DFNA3. or Bart-Pumphrey syndrome, hystrix-like ichthyosis with deafness (HID), palmoplantar keratoderma with deafness, keratitis-ichthyosis-deafness (KID) syndrome and Vohwinkel syndrome, respectively). Environmental causes of hearing impairment or loss may include, e.g., certain medications, specific infections before or after birth, and/or exposure to loud noise over an extended period. In some embodiments, hearing loss can result from noise, ototoxic agents, presbycusis, disease, infection or cancers that affect specific parts of the ear. In some embodiments, ischemic damage can cause hearing loss via pathophysiological mechanisms. In some embodiments, intrinsic abnormalities, like congenital mutations to genes that play an important role in cochlear anatomy or physiology, or genetic or anatomical changes in supporting and/or hair cells can be responsible for or contribute to hearing loss.
Hearing loss and/or deafness is one of the most common human sensory deficits, and can occur for many reasons. In some embodiments, a subject may be born with hearing loss or without hearing, while others may lose hearing slowly over time. Approximately 36 million American adults report some degree of hearing loss, and one in three people older than 60 and half of those older than 85 experience hearing loss. Approximately 1.5 in 1,000 children are born with profound hearing loss, and another two to three per 1,000 children are born with partial hearing loss (Smith et al., 2005, Lancet 365:879-890, which is incorporated in its entirety herein by reference). More than half of these cases are attributed to a genetic basis (Di Domenico, et al., 2011, J. Cell. Physiol. 226:2494-2499, which is incorporated in its entirety herein by reference).
Treatments for hearing loss currently consist of hearing amplification for mild to severe losses and cochlear implantation for severe to profound losses (Kral and O'Donoghue, 2010, N. Engl. J. Med. 363:1438-1450, which is incorporated in its entirety herein by reference). Recent research in this arena has focused on cochlear hair cell regeneration, applicable to the most common forms of hearing loss, including presbycusis, noise damage, infection, and ototoxicity. There remains a need for effective treatments, such as gene therapy, which can repair and/or mitigate a source of a hearing problem (see e.g., WO 2018/039375, WO 2019/165292, and PCT filing application US2019/060328, each of which is incorporated in its entirety herein by reference).
In some embodiments, nonsyndromic hearing loss and/or deafness is not associated with other signs and symptoms. In some embodiments, syndromic hearing loss and/or deafness occurs in conjunction with abnormalities in other parts of the body. Approximately 70 percent to 80 percent of genetic hearing loss and/or deafness cases are nonsyndromic; remaining cases are often caused by specific genetic syndromes. Nonsyndromic deafness and/or hearing loss can have different patterns of inheritance, and can occur at any age. Types of nonsyndromic deafness and/or hearing loss are generally named according to their inheritance patterns. For example, autosomal dominant forms are designated DFNA, autosomal recessive forms are DFNB, and X-linked forms are DFN. Each type is also numbered in the order in which it was first described. For example, DFNA1 was the first described autosomal dominant type of nonsyndromic deafness. Between 75 percent and 80 percent of genetically causative hearing loss and/or deafness cases are inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. Usually, each parent of an individual with autosomal recessive hearing loss and/or deafness is a carrier of one copy of the mutated gene, but is not affected by this form of hearing loss. Another 20 percent to 25 percent of nonsyndromic hearing loss and/or deafness cases are autosomal dominant, which means one copy of the altered gene in each cell is sufficient to result in deafness and/or hearing loss. People with autosomal dominant deafness and/or hearing loss most often inherit an altered copy of the gene from a parent who is deaf and/or has hearing loss. Between 1 to 2 percent of cases of deafness and/or hearing loss show an X-linked pattern of inheritance, which means the mutated gene responsible for the condition is located on the X chromosome (one of the two sex chromosomes). Males with X-linked nonsyndromic hearing loss and/or deafness tend to develop more severe hearing loss earlier in life than females who inherit a copy of the same gene mutation. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons. Mitochondrial nonsyndromic deafness, which results from changes to mitochondrial DNA, occurs in less than one percent of cases in the United States. The altered mitochondrial DNA is passed from a mother to all of her sons and daughters. This type of deafness is not inherited from fathers. The causes of syndromic and nonsyndromic deafness and/or hearing loss are complex. Researchers have identified more than 30 genes that, when altered, are associated with syndromic and/or nonsyndromic deafness and/or hearing loss; however, some of these genes have not been fully characterized. Different mutations in the same gene can be associated with different types of deafness and/or hearing loss, and some genes are associated with both syndromic and nonsyndromic deafness and/or hearing loss.
In some embodiments, deafness and/or hearing loss can be conductive (arising from the ear canal or middle ear), sensorineural (arising from the inner ear or auditory nerve), or mixed. In some embodiments, nonsyndromic deafness and/or hearing loss is associated with permanent hearing loss caused by damage to structures in the inner ear (sensorineural deafness). In some embodiments, sensorineural hearing loss can be due to poor hair cell function. In some embodiments, sensorineural hearing impairments involve the eighth cranial nerve (the vestibulocochlear nerve) or the auditory portions of the brain. In some such embodiments, only the auditory centers of the brain are affected. In such a situation, cortical deafness may occur, where sounds may be heard at normal thresholds, but quality of sound perceived is so poor that speech cannot be understood. Hearing loss that results from changes in the middle ear is called conductive hearing loss. Some forms of nonsyndromic deafness and/or hearing loss involve changes in both the inner ear and the middle ear, called mixed hearing loss. Hearing loss and/or deafness that is present before a child learns to speak can be classified as prelingual or congenital. Hearing loss and/or deafness that occurs after the development of speech can be classified as postlingual. Most autosomal recessive loci related to syndromic or nonsyndromic hearing loss cause prelingual severe-to-profound hearing loss.
As is known to those of skill in the art, hair cells are sensory receptors for both auditory and vestibular systems of vertebrate ears. Hair cells detect movement in the environment and, in mammals, hair cells are located within the cochlea of the ear, in the organ of Corti. Mammalian ears are known to have two types of hair cells—inner hair cells and outer hair cells. Outer hair cells can amplify low level sound frequencies, either through mechanical movement of hair cell bundles or electrically-driven movement of hair cell soma. Inner hair cells transform vibrations in cochlear fluid into electrical signals that the auditory nerve transmits to the brain. In some embodiments, hair cells may be abnormal at birth, or damaged during the lifetime of an individual. In some embodiments, outer hair cells may be able to regenerate. In some embodiments, inner hair cells are not capable of regeneration after illness or injury. In some embodiments, sensorineural hearing loss is due to abnormalities in hair cells.
As is known to those of skill in the art, hair cells do not occur in isolation, and their function is supported by a wide variety of cells which can collectively be referred to as supporting cells. Supporting cells may fulfil numerous functions, and include a number of cell types, including but not limited to Hensen's cells, Deiters' cells, pillar cells, Claudius cells, inner phalangeal cells, and border cells. In some embodiments, sensorineural hearing loss is due to abnormalities in supporting cells. In some embodiments, supporting cells may be abnormal at birth, or damaged during the lifetime of an individual. In some embodiments, supporting cells may be able to regenerate. In some embodiments, certain supporting cells may not be capable of regeneration.
The GJB2 gene is highly conserved across the mammalian class and encodes connexin 26 (Cx26) (also referred to as gap junction beta-2 (GJB2) protein). Connexin 26 is a member of the gap junction protein family, which is also known as the connexin family. Gap junction proteins are specialized proteins, involved in intracellular communication. Mutations in the human GJB2 gene have been associated with hearing loss and deafness (Amorini et al., Ann. Hum. Genet. 79(5):341-349, 2015; Qing et al., Genet. Test Mol. Biomarkers 19(1):52-58, 2015).
The human GJB2 gene is located on chromosome 13q12. It contains two transcriptional isoforms beginning from alternative transcriptional start sites, both of which contain two exons and a single intron encompassing a total of about 5 kilobases (kb) (approximately 5,469 or 4,675 nucleotides respectively) (NCBI Gene ID 2706, NCBI Reference Sequence: NG_008358.1). Both human GJB2 mRNA isoforms comprise a second exon, which completely encodes a full-length connexin 26 in exon two. This coding sequence is approximately 681 nucleotides, and encodes a connexin 26 that is 226 amino acids in length.
A monomer of connexin 26 includes four transmembrane helices linked by two extracellular loops and one shorter intracellular loop, with N- and C-termini on the cytosolic side of the plasma membrane. Gap junctions between cells can be formed in a homomeric and/or heteromeric manner. Connexin 26 has been shown to form functional homomeric channels, as well as functional heteromeric channels with at least connexin 30, connexin 32, connexin 46, and connexin 50. In some embodiments, GJB2 gene associated sensorineural hearing loss (e.g., nonsyndromic or syndromic) may be due to compound heterozygous mutations in GJB2 and in an alternative connexin protein encoding gene. The gap junctions created with connexin 26 transport potassium ions and certain other small molecules across cells. Connexin 26 helps maintain the correct level of intracellular potassium ions, and is required for the maturation of certain cells in the cochlea.
A human GJB2 gene is expressed in a number of tissues, but is known to be involved in important cellular homeostasis functions in the epidermis and inner ear. Within the inner ear, connexin 26 is synthesized by all supporting cell types within the organ of corti, including the inner and outer pillar cells, root cells, interdental cells, fibrocytes from the underlying connective tissue, and basal and intermediate cells from the stria vascularis. In addition, connexin 26 is known to be present in mesenchymal cells in the lateral wall, and type 1 neurons in the spiral ganglion.
The human GJB2 gene has a defined 128 bp long basal promoter just upstream of the canonical first exon in the most abundant isoform. This sequence includes a TATA box and two GC boxes, which are known to be bound by the Sp1 and Sp3 TFs.
There are over 200 defined mutations of GJB2, which show some level of pathogenicity, and various mutations in the GJB2 gene have been associated with hearing loss (e.g., non-syndromic sensorineural hearing loss or syndromic sensorineural hearing loss). For example, the c.35delG allele was found on 65.5% of patients from Eastern Sicily (Amorini et al., Ann. Hum. Genet. 79(5):341-349, 2015). Additional exemplary mutations in a GJB2 gene detected in subjects having nonsyndromic sensorineural hearing loss or syndromic sensorineural hearing loss, and methods of sequencing a nucleic acid encoding GJB2 are described in, e.g., Snoeckx et al., Am. J. Hum. Genet 77: 945-957, 2005; Welch et al., Am. J. Med. Genet A 143: 1567-1573, 2007; Zelante et al., Hum. Mol. Genet. 6:1605-1609, 1997; and Tsukada et al., Annals of Otology, Rhinology & Laryngology. 2015, Vol. 124(5S) 61S-76S, each of which is incorporated in its entirety herein by reference. Methods of detecting mutations in a gene are well-known in the art. Non-limiting examples of such techniques include: real-time polymerase chain reaction (RT-PCR), PCR, Sanger sequencing, Next-generation sequencing, Southern blotting, and Northern blotting.
Multiple disease states associated with sensorineural hearing loss with either non-syndromic or syndromic manifestations have been linked with specific mutations of the human GJB2 gene (see Nickel & Forge, Curr Opin Otolaryngol Head Neck Surg. 2008 October; 16(5):452-7, which is incorporated in its entirety herein by reference). Human GBJ2 gene mutations which lead to syndromic or nonsyndromic hearing loss vary from large deletions that remove either the entirety of GJB2 or GJB2 gene regulatory regions, to hundreds of small scale alterations including nonsense, missense, indels (leading to phase shifting), and splice-site point mutations.
In some embodiments, GJB2 gene mutations such as Gly59Ser, and Asn52Lys are associated with Bart-Pumphrey syndrome. A syndrome defined by manifestations of thickened skin, wart-like growths, and generally congenital moderate to profound sensorineural hearing loss. In other embodiments, GJB2 gene mutations such as Aspn50Asn are associated with Hystrix-like Ichthyosis with deafness & Keratitis-ichthyosis-deafness syndrome. These syndromes are associated with dry scaly skin, generally congenital profound sensorineural hearing loss, and in Keratitis-ichthyosis-deafness syndrome, additional inflammation of the cornea.
In some embodiments, GJB2 gene missense mutations are associated with Palmoplantar keratoderma with deafness. A syndrome associated with thick skin on the palms of the hands and soles of the feet, and mild to profound sensorineural hearing loss which begins in early childhood and gets worse over time, affected individuals may have particular trouble hearing high-pitched sounds. While in other embodiments, GJB2 gene missense mutations are associated with Vohwinkel syndrome. A syndrome associated with skin abnormalities (e.g., thick bands of fibrous tissue around their fingers and toes that may cut off the circulation to the digits and result in spontaneous amputation) and sensorineural hearing loss.
In some embodiments, GJB2 gene mutations are associated with nonsyndromic hearing loss, which may be inherited in either a dominant (e.g., DFNA3) or recessive manner (DFNB1). In some embodiments, loss of function GJB2 gene mutations are associated with nonsyndromic DFNB1 which is inherited in an autosomal recessive manner and presents as mild to profound hearing loss that is generally prelingual and does not become more severe over time. It is estimated that DFNB1 is present in approximately 14 out of every 100,000 live births in the US and EU5. It has been postulated that an early but not always congenital onset of DFNB1 hearing impairment could be followed by a quick progression of the hearing loss. In general, DFNB1 patents treatment options include education, hearing aids, and cochlear implants. Patients generally do not have additional symptoms, and live a normal lifespan. It is estimated that DFNB1 accounts for about 50% of congenital severe-to-profound autosomal recessive non-syndromic hearing loss in many first world countries (e.g., US, France, Britain, and Australia).
In some embodiments, sensorineural hearing loss due to GJB2 gene mutations are inherited in an autosomal dominant manner as nonsyndromic DFNA3. These mutations are generally dominant negative missense mutations that prevent the formation of necessary functional gap junctions. This disease state presents with hearing loss that can be either prelingual or postlingual, ranging from mild to profound, which generally becomes more severe over time.
Among other things, the present disclosure provides polynucleotides, e.g., polynucleotides comprising a GJB2 gene or characteristic portion thereof, as well as compositions including such polynucleotides and methods utilizing such polynucleotides and/or compositions.
In some embodiments, a polynucleotide comprising a GJB2 gene or characteristic portion thereof can be DNA or RNA. In some embodiments, DNA can be genomic DNA or cDNA. In some embodiments, RNA can be an mRNA. In some embodiments, a polynucleotide comprises exons and/or introns of a GJB2 gene.
In some embodiments, a gene product is expressed from a polynucleotide comprising a GJB2 gene or characteristic portion thereof. In some embodiments, expression of such a polynucleotide can utilize one or more control elements (e.g., promoters, enhancers, splice sites, poly-adenylation sites, translation initiation sites, etc.). Thus, in some embodiments, a polynucleotide provided herein can include one or more control elements.
In some embodiments, a GJB2 gene is a mammalian GJB2 gene. In some embodiments, a GJB2 gene is a murine GJB2 gene. In some embodiments, a GJB2 gene is a primate GJB2 gene. In some embodiments, a GJB2 gene is a human GJB2 gene. An exemplary human GJB2 coding cDNA sequence is or includes the sequence of SEQ ID NO: 1 or SEQ ID NO: 2. An exemplary human GJB2 spliced cDNA sequence with untranslated regions is or includes the sequence of SEQ ID NO: 3. An alternative transcriptional start site exemplary human GJB2 spliced cDNA sequence with untranslated regions is or includes the sequence of SEQ ID NO: 4. An exemplary human GJB2 genomic DNA sequence can be found in SEQ ID NO: 5.
The present disclosure recognizes that certain changes to a polynucleotide sequence will not impact its expression or a protein encoded by said polynucleotide. In some embodiments, a polynucleotide comprises a GJB2 gene having one or more silent mutations. In some embodiments, the disclosure provides a polynucleotide that comprises a GJB2 gene having one or more silent mutations, e.g., a GJB2 gene having a sequence different from SEQ ID NO: 1, 2, 3, 4, 5 or 6 but encoding the same amino acid sequence as a functional GJB2 gene. In some embodiments, the disclosure provides a polynucleotide that comprises a GJB2 gene having a sequence different from SEQ ID NO: 1, 2, 3, 4, 5 or 6 that encodes an amino acid sequence including one or more mutations (e.g., a different amino acid sequence when compared to that produced from a functional GJB2 gene), where the one or more mutations are conservative amino acid substitutions. In some embodiments, the disclosure provides a polynucleotide that comprises a GJB2 gene having a sequence different from SEQ ID NO: 1, 2, 3, 4, 5 or 6 that encodes an amino acid sequence including one or more mutations (e.g., a different amino acid sequence when compared to that produced from a functional GJB2 gene), where the one or more mutations are not within a characteristic portion of a GJB2 gene or an encoded connexin 26 protein. In some embodiments, a polynucleotide in accordance with the present disclosure comprises a GJB2 gene that is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to a sequence of SEQ ID NO: 1, 2, 3, 4, 5 or 6 In some embodiments, a polynucleotide in accordance with the present disclosure comprises a GJB2 gene that is identical to the sequence of SEQ ID NO: 1, 2, 3, 4, 5 or 6. As can be appreciated in the art, SEQ ID NO: 1, 2, 3, 4, 5 or 6 can be optimized (e.g., codon optimized) to achieve increased or optimal expression in an animal, e.g., a mammal, e.g., a human.
Among other things, the present disclosure provides polypeptides encoded by a GJB2 gene or characteristic portion thereof. In some embodiments, a GJB2 gene is a mammalian GJB2 gene. In some embodiments, a GJB2 gene is a murine GJB2 gene. In some embodiments, a GJB2 gene is a primate GJB2 gene. In some embodiments, a GJB2 gene is a human GJB2 gene.
In some embodiments, a polypeptide comprises a connexin 26 protein or characteristic portion thereof. In some embodiments, a connexin 26 protein or characteristic portion thereof is mammalian connexin 26 protein or characteristic portion thereof, e.g., primate connexin 26 protein or characteristic portion thereof. In some embodiments, a connexin 26 protein or characteristic portion thereof is a human connexin 26 protein or characteristic portion thereof.
In some embodiments, a polypeptide provided herein comprises post-translational modifications. In some embodiments, a connexin 26 protein or characteristic portion thereof provided herein comprises post-translational modifications. In some embodiments, post-translational modifications can comprise but is not limited to glycosylation (e.g., N-linked glycosylation, O-linked glycosylation), phosphorylation, acetylation, amidation, hydroxylation, methylation, ubiquitylation, sulfation, and/or a combination thereof. An exemplary human connexin 26 protein sequence is or includes the sequence of SEQ ID NO: 7.
The present disclosure recognizes that certain mutations in an amino acid sequence of a polypeptide described herein (e.g., including connexin 26 or a characteristic portion thereof) will not impact the expression, folding, or activity of the polypeptide. In some embodiments, a polypeptide (e.g., including connexin 26 or a characteristic portion thereof) includes one or more mutations, where the one or more mutations are conservative amino acid substitutions. In some embodiments, a polypeptide in accordance with the present disclosure comprises a connexin 26 or a characteristic portion thereof that is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to a sequence of SEQ ID NO: 7. In some embodiments, a polypeptide in accordance with the present disclosure comprises a connexin 26 or a characteristic portion thereof that is identical to the sequence of SEQ ID NO: 7. In some embodiments, a polypeptide in accordance with the present disclosure comprises a connexin 26 or a characteristic portion thereof that is at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to a sequence of SEQ ID NO: 7. In some embodiments, a polypeptide in accordance with the present disclosure comprises a connexin 26 protein or a characteristic portion thereof that is identical to the sequence of SEQ ID NO: 7.
Among other things, the present disclosure provides that some polynucleotides as described herein are polynucleotide constructs. Polynucleotide constructs according to the present disclosure include all those known in the art, including cosmids, plasmids (e.g., naked or contained in liposomes) and viral constructs (e.g., lentiviral, retroviral, adenoviral, and adeno-associated viral constructs) that incorporate a polynucleotide comprising a GJB2 gene or characteristic portion thereof. Those of skill in the art will be capable of selecting suitable constructs, as well as cells, for making any of the polynucleotides described herein. In some embodiments, a construct is a plasmid (i.e., a circular DNA molecule that can autonomously replicate inside a cell). In some embodiments, a construct can be a cosmid (e.g., pWE or sCos series).
In some embodiments, a construct is a viral construct. In some embodiments, a viral construct is a lentivirus, retrovirus, adenovirus, or adeno-associated virus construct. In some embodiments, a construct is an adeno-associated virus (AAV) construct (see, e.g., Asokan et al., Mol. Ther. 20: 699-7080, 2012, which is incorporated in its entirety herein by reference). In some embodiments, a viral construct is an adenovirus construct. In some embodiments, a viral construct may also be based on or derived from an alphavirus. Alphaviruses include Sindbis (and VEEV) virus, Aura virus, Babanki virus, Barmah Forest virus, Bebaru virus, Cabassou virus, Chikungunya virus, Eastern equine encephalitis virus, Everglades virus, Fort Morgan virus, Getah virus, Highlands J virus, Kyzylagach virus, Mayaro virus, Me Tri virus, Middelburg virus, Mosso das Pedras virus, Mucambo virus, Ndumu virus, O'nyong-nyong virus, Pixuna virus, Rio Negro virus, Ross River virus, Salmon pancreas disease virus, Semliki Forest virus, Southern elephant seal virus, Tonate virus, Trocara virus, Una virus, Venezuelan equine encephalitis virus, Western equine encephalitis virus, and Whataroa virus. Generally, the genome of such viruses encode nonstructural (e.g., replicon) and structural proteins (e.g., capsid and envelope) that can be translated in the cytoplasm of the host cell. Ross River virus, Sindbis virus, Semliki Forest virus (SFV), and Venezuelan equine encephalitis virus (VEEV) have all been used to develop viral constructs for coding sequence delivery. Pseudotyped viruses may be formed by combining alphaviral envelope glycoproteins and retroviral capsids. Examples of alphaviral constructs can be found in U.S. Publication Nos. 20150050243, 20090305344, and 20060177819; constructs and methods of their making are incorporated herein by reference to each of the publications in its entirety.
Constructs provided herein can be of different sizes. In some embodiments, a construct is a plasmid and can include a total length of up to about 1 kb, up to about 2 kb, up to about 3 kb, up to about 4 kb, up to about 5 kb, up to about 6 kb, up to about 7 kb, up to about 8 kb, up to about 9 kb, up to about 10 kb, up to about 11 kb, up to about 12 kb, up to about 13 kb, up to about 14 kb, or up to about 15 kb. In some embodiments, a construct is a plasmid and can have a total length in a range of about 1 kb to about 2 kb, about 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 1 kb to about 6 kb, about 1 kb to about 7 kb, about 1 kb to about 8 kb, about 1 kb to about 9 kb, about 1 kb to about 10 kb, about 1 kb to about 11 kb, about 1 kb to about 12 kb, about 1 kb to about 13 kb, about 1 kb to about 14 kb, or about 1 kb to about 15 kb.
In some embodiments, a construct is a viral construct and can have a total number of nucleotides of up to 10 kb. In some embodiments, a viral construct can have a total number of nucleotides in the range of about 1 kb to about 2 kb, 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 1 kb to about 6 kb, about 1 kb to about 7 kb, about 1 kb to about 8 kb, about 1 kb to about 9 kb, about 1 kb to about 10 kb, about 2 kb to about 3 kb, about 2 kb to about 4 kb, about 2 kb to about 5 kb, about 2 kb to about 6 kb, about 2 kb to about 7 kb, about 2 kb to about 8 kb, about 2 kb to about 9 kb, about 2 kb to about 10 kb, about 3 kb to about 4 kb, about 3 kb to about 5 kb, about 3 kb to about 6 kb, about 3 kb to about 7 kb, about 3 kb to about 8 kb, about 3 kb to about 9 kb, about 3 kb to about 10 kb, about 4 kb to about 5 kb, about 4 kb to about 6 kb, about 4 kb to about 7 kb, about 4 kb to about 8 kb, about 4 kb to about 9 kb, about 4 kb to about 10 kb, about 5 kb to about 6 kb, about 5 kb to about 7 kb, about 5 kb to about 8 kb, about 5 kb to about 9 kb, about 5 kb to about 10 kb, about 6 kb to about 7 kb, about 6 kb to about 8 kb, about 6 kb to about 9 kb, about 6 kb to about 10 kb, about 7 kb to about 8 kb, about 7 kb to about 9 kb, about 7 kb to about 10 kb, about 8 kb to about 9 kb, about 8 kb to about 10 kb, or about 9 kb to about 10 kb.
In some embodiments, a construct is a lentivirus construct and can have a total number of nucleotides of up to 8 kb. In some examples, a lentivirus construct can have a total number of nucleotides of about 1 kb to about 2 kb, about 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 1 kb to about 6 kb, about 1 kb to about 7 kb, about 1 kb to about 8 kb, about 2 kb to about 3 kb, about 2 kb to about 4 kb, about 2 kb to about 5 kb, about 2 kb to about 6 kb, about 2 kb to about 7 kb, about 2 kb to about 8 kb, about 3 kb to about 4 kb, about 3 kb to about 5 kb, about 3 kb to about 6 kb, about 3 kb to about 7 kb, about 3 kb to about 8 kb, about 4 kb to about 5 kb, about 4 kb to about 6 kb, about 4 kb to about 7 kb, about 4 kb to about 8 kb, about 5 kb to about 6 kb, about 5 kb to about 7 kb, about 5 kb to about 8 kb, about 6 kb to about 8 kb, about 6 kb to about 7 kb, or about 7 kb to about 8 kb
In some embodiments, a construct is an adenovirus construct and can have a total number of nucleotides of up to 8 kb. In some embodiments, an adenovirus construct can have a total number of nucleotides in the range of about 1 kb to about 2 kb, about 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 1 kb to about 6 kb, about 1 kb to about 7 kb, about 1 kb to about 8 kb, about 2 kb to about 3 kb, about 2 kb to about 4 kb, about 2 kb to about 5 kb, about 2 kb to about 6 kb, about 2 kb to about 7 kb, about 2 kb to about 8 kb, about 3 kb to about 4 kb, about 3 kb to about 5 kb, about 3 kb to about 6 kb, about 3 kb to about 7 kb, about 3 kb to about 8 kb, about 4 kb to about 5 kb, about 4 kb to about 6 kb, about 4 kb to about 7 kb, about 4 kb to about 8 kb, about 5 kb to about 6 kb, about 5 kb to about 7 kb, about 5 kb to about 8 kb, about 6 kb to about 7 kb, about 6 kb to about 8 kb, or about 7 kb to about 8 kb.
Any of the constructs described herein can further include a control sequence, e.g., a control sequence selected from the group of a transcription initiation sequence, a transcription termination sequence, a promoter sequence, an enhancer sequence, an RNA splicing sequence, a polyadenylation (poly(A)) sequence, a Kozak consensus sequence, and/or additional untranslated regions which may house pre- or post-transcriptional regulatory and/or control elements. In some embodiments, a promoter can be a native promoter, a constitutive promoter, an inducible promoter, and/or a tissue-specific promoter. Non-limiting examples of control sequences are described herein.
Among other things, the present disclosure provides AAV particles that comprise a construct encoding a GJB2 gene or characteristic portion thereof described herein, and a capsid described herein. In some embodiments, AAV particles can be described as having a serotype, which is a description of the construct strain and the capsid strain. For example, in some embodiments an AAV particle may be described as AAV2, wherein the particle has an AAV2 capsid and a construct that comprises characteristic AAV2 Inverted Terminal Repeats (ITRs). In some embodiments, an AAV particle may be described as a pseudotype, wherein the capsid and construct are derived from different AAV strains, for example, AAV2/9 would refer to an AAV particle that comprises a construct utilizing the AAV2 ITRs and an AAV9 capsid. In some aspects, an AAV capsid is an Anc80 capsid (e.g., an Anc80L65 capsid).
The present disclosure provides polynucleotide constructs that comprise a GJB2 gene or characteristic portion thereof. In some embodiments described herein, a polynucleotide comprising a GJB2 gene or characteristic portion thereof can be included in an AAV particle.
In some embodiments, a polynucleotide construct comprises one or more components derived from or modified from naturally occurring AAV genomic construct. In some embodiments, a sequence derived from an AAV construct is an AAV1 construct, an AAV2 construct, an AAV3 construct, an AAV4 construct, an AAV5 construct, an AAV6 construct, an AAV7 construct, an AAV8 construct, an AAV9 construct, an AAV2.7m8 construct, an AAV8BP2 construct, an AAV293 construct, or AAV Anc80 construct. Additional exemplary AAV constructs that can be used herein are known in the art. See, e.g., Kanaan et al., Mol. Ther. Nucleic Acids 8:184-197, 2017; Li et al., Mol. Ther. 16(7): 1252-1260, 2008; Adachi et al., Nat. Commun. 5: 3075, 2014; Isgrig et al., Nat. Commun. 10(1): 427, 2019; and Gao et al., J. Virol. 78(12): 6381-6388, 2004; each of which is incorporated in its entirety herein by reference.
In some embodiments, provided constructs comprise coding sequence, e.g., a GJB2 gene or a characteristic portion thereof, one or more regulatory and/or control sequences, and optionally 5′ and 3′ AAV derived inverted terminal repeats (ITRs). In some embodiments wherein a 5′ and 3′ AAV derived ITR is utilized, the polynucleotide construct may be referred to as a recombinant AAV (rAAV) construct. In some embodiments, provided rAAV constructs are packaged into an AAV capsid to form an AAV particle. In some aspects, an AAV capsid is an Anc80 capsid (e.g., an Anc80L65 capsid).
In some embodiments, AAV derived sequences (which are comprised in a polynucleotide construct) typically include the cis-acting 5′ and 3′ ITR sequences (see, e.g., B. J. Carter, in “Handbook of Parvoviruses,” ed., P. Tijsser, CRC Press, pp. 155 168, 1990, which is incorporated herein by reference in its entirety). Typical AAV2-derived ITR sequences are about 145 nucleotides in length. In some embodiments, at least 80% of a typical ITR sequence (e.g., at least 85%, at least 90%, or at least 95%) is incorporated into a construct provided herein. The ability to modify these ITR sequences is within the skill of the art. (See, e.g., texts such as Sambrook et al., “Molecular Cloning. A Laboratory Manual”, 2d ed., Cold Spring Harbor Laboratory, New York, 1989; and K. Fisher et al., J Virol. 70:520 532, 1996, each of which is incorporated in its entirety by reference). In some embodiments, any of the coding sequences and/or constructs described herein are flanked by 5′ and 3′ AAV ITR sequences. The AAV ITR sequences may be obtained from any known AAV, including presently identified AAV types.
In some embodiments, polynucleotide constructs described in accordance with this disclosure and in a pattern known to the art (see, e.g., Asokan et al., Mol. Ther. 20: 699-7080, 2012, which is incorporated herein by reference in its entirety) are typically comprised of, a coding sequence or a portion thereof, at least one and/or control sequence, and optionally 5′ and 3′ AAV inverted terminal repeats (ITRs). In some embodiments, provided constructs can be packaged into a capsid to create an AAV particle. An AAV particle may be delivered to a selected target cell. In some embodiments, provided constructs comprise an additional optional coding sequence that is a nucleic acid sequence (e.g., inhibitory nucleic acid sequence), heterologous to the construct sequences, which encodes a polypeptide, protein, functional RNA molecule (e.g., miRNA, miRNA inhibitor) or other gene product, of interest. In some embodiments, a nucleic acid coding sequence is operatively linked to and/or control components in a manner that permits coding sequence transcription, translation, and/or expression in a cell of a target tissue.
As shown in
In some aspects, an rAAV construct comprises a 5′ ITR, a promoter, a hGJB2 gene, a polyA, and a 3′ ITR (shown in
In some embodiments, a construct is a rAAV construct. In some embodiments, an rAAV construct can include at least 500 bp, at least 1 kb, at least 1.5 kb, at least 2 kb, at least 2.5 kb, at least 3 kb, at least 3.5 kb, at least 4 kb, or at least 4.5 kb. In some embodiments, an AAV construct can include at most 7.5 kb, at most 7 kb, at most 6.5 kb, at most 6 kb, at most 5.5 kb, at most 5 kb, at most 4.5 kb, at most 4 kb, at most 3.5 kb, at most 3 kb, or at most 2.5 kb. In some embodiments, an AAV construct can include about 1 kb to about 2 kb, about 1 kb to about 3 kb, about 1 kb to about 4 kb, about 1 kb to about 5 kb, about 2 kb to about 3 kb, about 2 kb to about 4 kb, about 2 kb to about 5 kb, about 3 kb to about 4 kb, about 3 kb to about 5 kb, or about 4 kb to about 5 kb.
Any of the constructs described herein can further include regulatory and/or control sequences, e.g., a control sequence selected from the group of a transcription initiation sequence, a transcription termination sequence, a promoter sequence, an enhancer sequence, an RNA splicing sequence, a polyadenylation (poly(A)) sequence, a Kozak consensus sequence, and/or any combination thereof. In some embodiments, a promoter can be a native promoter, a constitutive promoter, an inducible promoter, and/or a tissue-specific promoter. Non-limiting examples of control sequences are described herein.
Inverted Terminal Repeat Sequences (ITRs)
AAV derived sequences of a construct typically comprises the cis-acting 5′ and 3′ ITRs (See, e.g., B. J. Carter, in “Handbook of Parvoviruses”, ed., P. Tijsser, CRC Press, pp. 155 168 (1990), which is incorporated in its entirety herein by reference). Generally, ITRs are able to form a hairpin. The ability to form a hairpin can contribute to an ITRs ability to self-prime, allowing primase-independent synthesis of a second DNA strand. ITRs also play a role in integration of AAV construct (e.g., a coding sequence, e.g., a GJB2 gene) into a genome of a subject's cell. ITRs can also aid in efficient encapsidation of an AAV construct in an AAV particle.
An rAAV particle (e.g., an AAV2/Anc80 particle) of the present disclosure can comprise a rAAV construct comprising a coding sequence (e.g., GJB2 gene) and associated elements flanked by a 5′ and a 3′ AAV ITR sequences. In some embodiments, an ITR is or comprises about 145 nucleic acids. In some aspects, an ITR is or comprises about 119 nucleic acids. In some aspects, an ITR is or comprises about 130 nucleic acids. In some embodiments, all or substantially all of a sequence encoding an ITR is used. An AAV ITR sequence may be obtained from any known AAV, including presently identified mammalian AAV types. In some embodiments an ITR is an AAV2 ITR.
An example of a construct molecule employed in the present disclosure is a “cis-acting” construct containing a transgene, in which the selected transgene sequence and associated regulatory elements are flanked by 5′ or “left” and 3′ or “right” AAV ITR sequences. 5′ and left designations refer to a position of an ITR sequence relative to an entire construct, read left to right, in a sense direction. For example, in some embodiments, a 5′ or left ITR is an ITR that is closest to a promoter (as opposed to a polyadenylation sequence) for a given construct, when a construct is depicted in a sense orientation, linearly. Concurrently, 3′ and right designations refer to a position of an ITR sequence relative to an entire construct, read left to right, in a sense direction. For example, in some embodiments, a 3′ or right ITR is an ITR that is closest to a polyadenylation sequence (as opposed to a promoter sequence) for a given construct, when a construct is depicted in a sense orientation, linearly. ITRs as provided herein are depicted in 5′ to 3′ order in accordance with a sense strand. Accordingly, one of skill in the art will appreciate that a 5′ or “left” orientation ITR can also be depicted as a 3′ or “right” ITR when converting from sense to antisense direction. Further, it is well within the ability of one of skill in the art to transform a given sense ITR sequence (e.g., a 5′/left AAV ITR) into an antisense sequence (e.g., 3′/right ITR sequence). One of ordinary skill in the art would understand how to modify a given ITR sequence for use as either a 5′/left or 3′/right ITR, or an antisense version thereof.
For example, in some embodiments an ITR (e.g., a 5′ ITR) can have a sequence according to SEQ ID NO: 8. In some embodiments, an ITR (e.g., a 3′ ITR) can have a sequence according to SEQ ID NO: 9. In some embodiments, an ITR includes one or more modifications, e.g., truncations, deletions, substitutions or insertions, as is known in the art. In some embodiments, an ITR comprises fewer than 145 nucleotides, e.g., 127, 130, 134 or 141 nucleotides. For example, in some embodiments, an ITR comprises 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143 144, or 145 nucleotides. In some aspects, the ITR comprises about 119 nucleotides. In some aspects, the ITR comprises about 130 nucleotides. In some embodiments an ITR (e.g., a 5′ ITR) can have a sequence according to SEQ ID NO: 52. In some embodiments, an ITR (e.g., a 3′ ITR) can have a sequence according to SEQ ID NO: 53.
A non-limiting example of 5′ AAV ITR sequences includes SEQ ID NO: 8 or 52. A non-limiting example of 3′ AAV ITR sequences includes SEQ ID NO: 9 or 53. In some embodiments, the 5′ and a 3′ AAV ITRs (e.g., SEQ ID NOs: 8 and 9, or SEQ ID NOs: 52 and 53) flank a portion of a coding sequence, e.g., all or a portion of a GJB2 gene (e.g., SEQ ID NO: 1, 2, 3, 4, 5, or 6). The ability to modify these ITR sequences is within the skill of the art. (See, e.g., texts such as Sambrook et al. “Molecular Cloning. A Laboratory Manual”, 2d ed., Cold Spring Harbor Laboratory, New York (1989); and K. Fisher et al., J Virol., 70:520 532 (1996), each of which is incorporated in its entirety herein by reference). In some embodiments, a 5′ ITR sequence is at least 85%, 90%, 95%, 98% or 99% identical to a 5′ ITR sequence represented by SEQ ID NO: 8. In some embodiments, a 3′ ITR sequence is at least 85%, 90%, 95%, 98% or 99% identical to a 3′ ITR sequence represented by SEQ ID NO: 9. In some embodiments, a 5′ ITR sequence is at least 85%, 90%, 95%, 98% or 99% identical to a 5′ ITR sequence represented by SEQ ID NO: 52. In some embodiments, a 3′ ITR sequence is at least 85%, 90%, 95%, 98% or 99% identical to a 3′ ITR sequence represented by SEQ ID NO: 53.
Promoters
In some aspects, the disclosure is directed to constructs comprising a cell selective promoter which can be used to regulate (e.g., increase) expression of connexin 26 protein in a cell (e.g., an inner ear cell, e.g., a supporting cell). In some aspects, the constructs provide reduced toxicity that may be associated with expression of connexin 26 in some cells (e.g., an inner ear cell, e.g., a hair cell).
In some embodiments, a construct (e.g., an rAAV construct) comprises a promoter. The term “promoter” refers to a DNA sequence recognized by enzymes/proteins that can promote and/or initiate transcription of an operably linked gene (e.g., a GJB2 gene). For example, a promoter typically refers to, e.g., a nucleotide sequence to which an RNA polymerase and/or any associated factor binds and from which it can initiate transcription. Thus, in some embodiments, a construct (e.g., an rAAV construct) comprises a promoter operably linked to one of the non-limiting example promoters described herein.
In some embodiments, a promoter is an inducible promoter, a constitutive promoter, a mammalian cell promoter, a viral promoter, a chimeric promoter, an engineered promoter, a tissue-specific promoter, or any other type of promoter known in the art. In some embodiments, a promoter is a RNA polymerase II promoter, such as a mammalian RNA polymerase II promoter. In some embodiments, a promoter is a RNA polymerase III promoter, including, but not limited to, a HI promoter, a human U6 promoter, a mouse U6 promoter, or a swine U6 promoter. A promoter will generally be one that is able to promote transcription in an inner ear cell. In some embodiments, a promoter is a cochlea-specific promoter or a cochlea-oriented promoter. In some embodiments, a promoter is a hair cell specific promoter, or a supporting cell specific promoter.
A variety of promoters are known in the art, which can be used herein. Non-limiting examples of promoters that can be used herein include: human EF1α, human cytomegalovirus (CMV) (U.S. Pat. No. 5,168,062, which is incorporated in its entirety herein by reference), human ubiquitin C (UBC), mouse phosphoglycerate kinase 1, polyoma adenovirus, simian virus 40 (SV40), β-globin, β-actin, α-fetoprotein, γ-globin, β-interferon, γ-glutamyl transferase, mouse mammary tumor virus (MMTV), Rous sarcoma virus, rat insulin, glyceraldehyde-3-phosphate dehydrogenase, metallothionein II (MT II), amylase, cathepsin, MI muscarinic receptor, retroviral LTR (e.g., human T-cell leukemia virus HTLV), AAV ITR, interleukin-2, collagenase, platelet-derived growth factor, adenovirus 5 E2, stromelysin, murine MX gene, glucose regulated proteins (GRP78 and GRP94), α-2-macroglobulin, vimentin, MHC class I gene H-2K b, HSP70, proliferin, tumor necrosis factor, thyroid stimulating hormone a gene, immunoglobulin light chain, T-cell receptor, HLA DQa and DQ, interleukin-2 receptor, MHC class II, MHC class II HLA-DRa, muscle creatine kinase, prealbumin (transthyretin), elastase I, albumin gene, c-fos, c-HA-ras, neural cell adhesion molecule (NCAM), H2B (TH2B) histone, rat growth hormone, human serum amyloid (SAA), troponin I (TN I), duchenne muscular dystrophy, human immunodeficiency virus, ATOH1, GJB2, SLC26A4, LGR5, SYN1, GFAP, GDF6, IGFBP2, RBP7, GJB6, PARM1, and Gibbon Ape Leukemia Virus (GALV) promoters. Additional examples of promoters are known in the art. See, e.g., Lodish, Molecular Cell Biology, Freeman and Company, New York 2007, each of which is incorporated in its entirety herein by reference. In some embodiments, a promoter is the CMV immediate early promoter. In some embodiments, the promoter is a CBA promoter. In some embodiments, the promoter is a CAG promoter or a CAG/CBA promoter. In some embodiments, the promoter comprises or consists of SEQ ID NO: 10. In some embodiments, a promoter comprises or consists of SEQ ID NO: 11. In certain embodiments, a promoter comprises a CMV/CBA enhancer/promoter construct exemplified in SEQ ID NO: 12. In certain embodiments, a promoter comprises a CMV/CBA enhancer/promoter construct exemplified in SEQ ID NO: 13. In certain embodiments, a promoter comprises a CAG promoter or CMV/CBA/SV-40 enhancer/promoter construct exemplified in SEQ ID NO: 14. In certain embodiments, a promoter comprises a CAG promoter or CMV/CBA/SV-40 enhancer/promoter construct exemplified in SEQ ID NO: 15. In some aspects, a promoter comprises a ATOH1 enhance/promoter construct of SEQ ID NO: 16. In some aspects, a promoter comprises a GJB2 enhance/promoter construct of SEQ ID NO: 17. In some aspects, a promoter comprises a GJB2 enhance/promoter construct of SEQ ID NO: 61. In some aspects, a promoter is an endogenous human SLC26A4 enhancer-promoter sequence comprised within SEQ ID NO: 54. In some aspects, a promoter is an endogenous human LGR5 enhancer-promoter sequence comprised within SEQ ID NO: 55. In some aspects, a promoter is an endogenous human SYN1 enhancer-promoter sequence comprised within SEQ ID NO: 56. In some aspects, a promoter is an endogenous human GFAP enhancer-promoter sequence comprised within SEQ ID NO: 57 or SEQ ID NO: 62. In some aspects, a promoter is an endogenous human IGFBP2 enhancer-promoter sequence comprised within SEQ ID NO: 95. In certain aspects, a promoter is an endogenous human RBP7 promoter as set forth in SEQ ID NO: 98. In certain aspects, a promoter is an endogenous human GJB6 promoter as set forth in SEQ ID NO: 101. In certain aspects, a promoter is an endogenous human PARM1 promoter as set forth in SEQ ID NO: 104
In some aspects, the promoter comprises a GJB6 and a hGJB2 minimal promoter. In some aspects, the GJB6 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 91 and the hGJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% to SEQ ID NO: 91. In some aspects, the GJB6 has the nucleic acid sequence of SEQ ID NO: 91 and the hGJB2 minimal promoter has the nucleic acid sequence of SEQ ID NO: 91.
In some aspects, the promoter comprises a IGFBP2 promoter and a hGJB2 minimal promoter. In some aspects, the IGFBP2 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 95 and the hGJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% to SEQ ID NO: 91. In some aspects, the IGFBP2 has the nucleic acid sequence of SEQ ID NO: 95 and the hGJB2 minimal promoter has the nucleic acid sequence of SEQ ID NO: 91.
In some aspects, the promoter comprises a RBP7 promoter and a hGJB2 minimal promoter. In some aspects, the RBP7 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 98 and the hGJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90/a, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% to SEQ ID NO: 91. In some aspects, the RBP7 has the nucleic acid sequence of SEQ ID NO: 98 and the hGJB2 minimal promoter has the nucleic acid sequence of SEQ ID NO: 91.
In some aspects, the promoter comprises a GJB6 promoter and a hGJB2 minimal promoter. In some aspects, the GJB6 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 101 and the hGJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% to SEQ ID NO: 91. In some aspects, the GJB6 has the nucleic acid sequence of SEQ ID NO: 101 and the hGJB2 minimal promoter has the nucleic acid sequence of SEQ ID NO: 91.
In some aspects, the promoter comprises a PARM1 promoter and a hGJB2 minimal promoter. In some aspects, the PARM1 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 104 and the hGJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% to SEQ ID NO: 91. In some aspects, the PARM1 has the nucleic acid sequence of SEQ ID NO: 104 and the hGJB2 minimal promoter has the nucleic acid sequence of SEQ ID NO: 91.
In some embodiments, a promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to the promoter sequences represented by SEQ ID NO: 10. In some aspects, a promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to the promoter sequences represented by SEQ ID NO: 11. In some aspects, a promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to the promoter sequences represented by SEQ ID NO: 91. In some aspects, a promoter is an endogenous human GDF6 promoter sequence comprised within SEQ ID NO: 90. In some aspects, an promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to a promoter sequence represented by SEQ ID NO: 95. In some aspects, an promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to a promoter sequence represented by SEQ ID NO: 98. In some aspects, an promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to promoter sequence represented by SEQ ID NO: 101. In some aspects, a promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to promoter sequence represented by SEQ ID NO: 104.
In some aspects, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 12. In some aspects, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 13. In some aspects, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 14. In some aspects, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 15. In some aspects, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 16. In some aspects, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 17. In some aspects, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 61. In some aspects, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 54. In some aspects, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 55. In some aspects, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 56. In some aspects, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 57 or SEQ ID NO: 62. In some aspects, an promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 90.
The term “constitutive” promoter refers to a nucleotide sequence that, when operably linked with a nucleic acid encoding a protein (e.g., a connexin 26 protein), causes RNA to be transcribed from the nucleic acid in a cell under most or all physiological conditions.
Examples of constitutive promoters include, without limitation, the retroviral Rous sarcoma virus (RSV) LTR promoter, the cytomegalovirus (CMV) promoter (see, e.g., Boshart et al., Cell 41:521-530, 1985, which is incorporated in its entirety herein by reference), the SV40 promoter, the dihydrofolate reductase promoter, the beta-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EFl-alpha promoter (Invitrogen). In some aspects, the promoter is a constitutive promoter. In some aspects, the constitutive promoter is a CAG promoter, a CBA promoter, a CMV promoter, a CMV/CBA enhancer/promoter, or a CB7 promoter. In some aspects, the a CMV/CBA enhancer/promoter comprises a nucleic acid with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NOs: 12 or 13. In some aspects, the a CMV/CBA enhancer/promoter comprises a nucleic acid of SEQ ID NO: 12. In some aspects, the a CMV/CBA enhancer/promoter comprises a nucleic acid of SEQ ID NO: 13. In some aspects, the CBA promoter comprises a nucleic acid with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NOs: 10 or 11. In some aspects, the CBA promoter comprises a nucleic acid of SEQ ID NO: 10. In some aspects, the CBA promoter comprises a nucleic acid of SEQ ID NO: 11.
In some aspects, the CMV promoter comprises a nucleic acid with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NOs: 14 or 15. In some aspects, the CMV promoter comprises a nucleic acid of SEQ ID NO: 14. In some aspects, the CMV promoter comprises a nucleic acid of SEQ ID NO: 15.
Inducible promoters allow regulation of gene expression and can be regulated by exogenously supplied compounds, environmental factors such as temperature, or the presence of a specific physiological state, e.g., acute phase, a particular differentiation state of the cell, or in replicating cells only. Inducible promoters and inducible systems are available from a variety of commercial sources, including, without limitation, Invitrogen, Clontech, and Ariad. Additional examples of inducible promoters are known in the art.
Examples of inducible promoters regulated by exogenously supplied compounds include the zinc-inducible sheep metallothionein (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system (WO 98/10088, which is incorporated in its entirety herein by reference); the ecdysone insect promoter (No et al., Proc. Natl. Acad Sci. US.A. 93:3346-3351, 1996, which is incorporated in its entirety herein by reference), the tetracycline-repressible system (Gossen et al., Proc. Natl. Acad Sci. US.A. 89:5547-5551, 1992, which is incorporated in its entirety herein by reference), the tetracycline-inducible system (Gossen et al., Science 268:1766-1769, 1995, see also Harvey et al., Curr. Opin. Chem. Biol. 2:512-518, 1998, each of which is incorporated in their entirety herein by reference), the RU486-inducible system (Wang et al., Nat. Biotech. 15:239-243, 1997, and Wang et al., Gene Ther. 4:432-441, 1997, each of which is incorporated in their entirety herein by reference), and the rapamycin-inducible system (Magari et al., J Clin. Invest. 100:2865-2872, 1997, which is incorporated in its entirety herein by reference).
The term “tissue-specific” promoter refers to a promoter that is active only in certain specific cell types and/or tissues (e.g., transcription of a specific gene occurs only within cells expressing transcription regulatory and/or control proteins that bind to the tissue-specific promoter).
In some embodiments, regulatory and/or control sequences impart tissue-specific gene expression capabilities. In some cases, tissue-specific regulatory and/or control sequences bind tissue-specific transcription factors that induce transcription in a tissue-specific manner.
In some embodiments, a tissue-specific promoter is a cochlea-specific promoter. In some embodiments, a tissue-specific promoter is a cochlear hair cell-specific promoter. Non-limiting examples of cochlear hair cell-specific promoters include but are not limited to: a ATOH1 promoter, a POU4F3 promoter, a LHX3 promoter, a MYO7A promoter, a MYO6 promoter, a a9ACHR promoter, and a a10ACHR promoter. In some embodiments, a promoter is a cochlear hair cell-specific promoter such as a PRESTIN promoter or an ONCOMOD promoter. See, e.g., Zheng et al., Nature 405:149-155, 2000; Tian et al., Dev. Dyn. 23 1: 199-203, 2004; and Ryan et al., Adv. Otorhinolaryngol. 66: 99-115, 2009, each of which is incorporated in their entirety herein by reference.
In some embodiments, a tissue-specific promoter is an ear cell specific promoter. In some embodiments, a tissue-specific promoter is an inner ear cell specific promoter. In some embodiments, a promoter is a characteristic fragment of a tissue-specific promoter. Non-limiting examples of inner ear non-sensory cell-specific promoters include but are not limited to: GJB2, GJB6, SLC26A4, TECTA, DFNA5, COCH, NDP, SYN1, GFAP, PLP, TAK1, IGFBP2, RBP7, GDF6, PARM1, or SOX21. In some embodiments, a cochlear non-sensory cell specific promoter may be an inner ear supporting cell specific promoter. Non-limiting examples of inner ear supporting cell specific promoters include but are not limited to: SOX2, FGFR3, PROX1, GLAST1, LGR5, HES1, HES5, NOTCH1, JAG1, CDKN1A, CDKN1B, SOX10, P75, CD44, HEY2, LFNG, or S100b.
In some aspects, a cell selective promoter is an ear cell selective promoter. In some aspects, a cell selective promoter is an inner ear cell selective promoter. In some aspects, a promoter is a characteristic fragment of a cell selective promoter. In some aspects, the promoter is a supporting cell selective promoter. In some aspects, the promoter is an inner ear supporting cell selective promoter.
In some aspects, the promoter is a supporting cell selective promoter. In some aspects, the promoter is a hair cell selective promoter. In some aspects, the supporting cells are selected from one or more of inner phalangeal cells/border cells (IPhC), inner pillar cells (IPC), outer pillar cells (OPC), Deiters' cells rows 1 and 2 (DC1/2), Deiters' cells row 3 (DC3), Hensen's cells (Hec), Claudius cells/outer sulcus cells (CC/OSC), interdental cells (Idc), inner sulcus cells (ISC), Kolliker's organ cells (KO), Lateral greater epithelial ridge cells (LGER), and OC90+ cells (OC90).
In some aspects, supporting cell selective promoters are selected from one or more of GJB6, GDF6, PARM1, RBP7, and IGFBP2.
In some aspects, the promoter is an inner ear medial support cell selective promoter. In some aspects, inner ear medial support cells are selected from one or more of lateral greater epithelial ridge cells and inner sulcus cells. In some aspects, inner ear medial support cell selective promoters are selected from one or more of GJB6, IGFBP2, GDF6, PARM1, and GFAP. In some aspects, the promoter is an inner ear sensory epithelial support cell selective promoter. In some aspects, sensory epithelial support cells are selected from one or more of inner pillar cells, outer pillar cells, dieter cells, and inner phalangeal cells. In some aspects, inner ear sensory epithelial support cell selective promoters are selected from one or more of GJB6, IGFBP2, RBP7, GDF6, PARM1, and GFAP.
In some aspects, the inner ear supporting cell selective promoter is a GJB2 promoter. In some aspects, the GJB2 enhance/promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 17. In some aspects, the GJB2 enhance/promoter comprises the nucleic acid sequence of SEQ ID NO: 17. In some aspects, the GJB2 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 61. In some aspects, the GJB2 promoter comprises the nucleic acid sequence of SEQ ID NO: 61. In some aspects, the GJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 91. In some aspects, the GJB2 minimal promoter comprises the nucleic acid sequence of SEQ ID NO: 91.
In some aspects, the inner ear supporting cell selective promoter is a GJB6 promoter. In some aspects, the GJB6 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 101. In some aspects, the GJB6 promoter comprises the nucleic acid sequence of SEQ ID NO: 101.
In some aspects, the inner ear supporting cell selective promoter is a SLC26A4 promoter. In some aspects, the SLC26A4 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 54. In some aspects, the SLC26A4 promoter comprises the nucleic acid sequence of SEQ ID NO: 54.
In some aspects, the inner ear supporting cell selective promoter is a GFAP promoter. In some aspects, the GFAP promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 57. In some aspects, the GFAP promoter comprises the nucleic acid sequence of SEQ ID NO: 57. In some aspects, the GFAP promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 62. In some aspects, the GFAP promoter comprises the nucleic acid sequence of SEQ ID NO: 62.
In some aspects, the inner ear supporting cell selective promoter is a IGFBP2 promoter. In some aspects, the IGFBP2 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 95. In some aspects, the IGFBP2 promoter comprises the nucleic acid sequence of SEQ ID NO: 95.
In some aspects, the inner ear supporting cell selective promoter is a RBP7 promoter. In some aspects, the RBP7 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 98. In some aspects, the RBP7 promoter comprises the nucleic acid sequence of SEQ ID NO: 98.
In some aspects, the inner ear supporting cell selective promoter is a GDF6 promoter. In some aspects, the GDF6 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 90. In some aspects, the GDF6 promoter comprises the nucleic acid sequence of SEQ ID NO: 90.
In some aspects, the inner ear supporting cell selective promoter is a PARM1 promoter. In some aspects, the PARM1 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 40. In some aspects, the PARM1 promoter comprises the nucleic acid sequence of SEQ ID NO: 40.
In some aspects, the inner ear supporting cell selective promoter is a LGR5 promoter. In some aspects, the LGR5 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 55. In some aspects, the LGR5 promoter comprises the nucleic acid sequence of SEQ ID NO: 55.
In some aspects, the inner ear supporting cell selective promoter is a ATOH1 promoter. In some aspects, the ATOH1 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 16. In some aspects, the ATOH1 promoter comprises the nucleic acid sequence of SEQ ID NO: 16.
In some aspects, the inner ear supporting cell selective promoter comprises a GJB6 and a hGJB2 minimal promoter. In some aspects, the GJB6 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 91 and the hGJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% to SEQ ID NO: 91. In some aspects, the GJB6 has the nucleic acid sequence of SEQ ID NO: 91 and the hGJB2 minimal promoter has the nucleic acid sequence of SEQ ID NO: 91.
In some aspects, the inner ear supporting cell selective promoter comprises a IGFBP2 promoter and a hGJB2 minimal promoter. In some aspects, the IGFBP2 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 95 and the hGJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% to SEQ ID NO: 91. In some aspects, the IGFBP2 has the nucleic acid sequence of SEQ ID NO: 95 and the hGJB2 minimal promoter has the nucleic acid sequence of SEQ ID NO: 91.
In some aspects, the inner ear supporting cell selective promoter comprises a RBP7 promoter and a hGJB2 minimal promoter. In some aspects, the RBP7 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 98 and the hGJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% to SEQ ID NO: 91. In some aspects, the RBP7 has the nucleic acid sequence of SEQ ID NO: 98 and the hGJB2 minimal promoter has the nucleic acid sequence of SEQ ID NO: 91.
In some aspects, the inner ear supporting cell selective promoter comprises a GJB6 promoter and a hGJB2 minimal promoter. In some aspects, the GJB6 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 101 and the hGJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% to SEQ ID NO: 91. In some aspects, the GJB6 has the nucleic acid sequence of SEQ ID NO: 101 and the hGJB2 minimal promoter has the nucleic acid sequence of SEQ ID NO: 91.
In some aspects, the inner ear supporting cell selective promoter comprises a PARM1 promoter and a hGJB2 minimal promoter. In some aspects, the PARM1 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 104 and the hGJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% to SEQ ID NO: 91. In some aspects, the PARM1 has the nucleic acid sequence of SEQ ID NO: 104 and the hGJB2 minimal promoter has the nucleic acid sequence of SEQ ID NO: 91.
In some aspects, the inner ear supporting cell selective promoter comprises a GJB6 and a hGJB2 minimal promoter. In some aspects, the GJB6 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 91 and the hGJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% to SEQ ID NO: 91. In some aspects, the GJB6 has the nucleic acid sequence of SEQ ID NO: 91 and the hGJB2 minimal promoter has the nucleic acid sequence of SEQ ID NO: 91.
In some aspects, the inner ear supporting cell selective promoter comprises a IGFBP2 promoter and a hGJB2 minimal promoter. In some aspects, the IGFBP2 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 95 and the hGJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% to SEQ ID NO: 91. In some aspects, the IGFBP2 has the nucleic acid sequence of SEQ ID NO: 95 and the hGJB2 minimal promoter has the nucleic acid sequence of SEQ ID NO: 91.
In some aspects, the inner ear supporting cell selective promoter comprises a RBP7 promoter and a hGJB2 minimal promoter. In some aspects, the RBP7 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 98 and the hGJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% to SEQ ID NO: 91. In some aspects, the RBP7 has the nucleic acid sequence of SEQ ID NO: 98 and the hGJB2 minimal promoter has the nucleic acid sequence of SEQ ID NO: 91.
In some aspects, the inner ear supporting cell selective promoter comprises a GJB6 promoter and a hGJB2 minimal promoter. In some aspects, the GJB6 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 101 and the hGJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% to SEQ ID NO: 91. In some aspects, the GJB6 has the nucleic acid sequence of SEQ ID NO: 101 and the hGJB2 minimal promoter has the nucleic acid sequence of SEQ ID NO: 91.
In some aspects, the inner ear supporting cell selective promoter comprises a PARM1 promoter and a hGJB2 minimal promoter. In some aspects, the PARM1 promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 104 and the hGJB2 minimal promoter comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% to SEQ ID NO: 91. In some aspects, the PARM1 has the nucleic acid sequence of SEQ ID NO: 104 and the hGJB2 minimal promoter has the nucleic acid sequence of SEQ ID NO: 91.
In some embodiments, provided AAV constructs comprise a promoter sequence selected from a CAG, a CBA, a CMV, or a CB7 promoter. In some embodiments of any of the therapeutic compositions described herein, the first or sole AAV construct further includes at least one promoter sequence selected from Cochlea and/or inner ear specific promoters.
In certain embodiments, a promoter is an endogenous human ATOH1 enhancer-promoter as set forth in SEQ ID NO: 16. In some embodiments, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 16. In some embodiments, a promoter is an endogenous human ATOH1 enhancer-promoter sequence comprised within SEQ ID NO: 16.
In certain embodiments, a promoter is an endogenous human GJB2 enhancer-promoter as set forth in SEQ ID NO: 17, or SEQ ID NO: 61. In some embodiments, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 17 or SEQ ID NO: 61. In some embodiments, a promoter is an endogenous human GJB2 enhancer-promoter sequence comprised within SEQ ID NO: 61. In some aspects, a promoter is GJB2 minimal promoter of SEQ ID NO: 91. In some aspects, a promoter is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to SEQ ID NO: 91.
In certain embodiments, a promoter is an endogenous human SLC26A4 enhancer-promoter as set forth in SEQ ID NO: 54. In some embodiments, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 54. In some embodiments, a promoter is an endogenous human SLC26A4 enhancer-promoter sequence comprised within SEQ ID NO: 54.
In certain embodiments, a promoter is an endogenous human LGR5 enhancer-promoter as set forth in SEQ ID NO: 55. In some embodiments, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 55. In some embodiments, a promoter is an endogenous human LGR5 enhancer-promoter sequence comprised within SEQ ID NO: 55.
In certain embodiments, a promoter is an endogenous human SYN1 enhancer-promoter as set forth in SEQ ID NO: 56. In some embodiments, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 56. In some embodiments, a promoter is an endogenous human SYN1 enhancer-promoter sequence comprised within SEQ ID NO: 56.
In certain embodiments, a promoter is an endogenous human GFAP enhancer-promoter as set forth in SEQ ID NO: 57, or SEQ ID NO: 62. In some embodiments, an enhancer-promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to enhancer-promoter sequence represented by SEQ ID NO: 57 or SEQ ID NO: 62. In some embodiments, a promoter is an endogenous human GFAP enhancer-promoter sequence comprised within SEQ ID NO: 57 or SEQ ID NO: 62.
In certain aspects, a promoter is an endogenous human GDF6 promoter as set forth in SEQ ID NO: 90. In some aspects, an promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to a promoter sequence represented by SEQ ID NO: 90. In some aspects, a promoter is an endogenous human GDF6 promoter sequence comprised within SEQ ID NO: 90.
In certain aspects, a promoter is an endogenous human IGFBP2 promoter as set forth in SEQ ID NO: 95. In some aspects, an promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to a promoter sequence represented by SEQ ID NO: 95. In some aspects, a promoter is an endogenous human IGFBP2 enhancer-promoter sequence comprised within SEQ ID NO: 95.
In certain aspects, a promoter is an endogenous human RBP7 promoter as set forth in SEQ ID NO: 98. In some aspects, an promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to a promoter sequence represented by SEQ ID NO: 98. In some aspects, a promoter is an endogenous human RBP7 enhancer-promoter sequence comprised within SEQ ID NO: 98.
In certain aspects, a promoter is an endogenous human GJB6 promoter as set forth in SEQ ID NO: 101. In some aspects, an promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to promoter sequence represented by SEQ ID NO: 101. In some aspects, a promoter is an endogenous human GJB6 promoter sequence comprised within SEQ ID NO: 101.
In certain aspects, a promoter is an endogenous human PARM1 promoter as set forth in SEQ ID NO: 104. In some aspects, a promoter sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to promoter sequence represented by SEQ ID NO: 104. In some aspects, a promoter is an endogenous human PARM1 promoter sequence comprised within SEQ ID NO: 104.
Enhancers
In some instances, a construct can include an enhancer sequence. The term “enhancer” refers to a nucleotide sequence that can increase the level of transcription of a nucleic acid encoding a protein of interest (e.g., a connexin 26 protein). Enhancer sequences (generally 50-1500 bp in length) generally increase the level of transcription by providing additional binding sites for transcription-associated proteins (e.g., transcription factors). In some embodiments, an enhancer sequence is found within an intronic sequence. Unlike promoter sequences, enhancer sequences can act at much larger distance away from the transcription start site (e.g., as compared to a promoter). Non-limiting examples of enhancers include a RSV enhancer, a CMV enhancer, and/or a SV40 enhancer. In some embodiments, a construct comprises a CMV enhancer exemplified by SEQ ID NO: 18. In some embodiments, a construct comprises a CMV enhancer exemplified by SEQ ID NO: 63. In some embodiments, a construct comprises a chimeric intron enhancer exemplified by SEQ ID NO: 64. In some embodiments, a construct comprises a GJB2 enhancer exemplified by SEQ ID NO: 65. In some embodiments, an enhancer sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to the enhancer sequence represented by SEQ ID NO: 18. In some embodiments, an enhancer sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to the enhancer sequence represented by SEQ ID NO: 63. In some embodiments, an enhancer sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to the enhancer sequence represented by SEQ ID NO: 64. In some embodiments, an enhancer sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to the enhancer sequence represented by SEQ ID NO: 65. In some embodiments, an SV-40 derived enhancer is the SV-40 T intron sequence, which is exemplified by SEQ ID NO: 19. In some embodiments, an enhancer sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to the enhancer sequence represented by SEQ ID NO: 19.
Flanking Untranslated Regions, 5′ UTRs and 3′ UTRs
In some embodiments, any of the constructs described herein can include an untranslated region (UTR), such as a 5′ UTR or a 3′ UTR. UTRs of a gene are transcribed but not translated. A 5′ UTR starts at the transcription start site and continues to the start codon but does not include the start codon. A 3′ UTR starts immediately following the stop codon and continues until the transcriptional termination signal. The regulatory and/or control features of a UTR can be incorporated into any of the constructs, compositions, kits, or methods as described herein to enhance or otherwise modulate the expression of a connexin 26 protein.
Natural 5′ UTRs include a sequence that plays a role in translation initiation. in some embodiments, a 5′ UTR can comprise sequences, like Kozak sequences, which are commonly known to be involved in the process by which the ribosome initiates translation of many genes. Kozak sequences have the consensus sequence CCR(A/G)CCAUGG, where R is a purine (A or G) three bases upstream of the start codon (AUG), and the start codon is followed by another “G”. The 5′ UTRs have also been known to form secondary structures that are involved in elongation factor binding.
In some embodiments, a 5′ UTR is included in any of the constructs described herein. Non-limiting examples of 5′ UTRs, including those from the following genes: albumin, serum amyloid A, Apolipoprotein A/B/E, transferrin, alpha fetoprotein, erythropoietin, and Factor VIII, can be used to enhance expression of a nucleic acid molecule, such as an mRNA.
In some embodiments, a 5′ UTR from an mRNA that is transcribed by a cell in the cochlea can be included in any of the constructs, compositions, kits, and methods described herein. In some embodiments, a 5′ UTR is derived from the endogenous GJB2 gene loci and may include all or part of the endogenous sequence exemplified by SEQ ID NO: 20, SEQ ID NO: 21, or SEQ ID NO: 66. In some embodiments, a 5′ UTR sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to the 5′ UTR sequence represented by SEQ ID NO: 20, SEQ ID NO: 21, or SEQ ID NO: 66.
3′ UTRs are found immediately 3′ to the stop codon of the gene of interest. In some embodiments, a 3′ UTR from an mRNA that is transcribed by a cell in the cochlea can be included in any of the constructs, compositions, kits, and methods described herein. In some embodiments, a 3′ UTR is derived from the endogenous GJB2 gene loci and may include all or part of the endogenous sequence exemplified by SEQ ID NO: 22. In some embodiments, a 3′ UTR sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to the 3′ UTR sequence represented by SEQ ID NO: 22. In some embodiments, a 3′ UTR is derived from the endogenous GJB2 gene loci and may include all or part of the endogenous sequence exemplified by SEQ ID NO: 67, or SEQ ID NO: 68. In some embodiments, a 3′ UTR sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to the 3′ UTR sequence represented by SEQ ID NO: 67, or SEQ ID NO: 68.
In some embodiments, a UTR may comprise a non-endogenous regulatory region. In some embodiments, a UTR that comprises a non-endogenous regulatory region is a 3′ UTR. In some embodiments, a UTR that comprises a non-endogenous regulatory region is a 5′ UTR. In some embodiments, a non-endogenous regulatory region may be a target of at least one inhibitory nucleic acid. In some embodiments, an inhibitory nucleic acid inhibits expression and/or activity of a target gene. In some embodiments, an inhibitory nucleic acid is a short interfering RNA (siRNA), a short hairpin RNA (shRNA), a microRNA (miRNA), an antisense oligonucleotide, a guide RNA (gRNA), or a ribozyme. In some embodiments, an inhibitory nucleic acid is an endogenous molecule. In some embodiments, an inhibitory nucleic acid is a non-endogenous molecule. In some embodiments, an inhibitory nucleic acid displays a tissue specific expression pattern. In some embodiments, an inhibitory nucleic acid displays a cell specific expression pattern. In some embodiments, an inhibitory nucleic acid is expressed in inner ear hair cells (e.g., IHCs and/or OHCs). In some aspects, an inhibitory nucleic acid is expressed in inner ear hair cells, spiral ganglion cells, lateral supporting cells, basilar membrane cells, medial supporting cells, spiral limbus cells, inner sulcus cells, or any combination thereof. In some aspects, the inhibitory nucleic acid reduces, suppresses, inhibits, or eliminates expression of Connexin 26. In some aspects, the inhibitory nucleic acid reduces, suppresses, inhibits, or eliminates expression of Connexin 26 in inner ear hair cells, spiral ganglion cells, lateral supporting cells, basilar membrane cells, medial supporting cells, spiral limbus cells, inner sulcus cells, or any combination thereof.
In some aspects, the inhibitory nucleic acid reduces, suppresses, inhibits, or eliminates toxicity associated with the expression of Connexin 26. In some aspects, the inhibitory nucleic acid reduces, suppresses, inhibits, or eliminates toxicity associated with the expression of Connexin 26 in inner ear hair cells, spiral ganglion cells, lateral supporting cells, basilar membrane cells, medial supporting cells, spiral limbus cells, inner sulcus cells, or any combination thereof.
In some embodiments, a construct may comprise more than one non-endogenous regulatory regions, e.g., two, three, four, five, six, seven, eight, nine, or ten regulatory regions. In some embodiments, a construct may comprise four non-endogenous regulatory regions. In some embodiments, a construct may comprise more than one non-endogenous regulatory regions, wherein at least one of the more than one non-endogenous regulatory regions are not the same as at least one of the other non-endogenous regulatory regions.
In some aspects, the disclosure is directed to constructs comprising microRNA regulatory target site (miRTS) which can be used to regulate (e.g., reduce) expression of connexin 26 in a cell (e.g., an inner ear cell, e.g., a hair cell). In some aspects, the constructs provide reduced toxicity that may be associated with expression of connexin 26 in some cells (e.g., an inner ear cell, e.g., a hair cell).
In some embodiments, a non-endogenous regulatory region included in a UTR may comprise a miRNA regulatory target sites (miRTS). In some embodiments, a miRTS may be a human miRNA-182 target sequence. In some embodiments, a UTR may include all or part of the miRNA-182 target sequence. In some embodiments, a UTR may contain more than one miRNA-182 target sequence. In some embodiments, more than one miRNA-182 target sequences may be dispersed at multiple locations in a UTR. In some aspects, the 3′ UTR may include all or part of the miRNA-182 target sequence. In some aspects, the 3′ UTR may contain more than one miRNA-182 target sequence. In some aspects, more than one miRNA-182 target sequences may be dispersed at multiple locations in the 3′ UTR. In some aspects, the miRNA-182 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 78. In some aspects, the miRNA-182 target sequence comprises the nucleic acid sequence of SEQ ID NO: 78.
In some embodiments, a miRTS may be a human miRNA-183 target sequence. In some embodiments, a UTR may include all or part of the miRNA-183 target sequence. In some embodiments, a UTR may contain more than one miRNA-183 target sequence. In some embodiments, more than one miRNA-183 target sequences may be dispersed at multiple locations in a UTR. In some aspects, the 3′ UTR may include all or part of the miRNA-183 target sequence. In some aspects, the 3′ UTR may contain more than one miRNA-183 target sequence. In some aspects, more than one miRNA-183 target sequences may be dispersed at multiple locations in the 3′ UTR. In some aspects, the miRNA-183 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 79. In some aspects, the miRNA-183 target sequence comprises the nucleic acid sequence of SEQ ID NO: 79.
In some aspects, a miRTS may be a human miRNA-194 target sequence. In some aspects, a UTR may include all or part of the miRNA-194 target sequence. In some aspects, a UTR may contain more than one miRNA-194 target sequence. In some aspects, more than one miRNA-194 target sequences may be dispersed at multiple locations in a UTR. In some aspects, the 3′ UTR may include all or part of the miRNA-194 target sequence. In some aspects, the 3′ UTR may contain more than one miRNA-194 target sequence. In some aspects, more than one miRNA-194 target sequences may be dispersed at multiple locations in the 3′ UTR. In some aspects, the miRNA-194 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 107. In some aspects, the miRNA-194 target sequence comprises the nucleic acid sequence of SEQ ID NO: 107.
In some aspects, a miRTS may be a human miRNA-140 target sequence. In some aspects, a UTR may include all or part of the miRNA-140 target sequence. In some aspects, a UTR may contain more than one miRNA-140 target sequence. In some aspects, more than one miRNA-140 target sequences may be dispersed at multiple locations in a UTR. In some aspects, the 3′ UTR may include all or part of the miRNA-140 target sequence. In some aspects, the 3′ UTR may contain more than one miRNA-140 target sequence. In some aspects, more than one miRNA-140 target sequences may be dispersed at multiple locations in the 3′ UTR. In some aspects, the miRNA-140 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 108. In some aspects, the miRNA-140 target sequence comprises the nucleic acid sequence of SEQ ID NO: 108.
In some aspects, a miRTS may be a human miRNA-18a target sequence. In some aspects, a UTR may include all or part of the miRNA-18a target sequence. In some aspects, a UTR may contain more than one miRNA-18a target sequence. In some aspects, more than one miRNA-18a target sequences may be dispersed at multiple locations in a UTR. In some aspects, the 3′ UTR may include all or part of the miRNA-18a target sequence. In some aspects, the 3′ UTR may contain more than one miRNA-18a target sequence. In some aspects, more than one miRNA-18a target sequences may be dispersed at multiple locations in the 3′ UTR. In some aspects, the miRNA-18a target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 109. In some aspects, the miRNA-18a target sequence comprises the nucleic acid sequence of SEQ ID NO: 109.
In some aspects, a miRTS may be a human miRNA-99a target sequence. In some aspects, a UTR may include all or part of the miRNA-99a target sequence. In some aspects, a UTR may contain more than one miRNA-99a target sequence. In some aspects, more than one miRNA-99a target sequences may be dispersed at multiple locations in a UTR. In some aspects, the 3′ UTR may include all or part of the miRNA-99a target sequence. In some aspects, the 3′ UTR may contain more than one miRNA-99a target sequence. In some aspects, more than one miRNA-99a target sequences may be dispersed at multiple locations in the 3′ UTR. In some aspects, the miRNA-99a target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 110. In some aspects, the miRNA-99a target sequence comprises the nucleic acid sequence of SEQ ID NO: 110.
In some aspects, a miRTS may be a human miRNA-30b target sequence. In some aspects, a UTR may include all or part of the miRNA-30b target sequence. In some aspects, a UTR may contain more than one miRNA-30b target sequence. In some aspects, more than one miRNA-30b target sequences may be dispersed at multiple locations in a UTR. In some aspects, the 3′ UTR may include all or part of the miRNA-30b target sequence. In some aspects, the 3′ UTR may contain more than one miRNA-30b target sequence. In some aspects, more than one miRNA-30b target sequences may be dispersed at multiple locations in the 3′ UTR. In some aspects, the miRNA-30b target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 111. In some aspects, the miRNA-30b target sequence comprises the nucleic acid sequence of SEQ ID NO: 111.
In some aspects, a miRTS may be a human miRNA-15a target sequence. In some aspects, a UTR may include all or part of the miRNA-15a target sequence. In some aspects, a UTR may contain more than one miRNA-15a target sequence. In some aspects, more than one miRNA-15a target sequences may be dispersed at multiple locations in a UTR. In some aspects, the 3′ UTR may include all or part of the miRNA-15a target sequence. In some aspects, the 3′ UTR may contain more than one miRNA-15a target sequence. In some aspects, more than one miRNA-15a target sequences may be dispersed at multiple locations in the 3′ UTR. In some aspects, the miRNA-15a target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 112. In some aspects, the miRNA-15a target sequence comprises the nucleic acid sequence of SEQ ID NO: 112.
In some aspects, the miRTS may be a target sequence for a miRNA that is expressed in specific cells of the inner ear. In some aspects, the miRTS may be a target sequence for a miRNA that is expressed in ear hair cells, spiral ganglion cells, lateral supporting cells, basilar membrane cells, medial supporting cells, spiral limbus cells, inner sulcus cells, or any combination thereof.
In some aspects, the miRTS may be a target sequence for a miRNA that is expressed in ear hair cells. In some aspects, the miRNA that is expressed in ear hair cells reduces, decreases, or suppresses expression of the GJB2 protein (Connexin 26). In some aspects, miRNAs that are expressed in ear hair cells are miR-194, miR-140, miR-18a, miR-99a, miR-30b, miR-15a, miR182, or miR-183. In some aspects, the miRNA that is expressed in ear hair cells is miR-194. In some aspects, the miRNA-194 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 107. In some aspects, the miRNA-194 target sequence comprises the nucleic acid sequence of SEQ ID NO: 107. In some aspects, the miRNA that is expressed in ear hair cells is miR-140. In some aspects, the miRNA-140 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 108. In some aspects, the miRNA-140 target sequence comprises the nucleic acid sequence of SEQ ID NO: 108. In some aspects, the miRNA that is expressed in ear hair cells is miR-18a. In some aspects, the miRNA-18a target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 109. In some aspects, the miRNA-18a target sequence comprises the nucleic acid sequence of SEQ ID NO: 109. In some aspects, the miRNA that is expressed in ear hair cells is miR-99a. In some aspects, the miRNA-99a target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 110. In some aspects, the miRNA-99a target sequence comprises the nucleic acid sequence of SEQ ID NO: 110. In some aspects, the miRNA that is expressed in ear hair cells is miR-30b. In some aspects, the miRNA-30b target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 111. In some aspects, the miRNA-30b target sequence comprises the nucleic acid sequence of SEQ ID NO: 111. In some aspects, the miRNA that is expressed in ear hair cells is miR-15a. In some aspects, the miRNA-15a target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 112. In some aspects, the miRNA-15a target sequence comprises the nucleic acid sequence of SEQ ID NO: 112. In some aspects, the miRNA that is expressed in ear hair cells is miR-182. In some aspects, the miRNA-182 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 78. In some aspects, the miRNA-182 target sequence comprises the nucleic acid sequence of SEQ ID NO: 78. In some aspects, the miRNA that is expressed in ear hair cells is miR-183. In some aspects, the miRNA-183 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 79. In some aspects, the miRNA-183 target sequence comprises the nucleic acid sequence of SEQ ID NO: 79.
In some aspects, the miRTS may be a target sequence for a miRNA that is expressed in the spiral ganglion cells. In some aspects, the miRNA that is expressed in the spiral ganglion cells reduces, decreases, or suppresses expression of the GJB2 protein (Connexin 26). In some aspects, miRNAs that are expressed in the spiral ganglion cells are miR-194, miR-18a, miR-99a, miR-30b, miR-15a, miR182, or miR-183. In some aspects, the miRNA that is expressed in ear hair cells is miR-194. In some aspects, the miRNA-194 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 107. In some aspects, the miRNA-194 target sequence comprises the nucleic acid sequence of SEQ ID NO: 107. In some aspects, the miRNA that is expressed in ear hair cells is miR-18a. In some aspects, the miRNA-18a target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 109. In some aspects, the miRNA-18a target sequence comprises the nucleic acid sequence of SEQ ID NO: 109. In some aspects, the miRNA that is expressed in ear hair cells is miR-99a. In some aspects, the miRNA-99a target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 110. In some aspects, the miRNA-99a target sequence comprises the nucleic acid sequence of SEQ ID NO: 110. In some aspects, the miRNA that is expressed in ear hair cells is miR-30b. In some aspects, the miRNA-30b target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 111. In some aspects, the miRNA-30b target sequence comprises the nucleic acid sequence of SEQ ID NO: 111. In some aspects, the miRNA that is expressed in ear hair cells is miR-15a. In some aspects, the miRNA-15a target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 112. In some aspects, the miRNA-15a target sequence comprises the nucleic acid sequence of SEQ ID NO: 112. In some aspects, the miRNA that is expressed in ear hair cells is miR-182. In some aspects, the miRNA-182 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 78. In some aspects, the miRNA-182 target sequence comprises the nucleic acid sequence of SEQ ID NO: 78. In some aspects, the miRNA that is expressed in ear hair cells is miR-183. In some aspects, the miRNA-183 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 79. In some aspects, the miRNA-183 target sequence comprises the nucleic acid sequence of SEQ ID NO: 79.
In some aspects, the miRTS may be a target sequence for a miRNA that is expressed in basilar membrane cells. In some aspects, the miRNA that is expressed in the basilar membrane cells reduces, decreases, or suppresses expression of the GJB2 protein (Connexin 26). In some aspects, miRNAs that are expressed in basilar membrane cells are miR-99a, miR-30b, and miR-15a. In some aspects, the miRNA that is expressed in ear hair cells is miR-99a. In some aspects, the miRNA-99a target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 110. In some aspects, the miRNA-99a target sequence comprises the nucleic acid sequence of SEQ ID NO: 110. In some aspects, the miRNA that is expressed in ear hair cells is miR-30b. In some aspects, the miRNA-30b target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 111. In some aspects, the miRNA-30b target sequence comprises the nucleic acid sequence of SEQ ID NO: 111. In some aspects, the miRNA that is expressed in ear hair cells is miR-15a. In some aspects, the miRNA-15a target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 112. In some aspects, the miRNA-15a target sequence comprises the nucleic acid sequence of SEQ ID NO: 112.
In some aspects, the miRTS may be a target sequence for a miRNA that is expressed in lateral supporting cells. In some aspects, the miRNA that is expressed in lateral supporting cells reduces, decreases, or suppresses expression of the GJB2 protein (Connexin 26). In some aspects, miRNAs that are expressed in lateral supporting cells are miR-99a, miR-30b, and miR-15a. In some aspects, the miRNA that is expressed in ear hair cells is miR-99a. In some aspects, the miRNA-99a target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 110. In some aspects, the miRNA-99a target sequence comprises the nucleic acid sequence of SEQ ID NO: 110. In some aspects, the miRNA that is expressed in ear hair cells is miR-30b. In some aspects, the miRNA-30b target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 111. In some aspects, the miRNA-30b target sequence comprises the nucleic acid sequence of SEQ ID NO: 111. In some aspects, the miRNA that is expressed in ear hair cells is miR-15a. In some aspects, the miRNA-15a target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 112. In some aspects, the miRNA-15a target sequence comprises the nucleic acid sequence of SEQ ID NO: 112.
In some aspects, the miRTS may be a target sequence for a miRNA that is expressed in medial supporting cells. In some aspects, the miRNA that is expressed in medial supporting cells reduces, decreases, or suppresses expression of the GJB2 protein (Connexin 26). In some aspects, miRNAs that are expressed in medial supporting cells are miR182 and miR-183. In some aspects, the miRNA that is expressed in ear hair cells is miR-182. In some aspects, the miRNA-182 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 78. In some aspects, the miRNA-182 target sequence comprises the nucleic acid sequence of SEQ ID NO: 78. In some aspects, the miRNA that is expressed in ear hair cells is miR-183. In some aspects, the miRNA-183 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 79. In some aspects, the miRNA-183 target sequence comprises the nucleic acid sequence of SEQ ID NO: 79.
In some aspects, the miRTS may be a target sequence for a miRNA that is expressed in spiral limbus cells. In some aspects, the miRNA that is expressed in spiral limbus cells reduces, decreases, or suppresses expression of the GJB2 protein (Connexin 26). In some aspects, miRNAs that are expressed in spiral limbus cells are miR182 and miR-183. In some aspects, the miRNA that is expressed in ear hair cells is miR-182. In some aspects, the miRNA-182 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 78. In some aspects, the miRNA-182 target sequence comprises the nucleic acid sequence of SEQ ID NO: 78. In some aspects, the miRNA that is expressed in ear hair cells is miR-183. In some aspects, the miRNA-183 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 79. In some aspects, the miRNA-183 target sequence comprises the nucleic acid sequence of SEQ ID NO: 79.
In some aspects, the miRTS may be a target sequence for a miRNA that is expressed in inner sulcus cells. In some aspects, the miRNA that is expressed in inner sulcus cells reduces, decreases, or suppresses expression of the GJB2 protein (Connexin 26). In some aspects, miRNAs that are expressed in inner sulcus cells are miR182 and miR-183. In some aspects, the miRNA that is expressed in ear hair cells is miR-182. In some aspects, the miRNA-182 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 78. In some aspects, the miRNA-182 target sequence comprises the nucleic acid sequence of SEQ ID NO: 78. In some aspects, the miRNA that is expressed in ear hair cells is miR-183. In some aspects, the miRNA-183 target sequence comprises the nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 79. In some aspects, the miRNA-183 target sequence comprises the nucleic acid sequence of SEQ ID NO: 79.
In some embodiments, a non-endogenous regulatory region included in a UTR may comprise multiple miRNA regulatory target sites (miRTS). In some embodiments, a UTR may comprise at least one miRNA-182 target site and at least one miRNA-183 target site. In some embodiments, a non-endogenous regulatory region included in a UTR is a destabilizing domain, and is exemplified by SEQ ID NO: 80. In some embodiments, a UTR may include a sequence that is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to a non-endogenous regulatory region exemplified by SEQ ID NO: 80.
3′ UTRs are known to have stretches of adenosines and uridines (in the RNA form) or thymidines (in the DNA form) embedded in them. These AU-rich signatures are particularly prevalent in genes with high rates of turnover. Based on their sequence features and functional properties, the AU-rich elements (AREs) can be separated into three classes (Chen et al., Mol. Cell. Biol. 15:5777-5788, 1995; Chen et al., Mol. Cell Biol. 15:2010-2018, 1995, each of which is incorporated herein by reference in its entirety): Class I AREs contain several dispersed copies of an AUUUA motif within U-rich regions. For example, c-Myc and MyoD mRNAs contain class I AREs. Class II AREs possess two or more overlapping UUAUUUA(U/A) (U/A) nonamers. GM-CSF and TNF-alpha mRNAs are examples that contain class II AREs. Class III AREs are less well defined. These U-rich regions do not contain an AUUUA motif, two well-studied examples of this class are c-Jun and myogenin mRNAs.
Most proteins binding to the AREs are known to destabilize the messenger, whereas members of the ELAV family, most notably HuR, have been documented to increase the stability of mRNA. HuR binds to AREs of all the three classes. Engineering the HuR specific binding sites into the 3′ UTR of nucleic acid molecules will lead to HuR binding and thus, stabilization of the message in vivo.
In some embodiments, the introduction, removal, or modification of 3′ UTR AREs can be used to modulate the stability of an mRNA encoding a connexin 26 protein. In other embodiments, AREs can be removed or mutated to increase the intracellular stability and thus increase translation and production of a connexin 26 protein.
In other embodiments, non-ARE sequences may be incorporated into the 5′ or 3′ UTRs. In some embodiments, introns or portions of intron sequences may be incorporated into the flanking regions of the polynucleotides in any of the constructs, compositions, kits, and methods provided herein. Incorporation of intronic sequences may increase protein production as well as mRNA levels.
Internal Ribosome Entry Sites (IRES)
In some embodiments, a construct encoding a connexin 26 protein can include an internal ribosome entry site (IRES). An IRES forms a complex secondary structure that allows translation initiation to occur from any position with an mRNA immediately downstream from where the IRES is located (see, e.g., Pelletier and Sonenberg, Mol. Cell. Biol. 8(3):1103-1112, 1988).
There are several IRES sequences known to those in skilled in the art, including those from, e.g., foot and mouth disease virus (FMDV), encephalomyocarditis virus (EMCV), human rhinovirus (HRV), cricket paralysis virus, human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis C virus (HCV), and poliovirus (PV). See e.g., Alberts, Molecular Biology of the Cell, Garland Science, 2002; and Hellen et al., Genes Dev. 15(13):1593-612, 2001, each of which is incorporated in its entirety herein by reference.
In some embodiments, the IRES sequence that is incorporated into a construct that encodes a connexin 26 protein, or a C-terminal portion of a connexin 26 protein is the foot and mouth disease virus (FMDV) 2A sequence. The Foot and Mouth Disease Virus 2A sequence is a small peptide (approximately 18 amino acids in length) that has been shown to mediate the cleavage of polyproteins (Ryan, M D et al., EMBO 4:928-933, 1994; Mattion et al., J Virology 70:8124-8127, 1996; Furler et al., Gene Therapy 8:864-873, 2001; and Halpin et al., Plant Journal 4:453-459, 1999, each of which is incorporated in its entirety herein by reference). The cleavage activity of the 2A sequence has previously been demonstrated in artificial systems including plasmids and gene therapy constructs (AAV and retroviruses) (Ryan et al., EMBO 4:928-933, 1994; Mattion et al., J Virology 70:8124-8127, 1996; Furler et al., Gene Therapy 8:864-873, 2001; and Halpin et al., Plant Journal 4:453-459, 1999; de Felipe et al., Gene Therapy 6:198-208, 1999; de Felipe et al., Human Gene Therapy I I: 1921-1931, 2000; and Klump et al., Gene Therapy 8:811-817, 2001, each of which is incorporated in its entirety herein by reference).
An IRES can be utilized in an AAV construct. In some embodiments, a construct encoding the C-terminal portion of the connexin 26 protein can include a polynucleotide internal ribosome entry site (IRES). In some embodiments, an IRES can be part of a composition comprising more than one construct. In some embodiments, an IRES is used to produce more than one polypeptide from a single gene transcript.
Splice Sites
In some embodiments, any of the constructs provided herein can include splice donor and/or splice acceptor sequences, which are functional during RNA processing occurring during transcription. In some embodiments, splice sites are involved in trans-splicing.
Polyadenylation Sequences
In some embodiments, a construct provided herein can include a polyadenylation (poly(A)) signal sequence. Most nascent eukaryotic mRNAs possess a poly(A) tail at their 3′ end, which is added during a complex process that includes cleavage of the primary transcript and a coupled polyadenylation reaction driven by the poly(A) signal sequence (see, e.g., Proudfoot et al., Cell 108:501-512, 2002, which is incorporated herein by reference in its entirety). A poly(A) tail confers mRNA stability and transferability (Molecular Biology of the Cell, Third Edition by B. Alberts et al., Garland Publishing, 1994, which is incorporated herein by reference in its entirety). In some embodiments, a poly(A) signal sequence is positioned 3′ to the coding sequence.
As used herein, “polyadenylation” refers to the covalent linkage of a polyadenylyl moiety, or its modified variant, to a messenger RNA molecule. In eukaryotic organisms, most messenger RNA (mRNA) molecules are polyadenylated at the 3′ end. A 3′ poly(A) tail is a long sequence of adenine nucleotides (e.g., 50, 60, 70, 100, 200, 500, 1000, 2000, 3000, 4000, or 5000) added to the pre-mRNA through the action of an enzyme, polyadenylate polymerase. In some embodiments, a poly(A) tail is added onto transcripts that contain a specific sequence, e.g., a polyadenylation (or poly(A)) signal. A poly(A) tail and associated proteins aid in protecting mRNA from degradation by exonucleases. Polyadenylation also plays a role in transcription termination, export of the mRNA from the nucleus, and translation. Polyadenylation typically occurs in the nucleus immediately after transcription of DNA into RNA, but also can occur later in the cytoplasm. After transcription has been terminated, an mRNA chain is cleaved through the action of an endonuclease complex associated with RNA polymerase. A cleavage site is usually characterized by the presence of the base sequence AAUAAA near the cleavage site. After the mRNA has been cleaved, adenosine residues are added to the free 3′ end at the cleavage site.
As used herein, a “poly(A) signal sequence” or “polyadenylation signal sequence” is a sequence that triggers the endonuclease cleavage of an mRNA and the addition of a series of adenosines to the 3′ end of the cleaved mRNA.
There are several poly(A) signal sequences that can be used, including those derived from bovine growth hormone (bGH) (Woychik et al., Proc. Natl. Acad Sci. US.A. 81(13):3944-3948, 1984; U.S. Pat. No. 5,122,458, each of which is incorporated herein by reference in its entirety), mouse-β-globin, mouse-α-globin (Orkin et al., EMBO J 4(2):453-456, 1985; Thein et al., Blood 71(2):313-319, 1988, each of which is incorporated herein by reference in its entirety), human collagen, polyoma virus (Batt et al., Mol. Cell Biol. 15(9):4783-4790, 1995, which is incorporated herein by reference in its entirety), the Herpes simplex virus thymidine kinase gene (HSV TK), IgG heavy-chain gene polyadenylation signal (US 2006/0040354, which is incorporated herein by reference in its entirety), human growth hormone (hGH) (Szymanski et al., Mol. Therapy 15(7):1340-1347, 2007, which is incorporated herein by reference in its entirety), the group comprising a SV40 poly(A) site, such as the SV40 late and early poly(A) site (Schek et al., Mol. Cell Biol. 12(12):5386-5393, 1992, which is incorporated herein by reference in its entirety).
The poly(A) signal sequence can be AATAAA. The AATAAA sequence may be substituted with other hexanucleotide sequences with homology to AATAAA and that are capable of signaling polyadenylation, including ATTAAA, AGTAAA, CATAAA, TATAAA, GATAAA, ACTAAA, AATATA, AAGAAA, AATAAT, AAAAAA, AATGAA, AATCAA, AACAAA, AATCAA, AATAAC, AATAGA, AATTAA, or AATAAG (see, e.g., WO 06/12414, which is incorporated herein by reference in its entirety).
In some embodiments, a poly(A) signal sequence can be a synthetic polyadenylation site (see, e.g., the pCl-neo expression construct of Promega that is based on Levitt el al., Genes Dev. 3(7):1019-1025, 1989, which is incorporated herein by reference in its entirety). In some embodiments, a poly(A) signal sequence is the polyadenylation signal of soluble neuropilin-1 (sNRP) (AAATAAAATACGAAATG) (see, e.g., WO 05/073384, which is incorporated herein by reference in its entirety). In some embodiments, a poly(A) signal sequence comprises or consists of the SV40 poly(A) site. In some embodiments, a poly(A) signal comprises or consists of SEQ ID NO: 25. In some embodiments, a poly(A) signal sequence comprises or consists of bGHpA. In some embodiments, a poly(A) signal comprises or consists of SEQ ID NO: 26. Additional examples of poly(A) signal sequences are known in the art. In some embodiments, a poly(A) sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to the poly(A) sequence represented by SEQ ID NO: 25.
Additional Sequences
In some embodiments, constructs of the present disclosure may include one or more filler sequences. In some embodiments, filler sequences may function as regulatory elements, altering construct expression. In some such embodiments, filler sequences may not be fully removed prior to manufacturing for administration to a subject. In some embodiments, filler sequences may have functional roles including as linker sequences, as regulatory regions, or as stabilizing regions. As will be appreciated by those skilled in the art, filler sequences may vary significantly in primary sequence while retaining their desired function. In some embodiments, constructs may contain any combination of filler sequences, exemplary filler sequences which may function as regulatory sequences are represented by SEQ ID NO: 27, or 28.
In some embodiments, constructs of the present disclosure may comprise a T2A element or sequence. In some embodiments, constructs of the present disclosure may include one or more cloning sites. In some such embodiments, cloning sites may not be fully removed prior to manufacturing for administration to a subject. In some embodiments, cloning sites may have functional roles including as linker sequences, portions of a Kozak site, or as sites encoding a stop codon. As will be appreciated by those skilled in the art, cloning sites may vary significantly in primary sequence while retaining their desired function. In some embodiments, constructs may contain any combination of cloning sites, exemplary cloning sites are represented by SEQ ID NO: 29, 30, 31, 32, 33, 34, 35, 36, 37, or 92. In some embodiments, constructs may contain additional cloning sites less than five nucleotides in length.
In some embodiments, any of the constructs provided herein can optionally include a sequence encoding a destabilizing domain (“a destabilizing sequence”) for temporal control of protein expression. Non-limiting examples of destabilizing sequences include sequences encoding a FK506 sequence, a dihydrofolate reductase (DHFR) sequence, or other exemplary destabilizing sequences.
In the absence of a stabilizing ligand, a protein sequence operatively linked to a destabilizing sequence is degraded by ubiquitination. In contrast, in the presence of a stabilizing ligand, protein degradation is inhibited, thereby allowing the protein sequence operatively linked to the destabilizing sequence to be actively expressed. As a positive control for stabilization of protein expression, protein expression can be detected by conventional means, including enzymatic, radiographic, colorimetric, fluorescence, or other spectrographic assays; fluorescent activating cell sorting (FACS) assays; immunological assays (e.g., enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and immunohistochemistry).
Additional examples of destabilizing sequences are known in the art. In some embodiments, the destabilizing sequence is a FK506- and rapamycin-binding protein (FKBP12) sequence, and the stabilizing ligand is Shield-1 (Shld1) (Banaszynski et al., (2012) Cell 126(5): 995-1004, which is incorporated in its entirety herein by reference). In some embodiments, a destabilizing sequence is a DHFR sequence, and a stabilizing ligand is trimethoprim (TMP) (Iwamoto et al., (2010) Chem Biol 17:981-988, which is incorporated in its entirety herein by reference).
In some embodiments, a destabilizing sequence is a FKBP12 sequence, and a presence of an AAV construct carrying the FKBP12 gene in a subject cell (e.g., a supporting cochlear outer hair cell) is detected by western blotting. In some embodiments, a destabilizing sequence can be used to verify the temporally-specific activity of any of the AAV constructs described herein.
In some embodiments, a destabilizing domain may be a target site for an inhibitory nucleic acid. In some embodiments, a destabilizing domain is a non-endogenous sequence that has been introduced into a regulatory region of an RNA molecule. In some embodiments, a destabilizing domain may permit temporal and/or spatial control of an mRNA molecule. In some embodiments, a destabilizing domain may be a target of endogenously expressed inhibitory nucleic acid molecules. In some embodiments, a destabilizing domain may be an miRNA regulatory target site and/or sites (miRTS) as described herein. In some embodiments, a destabilizing domain is represented by SEQ ID NO: 78. In some embodiments, a destabilizing domain is represented by SEQ ID NO: 79. In some embodiments, a destabilizing domain is represented by SEQ ID NO: 80.
Reporter Sequences or Elements
In some embodiments, constructs provided herein can optionally include a sequence encoding a reporter polypeptide and/or protein (“a reporter sequence”). Non-limiting examples of reporter sequences include DNA sequences encoding: a beta-lactamase, a beta-galactosidase (LacZ), an alkaline phosphatase, a thymidine kinase, a green fluorescent protein (GFP), a red fluorescent protein, an mCherry fluorescent protein, a yellow fluorescent protein, a chloramphenicol acetyltransferase (CAT), and a luciferase. Additional examples of reporter sequences are known in the art. When associated with control elements which drive their expression, the reporter sequence can provide signals detectable by conventional means, including enzymatic, radiographic, colorimetric, fluorescence, or other spectrographic assays; fluorescent activating cell sorting (FACS) assays; immunological assays (e.g., enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and immunohistochemistry).
In some embodiments, a reporter sequence is the LacZ gene, and the presence of a construct carrying the LacZ gene in a mammalian cell (e.g., a cochlear hair cell) is detected by assays for beta-galactosidase activity. When the reporter is a fluorescent protein (e.g., green fluorescent protein) or luciferase, the presence of a construct carrying the fluorescent protein or luciferase in a mammalian cell (e.g., a cochlear hair cell) may be measured by fluorescent techniques (e.g., fluorescent microscopy or FACS) or light production in a luminometer (e.g., a spectrophotometer or an IVIS imaging instrument). In some embodiments, a reporter sequence can be used to verify the tissue-specific targeting capabilities and tissue-specific promoter regulatory and/or control activity of any of the constructs described herein.
In some embodiments, a reporter sequence is a FLAG tag (e.g., a 3×FLAG tag), and the presence of a construct carrying the FLAG tag in a mammalian cell (e.g., an inner ear cell, e.g., a cochlear hair or supporting cell) is detected by protein binding or detection assays (e.g., Western blots, immunohistochemistry, radioimmunoassay (RIA), mass spectrometry). An exemplary 3×FLAG tag sequence is provided as SEQ ID NO: 42.
AAV Capsids
The present disclosure provides one or more polynucleotide constructs packaged into an AAV capsid. In some embodiments, an AAV capsid is from or derived from an AAV capsid of an AAV2, 3, 4, 5, 6, 7, 8, 9, 10, rh8, rh10, rh39, rh43 or Anc80 serotype, or one or more hybrids thereof. In some embodiments, an AAV capsid is from an AAV ancestral serotype. In some embodiments, an AAV capsid is an ancestral (Anc) AAV capsid. An Anc capsid is created from a construct sequence that is constructed using evolutionary probabilities and evolutionary modeling to determine a probable ancestral sequence. Thus, an Anc capsid/construct sequence is not known to have existed in nature. For example, in some embodiments, an AAV capsid is an Anc80 capsid (e.g., an Anc80L65 capsid). In some embodiments, an AAV capsid is created using a template nucleotide coding sequence comprising SEQ ID NO: 43. In some embodiments, the capsid comprises a polypeptide represented by SEQ ID NO: 44. In some embodiments, the capsid comprises a polypeptide with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to the polypeptide represented by SEQ ID NO: 44.
As provided herein, any combination of AAV capsids and AAV constructs (e.g., comprising AAV ITRs) may be used in recombinant AAV (rAAV) particles of the present disclosure. For example, wild-type or variant AAV2 ITRs and Anc80 capsid, wild-type or variant AAV2 ITRs and AAV6 capsid, etc. In some embodiments of the present disclosure, an AAV particle is wholly comprised of AAV2 components (e.g., capsid and ITRs are AAV2 serotype). In some embodiments, an AAV particle is an AAV2/6, AAV2/8 or AAV2/9 particle (e.g., an AAV6, AAV8 or AAV9 capsid with an AAV construct having AAV2 ITRs). In some aspects, an AAV capsid is an Anc80 capsid (e.g., an Anc80L65 capsid). In some embodiments of the present disclosure, an AAV particle is an AAV2/Anc80 particle that comprises an Anc80 capsid (e.g., comprising a polypeptide of SEQ ID NO: 44) that encapsidates an AAV construct with AAV2 ITRs (e.g., SEQ ID NOs: 8 and 9) flanking a portion of a coding sequence, for example, a GJB2 gene or characteristic portion thereof (e.g., SEQ ID NO: 1, 2, 3, 4, 5, or 6). Other AAV particles are known in the art and are described in, e.g., Sharma et al., Brain Res Bull. 2010 Feb. 15; 81(2-3): 273, which is incorporated in its entirety herein by reference. In some embodiments, a capsid sequence is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identical to a capsid nucleotide or amino acid sequence represented by SEQ ID NO: 43 or 44, respectively.
Among other things, the present disclosure provides compositions. In some embodiments, a composition comprises a construct as described herein. In some embodiments, a composition comprises one or more constructs as described herein. In some embodiments, a composition comprises a plurality of constructs as described herein. In some embodiments, when more than one construct is included in the composition, the constructs are each different.
In some embodiments, a composition comprises an AAV particle as described herein. In some embodiments, a composition comprises one or more AAV particles as described herein. In some embodiments, a composition comprises a plurality of AAV particles. In come embodiments, when more than one AAV particle is included in the composition, the AAV particles are each different.
In some embodiments, a composition comprises connexin 26 protein. In some embodiments, a composition comprises a cell.
In some embodiments, a composition is or comprises a pharmaceutical composition.
Dosing and Volume of Administration
In some embodiments, a composition disclosed herein, e.g., one or a plurality of AAV vectors disclosed herein, is administered as a single dose or as a plurality of doses.
In some embodiments, a composition disclosed herein is administered as a single dose. In some embodiments, a composition disclosed herein is administered as a plurality of doses, e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses.
In some embodiments, a composition disclosed herein (e.g., a composition comprising one or a plurality of rAAV constructs disclosed herein) is administered at a volume of about 0.01 mL, about 0.02 mL, about 0.03 mL, about 0.04 mL, about 0.05 mL, about 0.06 mL, about 0.07 mL, about 0.08 mL, about 0.09 mL, about 1.00 mL, about 1.10 mL, about 1.20 mL, about 1.30 mL, about 1.40 mL, about 1.50 mL, about 1.60 mL, about 1.70 mL, about 1.80 mL, about 1.90 mL, or about 2.00 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 0.01 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 0.02 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 0.03 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 0.04 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 0.05 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 0.06 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 0.07 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 0.08 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 0.09 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 1.00 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 1.10 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 1.20 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 1.30 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 1.40 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 1.50 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 1.60 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 1.70 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 1.80 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 1.90 mL. In some embodiments, a composition disclosed herein is administered at a volume of about 2.00 mL.
In some embodiments, a composition disclosed herein (e.g., a composition comprising one or a plurality of rAAV constructs disclosed herein) is administered at a volume of about 0.01 to 2.00 mL, about 0.02 to 1.90 mL, about 0.03 to 1.8 mL, about 0.04 to 1.70 mL, about 0.05 to 1.60 mL, about 0.06 to 1.50 mL, about 0.06 to 1.40 mL, about 0.07 to 1.30 mL, about 0.08 to 1.20 mL, or about 0.09 to 1.10 mL. In some embodiments a composition disclosed herein (e.g., a composition comprising one or a plurality of rAAV constructs disclosed herein) is administered at a volume of about 0.01 to 2.00 mL, about 0.02 to 2.00 mL, about 0.03 to 2.00 mL, about 0.04 to 2.00 mL, about 0.05 to 2.00 mL, about 0.06 to 2.00 mL, about 0.07 to 2.00 mL, about 0.08 to 2.00 mL, about 0.09 to 2.00 mL, about 0.01 to 1.90 mL, about 0.01 to 1.80 mL, about 0.01 to 1.70 mL, about 0.01 to 1.60 mL, about 0.01 to 1.50 mL, about 0.01 to 1.40 mL, about 0.01 to 1.30 mL, about 0.01 to 1.20 mL, about 0.01 to 1.10 mL, about 0.01 to 1.00 mL, about 0.01 to 0.09 mL.
In some embodiments, a dosing regimen comprises delivery in a volume of at least 0.01 mL, at least 0.02 mL, at least 0.03 mL, at least 0.04 mL, at least 0.05 mL, at least 0.06 mL, at least 0.07 mL, at least 0.08 mL, at least 0.09 mL, at least 0.10 mL, at least 0.11 mL, at least 0.12 mL, at least 0.13 mL, at least 0.14 mL, at least 0.15 mL, at least 0.16 mL, at least 0.17 mL, at least 0.18 mL, at least 0.19 mL, or at least 0.20 mL per cochlea. In some embodiments, a dosing regimen comprises delivery in a volume of at most 0.30 mL, at most 0.25 mL, at most 0.20 mL, at most 0.15 mL, at most 0.14 mL, at most 0.13 mL, at most 0.12 mL, at most 0.11 mL, at most 0.10 mL, at most 0.09 mL, at most 0.08 mL, at most 0.07 mL, at most 0.06 mL, or at most 0.05 mL per cochlea. In some embodiments, the dosing regimen comprises delivery in a volume of about 0.05 mL, about 0.06 mL, about 0.07 mL, about 0.08 mL, about 0.09 mL, about 0.10 mL, about 0.11 mL, about 0.12 mL, about 0.13 mL, about 0.14 mL, or about 0.15 mL per cochlea, depending on the population.
Single A AV Construct Compositions
In some embodiments, the present disclosure provides compositions or systems comprising AAV particles comprised of a single construct. In some such embodiments, a single construct may deliver a polynucleotide that encodes a functional (e.g., wild-type or otherwise functional, e.g., codon optimized) copy of a GJB2 gene. In some embodiments, a construct is or comprises an rAAV construct. In some embodiments described herein, a single rAAV construct is capable of expressing a full-length GJB2 messenger RNA or a characteristic protein thereof in a target cell (e.g., an inner ear cell). In some embodiments, a single construct (e.g., any of the constructs described herein) can include a sequence encoding a functional connexin 26 protein (e.g., any construct that generates functional connexin 26 protein). In some embodiments, a single construct (e.g., any of the constructs described herein) can include a sequence encoding a functional connexin 26 protein (e.g., any construct that generates functional connexin 26 protein) and optionally additional polypeptide sequences (e.g., regulatory sequences, and/or reporter sequences).
In some embodiments, a single construct composition or system may comprise any or all of the exemplary construct components described herein. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 45. In some embodiments, an exemplary single construct is represented by SEQ ID NO: 45. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 46. In some embodiments, an exemplary single construct is represented by SEQ ID NO: 46. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 47. In some embodiments, an exemplary single construct is represented by SEQ ID NO: 47. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 48. In some embodiments, an exemplary single construct is represented by SEQ ID NO: 48. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 49. In some embodiments, an exemplary single construct is represented by SEQ ID NO: 49. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 50. In some embodiments, an exemplary single construct is represented by SEQ ID NO: 50. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 51. In some embodiments, an exemplary single construct is represented by SEQ ID NO: 51. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 82. In some embodiments, an exemplary single construct is represented by SEQ ID NO: 82. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 83. In some embodiments, an exemplary single construct is represented by SEQ ID NO: 83. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 84. In some embodiments, an exemplary single construct is represented by SEQ ID NO: 84. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 85. In some embodiments, an exemplary single construct is represented by SEQ ID NO: 85. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 86. In some embodiments, an exemplary single construct is represented by SEQ ID NO: 86. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 87. In some embodiments, an exemplary single construct is represented by SEQ ID NO: 87. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 88. In some embodiments, an exemplary single construct is represented by SEQ ID NO: 88. In some aspects, the construct comprises the nucleic acid sequence of SEQ ID NO: 94.
In some aspects, the construct comprises the nucleic acid sequence of SEQ ID NO: 97. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 97. In some aspects, the construct comprises the nucleic acid sequence of SEQ ID NO: 100. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 100. In some aspects, the construct comprises the nucleic acid sequence of SEQ ID NO: 103. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 103. In some aspects, the construct comprises the nucleic acid sequence of SEQ ID NO: 106. In some aspects, the, the construct comprises a nucleic acid sequence with at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99%, or 100% identity to SEQ ID NO: 106.One skilled in the art would recognize that constructs may undergo additional modifications including codon-optimization, introduction of novel but functionally equivalent (e.g., silent mutations), addition of reporter sequences, and/or other routine modification.
In some embodiments, an exemplary rAAVAnc80 particle comprises a construct represented by SEQ ID NO: 45.
In one embodiment, an exemplary construct comprises: a 5′ ITR exemplified by SEQ ID NO: 8, optionally a cloning site exemplified by SEQ ID NO: 29, a CMV enhancer exemplified by SEQ ID NO: 18, a CBA promoter exemplified by SEQ ID NO: 11, a chimeric intron exemplified by SEQ ID NO: 19, optionally a cloning site exemplified by SEQ ID NO: 30, a GJB2 coding region exemplified by SEQ ID NO: 1, optionally a cloning site exemplified by SEQ ID NO: 31, a poly(A) site exemplified by SEQ ID NO: 25, optionally a cloning site exemplified by SEQ ID NO: 32, and a 3′ ITR exemplified by SEQ ID NO: 9.
In some embodiments, an exemplary rAAVAnc80 particle comprises a construct represented by SEQ ID NO: 46.
In one embodiment, an exemplary construct comprises: a 5′ ITR exemplified by SEQ ID NO: 8, optionally a cloning site exemplified by SEQ ID NO: 29, a CMV enhancer exemplified by SEQ ID NO: 18, a CBA promoter exemplified by SEQ ID NO: 11, a chimeric intron exemplified by SEQ ID NO: 19, optionally a cloning site exemplified by SEQ ID NO: 30, a GJB2 coding region exemplified by SEQ ID NO: 1, optionally a cloning sequence exemplified by SEQ ID NO: 33, a 3′ UTR exemplified by SEQ ID NO: 22, optionally a cloning site exemplified by SEQ ID NO: 34, a poly(A) site exemplified by SEQ ID NO: 25, optionally a cloning site exemplified by SEQ ID NO: 32, and a 3′ ITR exemplified by SEQ ID NO: 9.
In some embodiments, an exemplary rAAVAnc80 particle comprises a construct represented by SEQ ID NO: 47.
In one embodiment, an exemplary construct comprises: a 5′ ITR exemplified by SEQ ID NO: 8, optionally a cloning site exemplified by SEQ ID NO: 29, a promoter/enhancer region as exemplified by SEQ ID NO: 17, optionally a cloning site exemplified by SEQ ID NO: 35, a GJB2 coding region exemplified by SEQ ID NO: 1, optionally a cloning site exemplified by SEQ ID NO: 31, a filler sequence exemplified by SEQ ID NO: 27, optionally a cloning site exemplified by SEQ ID NO: 36, a poly(A) site exemplified by SEQ ID NO: 25, optionally a cloning site exemplified by SEQ ID NO: 37, and a 3′ ITR exemplified by SEQ ID NO: 9.
In some embodiments, an exemplary rAAVAnc80 particle comprises a construct represented by SEQ ID NO: 48.
In one embodiment, an exemplary construct comprises: a 5′ ITR exemplified by SEQ ID NO: 8, optionally a cloning site exemplified by SEQ ID NO: 29, a promoter/enhancer region as exemplified by SEQ ID NO: 17, optionally a cloning site exemplified by SEQ ID NO: 35, a GJB2 coding region exemplified by SEQ ID NO: 1, optionally a cloning site exemplified by SEQ ID NO: 31, a filler sequence exemplified by SEQ ID NO: 28, optionally a cloning site exemplified by SEQ ID NO: 36, a poly(A) site exemplified by SEQ ID NO: 25, optionally a cloning site exemplified by SEQ ID NO: 37, and a 3′ ITR exemplified by SEQ ID NO: 9.
In some embodiments, an exemplary rAAVAnc80 particle comprises a construct represented by SEQ ID NO: 49.
In one embodiment, an exemplary construct comprises: a 5′ ITR exemplified by SEQ ID NO: 8, optionally a cloning site exemplified by SEQ ID NO: 29, a promoter/enhancer region as exemplified by SEQ ID NO: 17, optionally a cloning site exemplified by SEQ ID NO: 35, a GJB2 coding region exemplified by SEQ ID NO: 1, optionally a cloning site exemplified by SEQ ID NO: 31, a poly(A) site exemplified by SEQ ID NO: 25, optionally a cloning site exemplified by SEQ ID NO: 32, and a 3′ ITR exemplified by SEQ ID NO: 9.
In some embodiments, an exemplary rAAVAnc80 particle comprises a construct represented by SEQ ID NO: 50.
In one embodiment, an exemplary construct comprises: a 5′ ITR exemplified by SEQ ID NO: 8, optionally a cloning site exemplified by SEQ ID NO: 29, a CMV enhancer exemplified by SEQ ID NO: 18, a CBA promoter exemplified by SEQ ID NO: 10, a chimeric intron exemplified by SEQ ID NO: 19, optionally a cloning site exemplified by SEQ ID NO: 30, a GJB2 coding region exemplified by SEQ ID NO: 1, optionally a cloning site exemplified by SEQ ID NO: 31, a poly(A) site exemplified by SEQ ID NO: 25, optionally a cloning site exemplified by SEQ ID NO: 32, and a 3′ ITR exemplified by SEQ ID NO: 9.
In some embodiments, an exemplary rAAVAnc80 particle comprises a construct represented by SEQ ID NO: 51.
In one embodiment, an exemplary construct comprises: a 5′ ITR exemplified by SEQ ID NO: 8, optionally a cloning site exemplified by SEQ ID NO: 29, a CMV enhancer exemplified by SEQ ID NO: 18, a CBA promoter exemplified by SEQ ID NO: 10, a chimeric intron exemplified by SEQ ID NO: 19, optionally a cloning site exemplified by SEQ ID NO: 30, a GJB2 coding region exemplified by SEQ ID NO: 1, optionally a cloning site exemplified by SEQ ID NO: 33, a 3′ UTR exemplified by SEQ ID NO: 22, optionally a cloning site exemplified by SEQ ID NO: 34, a poly(A) site exemplified by SEQ ID NO: 25, optionally a cloning site exemplified by SEQ ID NO: 32, and a 3′ ITR exemplified by SEQ ID NO: 9.
In some embodiments, an exemplary rAAVAnc80 particle comprises a construct represented by SEQ ID NO: 82.
In one embodiment, an exemplary construct comprises: a 5′ ITR exemplified by SEQ ID NO: 52, optionally a cloning site exemplified by SEQ ID NO: 70, a CAG enhancer/promoter exemplified by SEQ ID NO: 14, optionally a cloning site exemplified by SEQ ID NO: 72, a GJB2 5′UTR sequence exemplified by SEQ ID NO: 66, optionally a cloning site exemplified by SEQ ID NO: 73, a GJB2 coding region exemplified by SEQ ID NO: 1, a linker sequence exemplified by SEQ ID NO: 77, a FLAG sequence with stop codon exemplified by SEQ ID NO: 81, a 3′ UTR exemplified by SEQ ID NO: 67, optionally a cloning site exemplified by SEQ ID NO: 75, a poly(A) site exemplified by SEQ ID NO: 25, optionally a cloning site exemplified by SEQ ID NO: 76, and a 3′ ITR exemplified by SEQ ID NO: 53.
In some embodiments, an exemplary rAAVAnc80 particle comprises a construct represented by SEQ ID NO: 83.
In one embodiment, an exemplary construct comprises: a 5′ ITR exemplified by SEQ ID NO: 52, optionally a cloning site exemplified by SEQ ID NO: 70, a CMV/CBA enhancer/promoter exemplified by SEQ ID NO: 12, a chimeric intron exemplified by SEQ ID NO: 64, optionally a cloning site exemplified by SEQ ID NO: 72, a GJB2 5′UTR sequence exemplified by SEQ ID NO: 66, optionally a cloning site exemplified by SEQ ID NO: 73, a GJB2 coding region exemplified by SEQ ID NO: 1, a linker sequence exemplified by SEQ ID NO: 77, a FLAG sequence with stop codon exemplified by SEQ ID NO: 81, a 3′ UTR exemplified by SEQ ID NO: 67, optionally a cloning site exemplified by SEQ ID NO: 75, a poly(A) site exemplified by SEQ ID NO: 25, optionally a cloning site exemplified by SEQ ID NO: 76, and a 3′ ITR exemplified by SEQ ID NO: 53.
In some embodiments, an exemplary rAAVAnc80 particle comprises a construct represented by SEQ ID NO: 84.
In one embodiment, an exemplary construct comprises: a 5′ ITR exemplified by SEQ ID NO: 52, optionally a cloning site exemplified by SEQ ID NO: 70, a CMV enhancer exemplified by SEQ ID NO: 63, a human GJB2 promoter exemplified by SEQ ID NO: 61, optionally a cloning site exemplified by SEQ ID NO: 72, a GJB2 5′UTR sequence exemplified by SEQ ID NO: 66, optionally a cloning site exemplified by SEQ ID NO: 73, a GJB2 coding region exemplified by SEQ ID NO: 1, a linker sequence exemplified by SEQ ID NO: 77, a FLAG sequence with stop codon exemplified by SEQ ID NO: 81, a 3′ UTR exemplified by SEQ ID NO: 67, optionally a cloning site exemplified by SEQ ID NO: 75, a poly(A) site exemplified by SEQ ID NO: 25, optionally a cloning site exemplified by SEQ ID NO: 76, and a 3′ ITR exemplified by SEQ ID NO: 53.
In some embodiments, an exemplary rAAVAnc80 particle comprises a construct represented by SEQ ID NO: 85.
In one embodiment, an exemplary construct comprises: a 5′ ITR exemplified by SEQ ID NO: 52, optionally a cloning site exemplified by SEQ ID NO: 70, a CMV enhancer exemplified by SEQ ID NO: 63, a GFAP enhancer-promoter exemplified by SEQ ID NO: 62, optionally a cloning site exemplified by SEQ ID NO: 72, a GJB2 5′UTR sequence exemplified by SEQ ID NO: 66, optionally a cloning site exemplified by SEQ ID NO: 73, a GJB2 coding region exemplified by SEQ ID NO: 1, a linker sequence exemplified by SEQ ID NO: 77, a FLAG sequence with stop codon exemplified by SEQ ID NO: 81, a 3′ UTR exemplified by SEQ ID NO: 67, optionally a cloning site exemplified by SEQ ID NO: 75, a poly(A) site exemplified by SEQ ID NO: 25, optionally a cloning site exemplified by SEQ ID NO: 76, and a 3′ ITR exemplified by SEQ ID NO: 53.
In some embodiments, an exemplary rAAVAnc80 particle comprises a construct represented by SEQ ID NO: 86.
In one embodiment, an exemplary construct comprises: a 5′ ITR exemplified by SEQ ID NO: 52, optionally a cloning site exemplified by SEQ ID NO: 71, a human GFAP enhancer-promoter exemplified by SEQ ID NO: 62, optionally a cloning site exemplified by SEQ ID NO: 72, a GJB2 5′UTR sequence exemplified by SEQ ID NO: 66, optionally a cloning site exemplified by SEQ ID NO: 73, a GJB2 coding region exemplified by SEQ ID NO: 1, a linker sequence exemplified by SEQ ID NO: 77, a FLAG sequence with stop codon exemplified by SEQ ID NO: 81, a 3′ UTR exemplified by SEQ ID NO: 67, optionally a cloning site exemplified by SEQ ID NO: 75, a poly(A) site exemplified by SEQ ID NO: 25, optionally a cloning site exemplified by SEQ ID NO: 76, and a 3′ ITR exemplified by SEQ ID NO: 53.
In some embodiments, an exemplary rAAVAnc80 particle comprises a construct represented by SEQ ID NO: 87.
In one embodiment, an exemplary construct comprises: a 5′ ITR exemplified by SEQ ID NO: 52, optionally a cloning site exemplified by SEQ ID NO: 70, a human GFAP enhancer-promoter exemplified by SEQ ID NO: 62, optionally a cloning site exemplified by SEQ ID NO: 72, a GJB2 5′UTR sequence exemplified by SEQ ID NO: 66, optionally a cloning site exemplified by SEQ ID NO: 73, a GJB2 coding region exemplified by SEQ ID NO: 1, a linker sequence exemplified by SEQ ID NO: 77, a FLAG sequence with stop codon exemplified by SEQ ID NO: 81, a destabilization domain exemplified by SEQ ID NO: 80, a 3′ UTR exemplified by SEQ ID NO: 68, optionally a cloning site exemplified by SEQ ID NO: 34, a poly(A) site exemplified by SEQ ID NO: 25, optionally a cloning site exemplified by SEQ ID NO: 76, and a 3′ ITR exemplified by SEQ ID NO: 53.
In some embodiments, an exemplary rAAVAnc80 particle comprises a construct represented by SEQ ID NO: 88.
In one embodiment, an exemplary construct comprises: a 5′ ITR exemplified by SEQ ID NO: 52, optionally a cloning site exemplified by SEQ ID NO: 70, a GJB2 enhancer region exemplified by SEQ ID NO: 65, a GJB2 promoter exemplified by SEQ ID NO: 61, optionally a cloning site exemplified by SEQ ID NO: 72, a GJB2 5′UTR sequence exemplified by SEQ ID NO: 20, optionally a cloning site exemplified by SEQ ID NO: 74, a GJB2 coding region exemplified by SEQ ID NO: 1, a linker sequence exemplified by SEQ ID NO: 77, a FLAG sequence with stop codon exemplified by SEQ ID NO: 81, a 3′ UTR exemplified by SEQ ID NO: 67, optionally a cloning site exemplified by SEQ ID NO: 76, and a 3′ ITR exemplified by SEQ ID NO: 53.
In some aspects, the rAAVAnc80 particle comprises a construct comprising the nucleic acid sequence of SEQ ID NO: 94.
In one aspect, the construct comprises a 5′ ITR comprising the nucleic acid sequence of SEQ ID NO: 52, optionally a cloning site comprising the nucleic acid sequence of SEQ ID NO: 71, a GDF6 promoter sequence comprising the nucleic acid sequence of SEQ ID NO: 90; a hGJB2 minimal promoter comprising the nucleic acid sequence of SEQ ID NO: 91, optionally a cloning site comprising the nucleic acid sequence of SEQ ID NO: 92; optionally a synthetic barcode comprising the nucleic acid sequence of SEQ ID NO: 93; a 5′UTR sequence comprising the nucleic acid sequence of SEQ ID NO: 66, a GJB2 coding region comprising the nucleic acid sequence of SEQ ID NO: 1, a linker sequence exemplified by SEQ ID NO: 77, a FLAG sequence with stop codon comprising the nucleic acid sequence of SEQ ID NO: 81, a 3′ UTR comprising the nucleic acid sequence of SEQ ID NO: 67, a poly(A) comprising the nucleic acid sequence of SEQ ID NO: 25, optionally a cloning site comprising the nucleic acid sequence of SEQ ID NO: 76, and a 3′ ITR comprising the nucleic acid sequence of SEQ ID NO: 53.
In some aspects, the rAAVAnc80 particle comprises a construct comprising the nucleic acid sequence of SEQ ID NO: 97.
In one aspect, the construct comprises a 5′ ITR comprising the nucleic acid sequence of SEQ ID NO: 52, optionally a cloning site comprising the nucleic acid sequence of SEQ ID NO: 71, a IGFBP2 promoter sequence comprising the nucleic acid sequence of SEQ ID NO: 95; a hGJB2 minimal promoter comprising the nucleic acid sequence of SEQ ID NO: 91, optionally a cloning site comprising the nucleic acid sequence of SEQ ID NO: 92; optionally a synthetic barcode comprising the nucleic acid sequence of SEQ ID NO: 96; a 5′UTR sequence comprising the nucleic acid sequence of SEQ ID NO: 66, a GJB2 coding region comprising the nucleic acid sequence of SEQ ID NO: 1, a linker sequence exemplified by SEQ ID NO: 77, a FLAG sequence with stop codon comprising the nucleic acid sequence of SEQ ID NO: 81, a 3′ UTR comprising the nucleic acid sequence of SEQ ID NO: 67, a poly(A) comprising the nucleic acid sequence of SEQ ID NO: 25, optionally a cloning site comprising the nucleic acid sequence of SEQ ID NO: 76, and a 3′ ITR comprising the nucleic acid sequence of SEQ ID NO: 53.
In some aspects, the rAAVAnc80 particle comprises a construct comprising the nucleic acid sequence of SEQ ID NO: 100.
In one aspect, the construct comprises a 5′ ITR comprising the nucleic acid sequence of SEQ ID NO: 52, optionally a cloning site comprising the nucleic acid sequence of SEQ ID NO: 71, a RBP7 promoter sequence comprising the nucleic acid sequence of SEQ ID NO: 98; a hGJB2 minimal promoter comprising the nucleic acid sequence of SEQ ID NO: 91, optionally a cloning site comprising the nucleic acid sequence of SEQ ID NO: 92; optionally a synthetic barcode comprising the nucleic acid sequence of SEQ ID NO: 99; a 5′UTR sequence comprising the nucleic acid sequence of SEQ ID NO: 66, a GJB2 coding region comprising the nucleic acid sequence of SEQ ID NO: 1, a linker sequence exemplified by SEQ ID NO: 77, a FLAG sequence with stop codon comprising the nucleic acid sequence of SEQ ID NO: 81, a 3′ UTR comprising the nucleic acid sequence of SEQ ID NO: 67, a poly(A) comprising the nucleic acid sequence of SEQ ID NO: 25, optionally a cloning site comprising the nucleic acid sequence of SEQ ID NO: 76, and a 3′ ITR comprising the nucleic acid sequence of SEQ ID NO: 53.
In some aspects, the rAAVAnc80 particle comprises a construct comprising the nucleic acid sequence of SEQ ID NO: 103.
In one aspect, the construct comprises a 5′ ITR comprising the nucleic acid sequence of SEQ ID NO: 52, optionally a cloning site comprising the nucleic acid sequence of SEQ ID NO: 71, a GJB6 promoter sequence comprising the nucleic acid sequence of SEQ ID NO: 101; a hGJB2 minimal promoter comprising the nucleic acid sequence of SEQ ID NO: 91, optionally a cloning site comprising the nucleic acid sequence of SEQ ID NO: 92; optionally a synthetic barcode comprising the nucleic acid sequence of SEQ ID NO: 102; a 5′UTR sequence comprising the nucleic acid sequence of SEQ ID NO: 66, a GJB2 coding region comprising the nucleic acid sequence of SEQ ID NO: 1, a linker sequence exemplified by SEQ ID NO: 77, a FLAG sequence with stop codon comprising the nucleic acid sequence of SEQ ID NO: 81, a 3′ UTR comprising the nucleic acid sequence of SEQ ID NO: 67, a poly(A) comprising the nucleic acid sequence of SEQ ID NO: 25, optionally a cloning site comprising the nucleic acid sequence of SEQ ID NO: 76, and a 3′ ITR comprising the nucleic acid sequence of SEQ ID NO: 53.
In some aspects, the rAAVAnc80 particle comprises a construct comprising the nucleic acid sequence of SEQ ID NO: 106.
In one aspect, the construct comprises a 5′ ITR comprising the nucleic acid sequence of SEQ ID NO: 52, optionally a cloning site comprising the nucleic acid sequence of SEQ ID NO: 71, a PARM1 promoter sequence comprising the nucleic acid sequence of SEQ ID NO: 104; a hGJB2 minimal promoter comprising the nucleic acid sequence of SEQ ID NO: 91, optionally a cloning site comprising the nucleic acid sequence of SEQ ID NO: 92; optionally a synthetic barcode comprising the nucleic acid sequence of SEQ ID NO: 105; a 5′UTR sequence comprising the nucleic acid sequence of SEQ ID NO: 66, a GJB2 coding region comprising the nucleic acid sequence of SEQ ID NO: 1, a linker sequence exemplified by SEQ ID NO: 77, a FLAG sequence with stop codon comprising the nucleic acid sequence of SEQ ID NO: 81, a 3′ UTR comprising the nucleic acid sequence of SEQ ID NO: 67, a poly(A) comprising the nucleic acid sequence of SEQ ID NO: 25, optionally a cloning site comprising the nucleic acid sequence of SEQ ID NO: 76, and a 3′ ITR comprising the nucleic acid sequence of SEQ ID NO: 53.
Multiple AAV Construct Compositions
The present disclosure recognizes that some coding sequences encoding a protein (e.g., connexin 26 protein) may be delivered by dividing the coding sequence into multiple portions, which are each included in a different construct. In some embodiments, provided herein are compositions or systems comprising at least two different constructs, (e.g., two, three, four, five, or six). In some embodiments, each of the at least two different constructs includes a coding sequence that encodes a different portion of a coding region (e.g., encoding a target protein (e.g., an inner ear target protein, e.g., a connexin 26 protein)), each of the encoded portions being at least 10 amino acids (e.g., at least about 10 amino acids, at least about 20 amino acids, at least about 30 amino acids, at least about 60 amino acids, at least about 70 amino acids, at least about 80 amino acids, at least about 90 amino acids, at least about 100 amino acids, at least about 110 amino acids, at least about 120 amino acids, at least about 130 amino acids, at least about 140 amino acids, at least about 150 amino acids, at least about 160 amino acids, at least about 170 amino acids, at least about 180 amino acids, at least about 190 amino acids, at least about 200 amino acids, at least about 210 amino acids, at least about 220 amino acids, at least about 230 amino acids, at least about 240 amino acids, at least about 250 amino acids, or at least about 260 amino acids) where the amino acid sequence of each of the encoded portions may optionally partially overlap with the amino acid sequence of a different one of the encoded portions; no single construct of the at least two different constructs encodes the active target protein; and, when introduced into a subject cell (e.g., an animal cell, e.g., a primate cell, e.g., a human cell), the at least two different constructs undergo homologous recombination with each other, where the recombined nucleic acid encodes an active target protein (e.g., a gene product encoded by a GJB2 gene or a characteristic portion thereof). In some embodiments, one of the nucleic acid constructs can include a coding sequence that encodes a portion of a target protein (e.g., an inner ear target protein, e.g., a connexin 26 protein), where the encoded portion is at most about 260 amino acids (e.g., at most about 10 amino acids, at most about 20 amino acids, at most about 30 amino acids, at most about 60 amino acids, at most about 70 amino acids, at most about 80 amino acids, at most about 90 amino acids, at most about 100 amino acids, at most about 110 amino acids, at most about 120 amino acids, at most about 130 amino acids, at most about 140 amino acids, at most about 150 amino acids, at most about 160 amino acids, at most about 170 amino acids, at most about 180 amino acids, at most about 190 amino acids, at most about 200 amino acids, at most about 210 amino acids, at most about 220 amino acids, at most about 230 amino acids, at most about 240 amino acids, at most about 250 amino acids, or at most about 260 amino acids).
In some embodiments, at least one of the constructs includes a nucleotide sequence spanning two neighboring exons of target genomic DNA (e.g., an inner ear target genomic DNA, e.g., GJB2 genomic DNA), and lacks the intronic sequence that naturally occurs between the two neighboring exons.
In some embodiments, an amino acid sequence of an encoded portion of each of the constructs does not overlap, even in part, with an amino acid sequence of a different one of the encoded portions. In some embodiments, an amino acid sequence of an encoded portion of a construct partially overlaps with an amino acid sequence of an encoded portion of a different construct. In some embodiments, an amino acid sequence of an encoded portion of each construct partially overlaps with an amino acid sequence of an encoded portion of at least one different construct. In some embodiments, an overlapping amino acid sequence is between about 10 amino acid residues to about 260 amino acids, or any of the subranges of this range (e.g., about 10 amino acids, about 20 amino acids, about 30 amino acids, about 60 amino acids, about 70 amino acids, about 80 amino acids, about 90 amino acids, about 100 amino acids, about 110 amino acids, about 120 amino acids, about 130 amino acids, about 140 amino acids, about 150 amino acids, about 160 amino acids, about 170 amino acids, about 180 amino acids, about 190 amino acids, about 200 amino acids, about 210 amino acids, about 220 amino acids, about 230 amino acids, about 240 amino acids, about 250 amino acids, or about 260 amino acids) in length.
In some examples, a desired gene product (e.g., a therapeutic gene product) is encoded by at least two different constructs. In some embodiments, each of at least two different constructs includes a different segment of an intron, where the intron includes a nucleotide sequence of an intron that is present in a target genomic DNA (e.g., an inner ear cell target genomic DNA (e.g., GJB2 genomic DNA) (e.g., any of the exemplary introns in SEQ ID NO: 5 described herein). In some embodiments, different intron segments overlap. In some embodiments, different intron segments overlap in sequence by at most about 3,000 nucleotides (e.g., at most about 100 nucleotides, at most about 200 nucleotides, at most about 300 nucleotides, at most about 600 nucleotides, at most about 700 nucleotides, at most about 800 nucleotides, at most about 900 nucleotides, at most about 1,000 nucleotides, at most about 1,100 nucleotides, at most about 1,200 nucleotides, at most about 1,300 nucleotides, at most about 1,400 nucleotides, at most about 1,500 nucleotides, at most about 1,600 nucleotides, at most about 1,700 nucleotides, at most about 1,800 nucleotides, at most about 1,900 nucleotides, at most about 2,000 nucleotides, at most about 2,100 nucleotides, at most about 2,200 nucleotides, at most about 2,300 nucleotides, at most about 2,400 nucleotides, at most about 2,500 nucleotides, at most about 2,600 nucleotides, at most about 2,700 nucleotides, at most about 2,800 nucleotides, at most about 2,900 nucleotides, or at most about 3,000 nucleotides) in length. In some embodiments, the overlapping nucleotide sequence in any two of the different constructs can include part or all of one or more exons of a target gene (e.g., an inner ear cell target gene (e.g., a GJB2 gene) (e.g., any one or more of the exemplary exons in SEQ ID NO: 5 described herein).
In some embodiments, a composition or system is or comprises two, three, four, or five different constructs. In compositions where the number of different constructs in the composition is two, the first of the two different constructs can include a coding sequence that encodes an N-terminal portion of a protein (e.g., connexin 26 protein), which may be referred to as a lead portion, a first construct, or a 5′ portion (e.g., an N-terminal portion of an inner ear cell protein, e.g., an N-terminal portion of a connexin 26 protein). In some examples, an N-terminal portion of the target gene is at least about 10 amino acids (e.g., at least about 10 amino acids, at least about 20 amino acids, at least about 30 amino acids, at least about 60 amino acids, at least about 70 amino acids, at least about 80 amino acids, at least about 90 amino acids, at least about 100 amino acids, at least about 110 amino acids, at least about 120 amino acids, at least about 130 amino acids, at least about 140 amino acids, at least about 150 amino acids, at least about 160 amino acids, at least about 170 amino acids, at least about 180 amino acids, at least about 190 amino acids, at least about 200 amino acids, at least about 210 amino acids, at least about 220 amino acids, at least about 230 amino acids, at least about 240 amino acids, at least about 250 amino acids, or at least about 260 amino acids) in length. In some examples, a first construct includes one or both of a promoter (e.g., any of the promoters described herein or known in the art) and a Kozak sequence (e.g., any of the exemplary Kozak sequences described herein or known in the art). In some examples, a first construct includes a promoter that is an inducible promoter, a constitutive promoter, or a tissue-specific promoter. In some examples, a second of the two different constructs includes a coding sequence that encodes a C-terminal portion of the protein, which may be referred to as a terminal portion, a second construct, or a 3′ portion (e.g., a C-terminal portion of an inner ear cell target protein, e.g., a C-terminal portion of a connexin 26 protein). In some examples, a C-terminal portion of the target protein is at least about 10 amino acids (e.g., at least about 10 amino acids, at least about 20 amino acids, at least about 30 amino acids, at least about 60 amino acids, at least about 70 amino acids, at least about 80 amino acids, at least about 90 amino acids, at least about 100 amino acids, at least about 110 amino acids, at least about 120 amino acids, at least about 130 amino acids, at least about 140 amino acids, at least about 150 amino acids, at least about 160 amino acids, at least about 170 amino acids, at least about 180 amino acids, at least about 190 amino acids, at least about 200 amino acids, at least about 210 amino acids, at least about 220 amino acids, at least about 230 amino acids, at least about 240 amino acids, at least about 250 amino acids, or at least about 260 amino acids) in length. In some examples, a second construct further includes a poly(A) sequence.
In some examples where the number of different constructs in the composition is two, an N-terminal portion encoded by one of the two constructs can include a portion including amino acid position 1 to about amino acid position 260, or any subrange of this range, (e.g., amino acid 1 to at least about amino acid 10, amino acid 1 to at least about amino acid 20, amino acid 1 to at least about amino acid 30, amino acid 1 to at least about amino acid 60, amino acid 1 to at least about amino acid 70, amino acid 1 to at least about amino acid 80, amino acid 1 to at least about amino acid 90, amino acid 1 to at least about amino acid 100, amino acid 1 to at least about amino acid 110, amino acid 1 to at least about amino acid 120, amino acid 1 to at least about amino acid 130, amino acid 1 to at least about amino acid 140, amino acid 1 to at least about amino acid 150, amino acid 1 to at least about amino acid 160, amino acid 1 to at least about amino acid 170, amino acid 1 to at least about amino acid 180, amino acid 1 to at least about amino acid 190, amino acid 1 to at least about amino acid 200, amino acid 1 to at least about amino acid 210, amino acid 1 to at least about amino acid 220, amino acid 1 to at least about amino acid 230, amino acid 1 to at least about amino acid 240, amino acid 1 to at least about amino acid 250, or amino acid 1 to at least about amino acid 260) of an inner ear cell target protein (e.g., SEQ ID NO: 7). In some examples where the number of different constructs in the composition is two, an N-terminal portion of the precursor inner ear cell target protein can include a portion including at most amino acid position 1 to amino acid position 260 or any subrange of this range (e.g., amino acid 1 to at most about amino acid 10, amino acid 1 to at most about amino acid 20, amino acid 1 to at most about amino acid 30, amino acid 1 to at most about amino acid 60, amino acid 1 to at most about amino acid 70, amino acid 1 to at most about amino acid 80, amino acid 1 to at most about amino acid 90, amino acid 1 to at most about amino acid 100, amino acid 1 to at most about amino acid 110, amino acid 1 to at most about amino acid 120, amino acid 1 to at most about amino acid 130, amino acid 1 to at most about amino acid 140, amino acid 1 to at most about amino acid 150, amino acid 1 to at most about amino acid 160, amino acid 1 to at most about amino acid 170, amino acid 1 to at most about amino acid 180, amino acid 1 to at most about amino acid 190, amino acid 1 to at most about amino acid 200, amino acid 1 to at most about amino acid 210, amino acid 1 to at most about amino acid 220, amino acid 1 to at most about amino acid 230, amino acid 1 to at most about amino acid 240, amino acid 1 to at most about amino acid 250, or amino acid 1 to at most about amino acid 260) of an inner ear cell target protein (e.g., SEQ ID NO: 7)
In some examples where the number of different constructs in the composition is two, a C-terminal portion encoded by one of the two constructs can include a portion including the final amino acid (e.g., about amino acid position 260) to about amino acid position 1, or any subrange of this range, (e.g., amino acid 260 to at least about amino acid 10, amino acid 260 to at least about amino acid 20, amino acid 260 to at least about amino acid 30, amino acid 260 to at least about amino acid 60, amino acid 260 to at least about amino acid 70, amino acid 260 to at least about amino acid 80, amino acid 260 to at least about amino acid 90, amino acid 260 to at least about amino acid 100, amino acid 260 to at least about amino acid 110, amino acid 260 to at least about amino acid 120, amino acid 260 to at least about amino acid 130, amino acid 260 to at least about amino acid 140, amino acid 260 to at least about amino acid 150, amino acid 260 to at least about amino acid 160, amino acid 260 to at least about amino acid 170, amino acid 260 to at least about amino acid 180, amino acid 260 to at least about amino acid 190, amino acid 260 to at least about amino acid 200, amino acid 260 to at least about amino acid 210, amino acid 260 to at least about amino acid 220, amino acid 260 to at least about amino acid 230, amino acid 260 to at least about amino acid 240, amino acid 260 to at least about amino acid 250, amino acid 260 to at least about amino acid 260) of an inner ear cell target protein (e.g., SEQ ID NO: 7). In some examples where the number of different constructs in the composition is two, a C-terminal portion of the precursor inner ear cell target protein can include a portion including the final amino acid (e.g., about amino acid position 2600) to at most about amino acid position 1, or any subrange of this range (e.g., amino acid 260 to at most about amino acid 10, amino acid 260 to at most about amino acid 20, amino acid 260 to at most about amino acid 30, amino acid 260 to at most about amino acid 60, amino acid 260 to at most about amino acid 70, amino acid 260 to at most about amino acid 80, amino acid 260 to at most about amino acid 90, amino acid 260 to at most about amino acid 100, amino acid 260 to at most about amino acid 110, amino acid 260 to at most about amino acid 120, amino acid 260 to at most about amino acid 130, amino acid 260 to at most about amino acid 140, amino acid 260 to at most about amino acid 150, amino acid 260 to at most about amino acid 160, amino acid 260 to at most about amino acid 170, amino acid 260 to at most about amino acid 180, amino acid 260 to at most about amino acid 190, amino acid 260 to at most about amino acid 200, amino acid 260 to at most about amino acid 210, amino acid 260 to at most about amino acid 220, amino acid 260 to at most about amino acid 230, amino acid 260 to at most about amino acid 240, amino acid 260 to at most about amino acid 250, amino acid 260 to at most about amino acid 260), or any length sequence there between of an inner ear cell target protein (e.g., SEQ ID NO: 7).
In some embodiments, splice sites are involved in trans-splicing. In some embodiments, a splice donor site (Trapani et al., EMBO Mol. Med. 6(2):194-211, 2014, which is incorporated in its entirety herein by reference) follows the coding sequence in the N-terminal construct. In the C-terminal construct, a splice acceptor site may be subcloned just before the coding sequence for GJB2. In some embodiments, within the coding sequence, a silent mutation can be introduced, generating an additional site for restriction digestion.
In some embodiments, any of the constructs provided herein can be included in a composition suitable for administration to an animal for the amelioration of symptoms associated with syndromic and/or nonsyndromic hearing loss.
Pharmaceutical Compositions
Among other things, the present disclosure provides pharmaceutical compositions. In some embodiments, compositions provided herein are suitable for administration to an animal for the amelioration of symptoms associated with syndromic and/or nonsyndromic hearing loss.
In some embodiments, pharmaceutical compositions of the present disclosure may comprise, e.g., a polynucleotide, e.g., one or more constructs, as described herein. In some embodiments, a pharmaceutical composition may comprise one or more AAV particles, e.g., one or more rAAV construct encapsidated by one or more AAV serotype capsids, as described herein.
In some embodiments, a pharmaceutical composition comprises one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. As used herein, the term “pharmaceutically acceptable carrier” includes solvents, dispersion media, coatings, antibacterial agents, antifungal agents, and the like that are compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into any of the compositions described herein. Such compositions may include one or more buffers, such as neutral-buffered saline, phosphate-buffered saline, and the like; one or more carbohydrates, such as glucose, mannose, sucrose, and dextran; mannitol; one or more proteins, polypeptides, or amino acids, such as glycine; one or more antioxidants; one or more chelating agents, such as EDTA or glutathione; and/or one or more preservatives. In some embodiments, formulations are in a dosage forms, such as injectable solutions, injectable gels, drug-release capsules, and the like.
In some embodiments, compositions of the present disclosure are formulated for intravenous administration. In some embodiments compositions of the present disclosure are formulated for intra-cochlear administration. In some embodiments, a therapeutic composition is formulated to comprise a lipid nanoparticle, a polymeric nanoparticle, a mini-circle DNA and/or a CELiD DNA.
In some embodiments, a composition disclosed herein is formulated as a sterile suspension for intracochlear administration. In some embodiments, a composition comprises constructs in an amount of at least IE11, at least 5E11, at least 1E12, at least 5E12, at least 1E13, at least 2E13, at least 3E13, at least 4E13, at least 5E13, at least 6E13, at least 7E13, at least 8E13, at least 9E13, or at least 1E14 vector genomes (vg) per milliliter (mL). In some embodiments, a composition comprises constructs in an amount of at most 1E15, at most 5E14, at most 1E14, at most 5E13, at most 1E13, at most 9E12, at most 8E12, at most 7E12, at most 6E12, at most 5E12, at most 4E12, at most 3E12, at most 2E12, or at most 1E12 vector genomes (vg) per milliliter (mL). In some embodiments, a composition comprises constructs in an amount of 1E12 to 1E13, 5E12 to 5E13, or 1E13 to 2E13 vector genomes (vg) per milliliter (mL).
In some embodiments, a therapeutic composition is formulated to comprise a synthetic perilymph solution. For example, in some embodiments, a synthetic perilymph solution includes 20-200 mM NaCl; 1-5 mM KCl; 0.1-10 mM CaCl2); 1-10 mM glucose; and 2-50 mM HEPES, with a pH between about 6 and about 9. In some embodiments, a therapeutic composition is formulated to comprise a physiologically suitable solution. For example, in some embodiments, a physiologically suitable solution comprises commercially available 1×PBS with pluronic acid F68, prepared to a final concentration of: 8.10 mM Sodium Phosphate Dibasic, 1.5 mM Monopotassium Phosphate, 2.7 mM Potassium Chloride, 172 mM Sodium Chloride, and 0.001% Pluronic Acid F68). In some embodiments, alternative pluronic acids are utilized. In some embodiments, alternative ion concentrations are utilized.
In some embodiments, any of the pharmaceutical compositions described herein may further comprise one or more agents that promote the entry of a nucleic acid or any of the constructs described herein into a mammalian cell (e.g., a liposome or cationic lipid). In some embodiments, any of the constructs described herein can be formulated using natural and/or synthetic polymers. Non-limiting examples of polymers that may be included in any of the compositions described herein can include, but are not limited to, DYNAMIC POLYCONJUGATE® (Arrowhead Research Corp., Pasadena, Calif.), formulations from Mirus Bio (Madison, Wis.) and Roche Madison (Madison, Wis.), PhaseRX polymer formulations such as, without limitation, SMARTT POLYMER TECHNOLOGY® (PhaseRX, Seattle, Wash.), DMRI/DOPE, poloxamer, VAXFECTIN® adjuvant from Vical (San Diego, Calif.), chitosan, cyclodextrin from Calando Pharmaceuticals (Pasadena, Calif.), dendrimers and poly (lactic-co-glycolic acid) (PLGA) polymers, RONDEL™ (RNAi/Oligonucleotide Nanoparticle Delivery) polymers (Arrowhead Research Corporation, Pasadena, Calif.), and pH responsive co-block polymers, such as, but not limited to, those produced by PhaseRX (Seattle, Wash.). Many of these polymers have demonstrated efficacy in delivering oligonucleotides in vivo into a mammalian cell (see, e.g., deFougerolles, Human Gene Ther. 19:125-132, 2008; Rozema et al., Proc. Natl. Acad. Sci. U.S.A. 104:12982-12887, 2007; Rozema et al., Proc. Natl. Acad. Sci. U.S.A. 104:12982-12887, 2007; Hu-Lieskovan et al., Cancer Res. 65:8984-8982, 2005; Heidel et al., Proc. Natl. Acad. Sci. U.S.A. 104:5715-5721, 2007, each of which is incorporated in its entirety herein by reference).
In some embodiments, a composition includes a pharmaceutically acceptable carrier (e.g., phosphate buffered saline, saline, or bacteriostatic water). Upon formulation, solutions will be administered in a manner compatible with a dosage formulation and in such amount as is therapeutically effective. Formulations are easily administered in a variety of dosage forms such as injectable solutions, injectable gels, drug-release capsules, and the like.
In some embodiments, a composition provided herein can be, e.g., formulated to be compatible with their intended route of administration. A non-limiting example of an intended route of administration is local administration (e.g., intra-cochlear administration). In some embodiments, a provided composition comprises one nucleic acid construct. In some embodiments, a provided composition comprises two or more different constructs. In some embodiments, a composition that include a single nucleic acid construct comprising a coding sequence that encodes a connexin 26 protein and/or a functional characteristic portion thereof. In some embodiments, compositions comprise a single nucleic acid construct comprising a coding sequence that encodes a connexin 26 protein and/or a functional characteristic portion thereof, which, when introduced into a mammalian cell, that coding sequence is integrated into the genome of the mammalian cell. In some embodiments, a composition comprising at least two different constructs, e.g., constructs comprise coding sequences that encode a different portion of a connexin 26 protein, the constructs can be combined to generate a sequence encoding an active connexin 26 protein (e.g., a full-length connexin 26 protein) in a mammalian cell, and thereby treat associated syndromic or nonsyndromic sensorineural hearing loss in a subject in need thereof.
Also provided are kits including any of the compositions described herein. In some embodiments, a kit can include a solid composition (e.g., a lyophilized composition including the at least two different constructs described herein) and a liquid for solubilizing the lyophilized composition. In some embodiments, a kit can include a pre-loaded syringe including any of the compositions described herein.
In some embodiments, the kit includes a vial comprising any of the compositions described herein (e.g., formulated as an aqueous composition, e.g., an aqueous pharmaceutical composition).
In some embodiments, the kits can include instructions for performing any of the methods described herein.
The present disclosure also provides a cell (e.g., an animal cell, e.g., a mammalian cell, e.g., a primate cell, e.g., a human cell) that includes any of the nucleic acids, constructs or compositions described herein. In some embodiments, an animal cell is a human cell (e.g., a human supporting cell or a human hair cell). In other embodiments, an animal cell is a non-human mammal (e.g., Simian cell, Felidae cell, Canidae cell etc.). A person skilled in the art will appreciate that the nucleic acids and constructs described herein can be introduced into any animal cell (e.g., the supporting or hair cells of any animal suitable for veterinary intervention). Non-limiting examples of constructs and methods for introducing constructs into animal cells are described herein.
In some embodiments, an animal cell can be any cell of the inner ear, including hair and/or supporting cells. Non-limiting examples such cells include: Hensen's cells, Deiters' cells, cells of the endolymphatic sac and duct, transitional cells in the saccule, utricle, and ampulla, inner and outer hair cells, spiral ligament cells, spiral ganglion cells, spiral prominence cells, external saccule cells, marginal cells, intermediate cells, basal cells, inner pillar cells, outer pillar cells, Claudius cells, inner border cells, inner phalangeal cells, or cells of the stria vascularis.
In some embodiments, an animal cell is a specialized cell of the cochlea. In some embodiments, an animal cell is a hair cell. In some embodiments, an animal cell is a cochlear inner hair cell or a cochlear outer hair cell. In some embodiments, an animal cell is a cochlear inner hair cell. In some embodiments, an animal cell is a cochlear outer hair cell.
In some embodiments, an animal cell is in vitro. In some embodiments, an animal cell is of a cell type which is endogenously present in an animal, e.g., in a primate and/or human. In some embodiments, an animal cell is an autologous cell obtained from an animal and cultured ex vivo.
Among other things, the present disclosure provides methods. In some embodiments, a method comprises introducing a composition as described herein into the inner ear (e.g., a cochlea) of a subject. For example, provided herein are methods that in some embodiments include administering to an inner ear (e.g., cochlea) of a subject (e.g., an animal, e.g., a mammal, e.g., a primate, e.g., a human) a therapeutically effective amount of any composition described herein. In some embodiments of any of these methods, the subject has been previously identified as having a defective inner ear cell target gene (e.g., a supporting and/or hearing cell target gene having a mutation that results in a decrease in the expression and/or activity of a supporting and/or hearing cell target protein encoded by the gene). Some embodiments of any of these methods further include, prior to the introducing or administering step, determining that the subject has a defective inner ear cell target gene. Some embodiments of any of these methods can further include detecting a mutation in an inner ear cell target gene in a subject. Some embodiments of any of the methods can further include identifying or diagnosing a subject as having nonsyndromic or syndromic sensorineural hearing loss.
In some embodiments, provided herein are methods of correcting an inner ear cell target gene defect (e.g., a defect in GJB2) in an inner ear of a subject, e.g., an animal, e.g., a mammal, e.g., a primate, e.g., a human. In some embodiments, methods include administering to the inner ear of a subject a therapeutically effective amount of any of the compositions described herein, where the administering repairs and or ameliorates the inner ear cell target gene defect in any cell subset of the inner ear of a subject. In some embodiments, the inner ear target cell may be a sensory cell, e.g., a hair cell, and/or a non-sensory cell, e.g., a supporting cell, and/or all or any subset of inner ear cells.
Also provided herein are methods of increasing the expression level of an inner ear cell target protein in any subset of inner ear cells of a subject (e.g., an animal, e.g., a mammal, e.g., a primate, e.g., a human) that include: administering to the inner ear of the subject a therapeutically effective amount of any of the compositions described herein, where the administering results in an increase in the expression level of the inner ear cell target protein (e.g., connexin 26 protein) in any cell subset of the inner ear of a subject. In some embodiments, the inner ear target cell may be a sensory cell, e.g., a hair cell, and/or a non-sensory cell, e.g., a supporting cell, and/or all or any subset of inner ear cells.
Also provided herein are methods of treating hearing loss, e.g., nonsyndromic sensorineural hearing loss or syndromic sensorineural hearing loss, in a subject (e.g., an animal, e.g., a mammal, e.g., a primate, e.g., a human) identified as having a defective inner ear cell target gene that include: administering to the inner ear of the subject a therapeutically effective amount of any of the compositions described herein.
Also provided herein are methods of restoring synapses and/or preserving spiral ganglion nerves in a subject identified or diagnosed as having an inner ear disorder that include: administering to the inner ear of the subject a therapeutically effective amount of any of the compositions described herein.
Also provided herein are methods of reducing the size of, and/or restoring the vestibular aqueduct to an appropriate size. Also provided herein are methods of restoring endolymphatic pH to an appropriate and/or acceptable level in a subject identified or diagnosed as having an inner ear disorder that include: administering to the inner ear of the subject a therapeutically effective amount of any of the compositions described herein.
Also provided herein are methods that include administering to an inner ear of a subject a therapeutically effective amount of any of the compositions described herein.
Also provided herein are surgical methods for treatment of hearing loss (e.g., nonsyndromic sensorineural hearing loss or syndromic sensorineural hearing loss). In some embodiments, the methods include the steps of: introducing into a cochlea of a subject a first incision at a first incision point; and administering intra-cochlearly a therapeutically effective amount of any of the compositions provided herein. In some embodiments, the composition is administered to the subject at the first incision point. In some embodiments, the composition is administered to the subject into or through the first incision.
In some embodiments of any of the methods described herein, any composition described herein is administered to the subject into or through the cochlea oval window membrane. In some embodiments of any of the methods described herein, any of the compositions described herein is administered to the subject into or through the cochlea round window membrane. In some embodiments of any of the methods described herein, the composition is administered using a medical device capable of creating a plurality of incisions in the round window membrane. In some embodiments, the medical device includes a plurality of micro-needles. In some embodiments, the medical device includes a plurality of micro-needles including a generally circular first aspect, where each micro-needle has a diameter of at least about 10 microns. In some embodiments, the medical device includes a base and/or a reservoir capable of holding the composition. In some embodiments, the medical device includes a plurality of hollow micro-needles individually including a lumen capable of transferring the composition. In some embodiments, the medical device includes a means for generating at least a partial vacuum.
In some embodiments, technologies of the present disclosure are used to treat subjects with or at risk of hearing loss. For example, in some embodiments, a subject has an autosomal recessive hearing loss attributed to at least one pathogenic variant of GJB2. It will be understood by those in the art that many different mutations in GJB2 can result in a pathogenic variant. In some such embodiments, a pathogenic variant causes or is at risk of causing hearing loss.
In some embodiments, a subject experiencing hearing loss will be evaluated to determine if and where one or more mutations may exist that may cause hearing loss. In some such embodiments, the status of GJB2 gene products or function (e.g., via protein or sequencing analyses) will be evaluated. In some embodiments of any of the methods described herein, the subject or animal is a mammal, in some embodiments the mammal is a domestic animal, a farm animal, a zoo animal, a non-human primate, or a human. In some embodiments of any of the methods described herein, the animal, subject, or mammal is an adult, a teenager, a juvenile, a child, a toddler, an infant, or a newborn. In some embodiments of any of the methods described herein, the animal, subject, or mammal is 1-5, 1-10, 1-20, 1-30, 1-40, 1-50, 1-60, 1-70, 1-80, 1-90, 1-100, 1-110, 2-5, 2-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 10-30, 10-40, 10-50, 10-60, 10-70, 10-80, 10-90, 10-100, 10-110, 20-40, 20-50, 20-60, 20-70, 20-80, 20-90, 20-100, 20-110, 30-50, 30-60, 30-70, 30-80, 30-90, 30-100, 40-60, 40-70, 40-80, 40-90, 40-100, 50-70, 50-80, 50-90, 50-100, 60-80, 60-90, 60-100, 70-90, 70-100, 70-110, 80-100, 80-110, or 90-110 years of age. In some embodiments of any of the methods described herein, the subject or mammal is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 months of age.
In some embodiments of any of the methods described herein, the methods result in improvement in hearing (e.g., any of the metrics for determining improvement in hearing described herein) in a subject in need thereof for at least 10 days, at least 15 days, at least 20 days, at least 25 days, at least 30 days, at least 35 days, at least 40 days, at least 45 days, at least 50 days, at least 55 days, at least 60 days, at least 65 days, at least 70 days, at least 75 days, at least 80 days, at least 85 days, at least 100 days, at least 105 days, at least 110 days, at least 115 days, at least 120 days, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, or at least 12 months.
In some embodiments a subject (e.g., an animal, e.g., a mammal, e.g., a human) has or is at risk of developing syndromic or nonsyndromic sensorineural hearing loss. In some embodiments a subject (e.g., an animal, e.g., a mammal, e.g., a human) has been previously identified as having a mutation in a GJB2 gene. In some embodiments a subject (e.g., an animal, e.g., a mammal, e.g., a human) has any of the mutations in a GJB2 gene that are described herein or are known in the art to be associated with syndromic or nonsyndromic sensorineural hearing loss.
In some embodiments, a subject (e.g., an animal, e.g., a mammal, e.g., a human) has been identified as being a carrier of a mutation in a GJB2 gene (e.g., via genetic testing). In some embodiments, a subject (e.g., an animal, e.g., a mammal, e.g., a human) has been identified as having a mutation in a GJB2 gene and has been diagnosed with syndromic or nonsyndromic sensorineural hearing loss. In some embodiments, a subject (e.g., an animal, e.g., a mammal, e.g., a human) has been identified as having syndromic or nonsyndromic sensorineural hearing loss.
In some embodiments, a subject (e.g., an animal, e.g., a mammal, e.g., a human) has been identified as being at risk of hearing loss (e.g., at risk of being a carrier of a gene mutation, e.g., a GJB2 mutation). In some such embodiments, a subject (e.g., an animal, e.g., a mammal, e.g., a human) may have certain risk factors of hearing loss or risk of hearing loss (e.g., known parental carrier, afflicted sibling, or symptoms of hearing loss). In some such embodiments, a subject (e.g., an animal, e.g., a mammal, e.g., a human) has been identified as being a carrier of a mutation in a GJB2 gene (e.g., via genetic testing) that has not previously been identified (i.e., is not a published or otherwise known variant of GJB2). In some such embodiments, identified mutations may be novel (i.e., not previously described in the literature), and methods of treatment for a subject suffering from or susceptible to hearing loss will be personalized to the mutation(s) of the particular patient.
In some embodiments, successful treatment of syndromic or nonsyndromic sensorineural hearing loss can be determined in a subject using any of the conventional functional hearing tests known in the art. Non-limiting examples of functional hearing tests are various types of audiometric assays (e.g., pure-tone testing, speech testing, test of the middle ear, auditory brainstem response, and otoacoustic emissions).
In some embodiments of any method provided herein, two or more doses of any composition described herein are introduced or administered into a cochlea of a subject. Some embodiments of any of these methods can include introducing or administering a first dose of a composition into a cochlea of a subject, assessing hearing function of the subject following introduction or administration of a first dose, and administering an additional dose of a composition into the cochlea of the subject found not to have a hearing function within a normal range (e.g., as determined using any test for hearing known in the art).
In some embodiments of any method provided herein, the composition can be formulated for intra-cochlear administration. In some embodiments of any of the methods described herein, the compositions described herein can be administered via intra-cochlear administration or local administration. In some embodiments of any of the methods described herein, the compositions are administered through the use of a medical device (e.g., any of the exemplary medical devices described herein).
In some embodiments, intra-cochlear administration can be performed using any of the methods described herein or known in the art. For example, in some embodiments, a composition can be administered or introduced into the cochlea using the following surgical technique: first using visualization with a 0 degree, 2.5-mm rigid endoscope, the external auditory canal is cleared and a round knife is used to sharply delineate an approximately 5-mm tympanomeatal flap. The tympanomeatal flap is then elevated and the middle ear is entered posteriorly. The chorda tympani nerve is identified and divided, and a curette is used to remove the scutal bone, exposing the round window membrane. To enhance apical distribution of the administered or introduced composition, a surgical laser may be used to make a small 2-mm fenestration in the oval window to allow for perilymph displacement during trans-round window membrane infusion of the composition. The microinfusion device is then primed and brought into the surgical field. The device is maneuvered to the round window, and the tip is seated within the bony round window overhang to allow for penetration of the membrane by the microneedle(s). The footpedal is engaged to allow for a measured, steady infusion of the composition. The device is then withdrawn and the round window and stapes foot plate are sealed with a gelfoam patch.
In some embodiments of any method provided herein, a subject has or is at risk of developing syndromic or nonsyndromic sensorineural hearing loss. In some embodiments of any method provided herein, a subject has been previously identified as having a mutation in an inner ear cell target gene, a gene which may be expressed in supporting cells and/or hair cells.
In some embodiments of any method provided herein, a subject has been identified as being a carrier of a mutation in an inner ear cell target gene (e.g., via genetic testing). In some embodiments of any method provided herein, a subject has been identified as having a mutation in an inner ear cell target gene and has been diagnosed with hearing loss (e.g., nonsyndromic sensorineural hearing loss or syndromic sensorineural hearing loss, e.g., DFNB1, DFNA3). Bart-Pumphrey syndrome, hystrix-like ichthyosis with deafness (HID), palmoplantar keratoderma with deafness, keratitis-ichthyosis-deafness (KID) syndrome, or Vohwinkel syndrome, respectively). In some embodiments of any of the methods described herein, the subject has been identified as having hearing loss (e.g., nonsyndromic sensorineural hearing loss or syndromic sensorineural hearing loss). In some embodiments, successful treatment of hearing loss (e.g., nonsyndromic sensorineural hearing loss or syndromic sensorineural hearing loss) can be determined in a subject using any of the conventional functional hearing tests known in the art. Non-limiting examples of functional hearing tests include various types of audiometric assays (e.g., pure-tone testing, speech testing, test of the middle ear, auditory brainstem response, and otoacoustic emissions).
In some embodiments, a subject cell is in vitro. In some embodiments, a subject cell is originally obtained from a subject and is cultured ex vivo. In some embodiments, a subject cell has previously been determined to have a defective inner ear cell target gene. In some embodiments, a subject cell has previously been determined to have a defective hair cell target gene. In some embodiments, a subject cell has previously been determined to have a defective supporting cell target gene.
In some embodiments of these methods, following treatment e.g., one or two or more administrations of compositions described herein, there is an increase in expression of an active inner ear cell target protein (e.g., connexin 26 protein). In some embodiments, an increase in expression of an active inner ear target protein as described herein (e.g., connexin 26 protein) is relative to a control level, e.g., as compared to the level of expression of an inner ear cell target protein prior to introduction of the compositions comprising any construct(s) as described herein.
Methods of detecting expression and/or activity of a target protein (e.g., connexin 26 protein) are known in the art. In some embodiments, a level of expression of an inner ear cell target protein can be detected directly (e.g., detecting inner ear cell target protein or target mRNA. Non-limiting examples of techniques that can be used to detect expression and/or activity of a target RNA or protein (e.g., a GJB2 gene product and/or connexin 26 protein or functional characteristic portion thereof) directly include: real-time PCR, Western blotting, immunoprecipitation, immunohistochemistry, mass spectrometry, or immunofluorescence. In some embodiments, expression of an inner ear cell target protein can be detected indirectly (e.g., through functional hearing tests).
Devices, Adninistration, and Surgical Methods
Provided herein are therapeutic delivery systems for treating hearing loss (e.g., nonsyndromic sensorineural hearing loss or syndromic sensorineural hearing loss). In one aspect, a therapeutic delivery system includes: i) a medical device capable of creating one or a plurality of incisions in a round window membrane of an inner ear of a subject in need thereof, and ii) an effective dose of a composition (e.g., any of the compositions described herein). In some embodiments, a medical device includes a plurality of micro-needles.
Also provided herein are surgical methods for treatment of hearing loss (e.g., nonsyndromic sensorineural hearing loss or syndromic sensorineural hearing loss). In some embodiments, a method the steps of: introducing into a cochlea of a subject a first incision at a first incision point; and administering intra-cochlearly a therapeutically effective amount of any of the compositions provided herein. In some embodiments, a composition is administered to a subject at the first incision point. In some embodiments, a composition is administered to a subject into or through the first incision.
In some embodiments of any method provided herein, any of the compositions described herein is administered to the subject into or through the cochlea oval window membrane. In some embodiments of any method provided herein, any of the compositions described herein is administered to the subject into or through the cochlea round window membrane. In some embodiments of any method provided herein, the composition is administered using a medical device capable of creating a plurality of incisions in the round window membrane. In some embodiments, a medical device includes a plurality of micro-needles. In some embodiments, a medical device includes a plurality of micro-needles including a generally circular first aspect, where each micro-needle has a diameter of at least about 10 microns. In some embodiments, a medical device includes a base and/or a reservoir capable of holding a composition. In some embodiments, a medical device includes a plurality of hollow micro-needles individually including a lumen capable of transferring a composition. In some embodiments, a medical device includes a means for generating at least a partial vacuum.
In some embodiments, the present disclosure describes a delivery approach that utilizes a minimally invasive, well-accepted surgical technique for accessing the middle ear and/or inner ear through the external auditory canal. The procedure includes opening one of the physical barriers between the middle and inner ear at the oval window, and subsequently using a device disclosed herein, e.g., as shown in
In some embodiments, surgical procedures for mammals (e.g., rodents (e.g., mice, rats, hamsters, or rabbits), primates (e.g., NHP (e.g., macaque, chimpanzees, monkeys, or apes) or humans) may include venting to increase AAV vector transduction rates along the length of the cochlea. In some embodiments, absence of venting during surgery may result in lower AAV vector cochlear cell transduction rates when compared to AAV vector cochlear cell transduction rates following surgeries performed with venting. In some embodiments, venting facilitates transduction rates of about 75-100% of IHCs throughout the cochlea. In some embodiments, venting permits IHC transduction rates of about 50-70%, about 60-80%, about 70-90%, or about 80-100% at the base of the cochlea. In some embodiments, venting permits IHC transduction rates of about 50-70%, about 60-80%, about 70-90%, or about 80-100% at the apex of the cochlea.
A delivery device described herein may be placed in a sterile field of an operating room and the end of a tubing may be removed from the sterile field and connected to a syringe that has been loaded with a composition disclosed herein (e.g., one or more AAV vectors) and mounted in the pump. After appropriate priming of the system in order to remove any air, a needle may then be passed through the middle ear under visualization (surgical microscope, endoscope, and/or distal tip camera). A needle (or microneedle) may be used to puncture the RWM. The needle may be inserted until a stopper contacts the RWM. The device may then be held in that position while a composition disclosed herein is delivered at a controlled flow rate to the inner ear, for a selected duration of time. In some embodiments, the flow rate (or infusion rate) may include a rate of about 30 μL/min, or from about 25 μL/min to about 35 μL/min, or from about 20 μL/min to about 40 μL/min, or from about 20 μL/min to about 70 μL/min, or from about 20 μL/min to about 90 μL/min, or from about 20 μL/min to about 100 μL/min. In some embodiments, the flow rate is about 20 μL/min, about 30 μL/min, about 40 μL/min, about 50 μL/min, about 60 μL/min, about 70 μL/min, about 80 μL/min, about 90 μL/min or about 100 μL/min. In some embodiments, the selected duration of time (that is, the time during which a composition disclosed herein is flowing) may be about 3 minutes, or from about 2.5 minutes to about 3.5 minutes, or from about 2 minutes to about 4 minutes, or from about 1.5 minutes to about 4.5 minutes, or from about 1 minute to about 5 minutes. In some embodiments, the total volume of a composition disclosed herein that flows to the inner ear may be about 0.09 mL, or from about 0.08 mL to about 0.10 mL, or from about 0.07 mL to about 0.11 mL. In some embodiments, the total volume of a composition disclosed herein equates to from about 40% to about 50% of the volume of the inner ear.
Once the delivery has been completed, the device may be removed. In some embodiments, a device described herein, may be configured as a single-use disposable product. In other embodiments, a device described herein may be configured as a multi-use, sterilizable product, for example, with a replaceable and/or sterilizable needle sub-assembly. Single use devices may be appropriately discarded (for example, in a biohazard sharps container) after administration is complete.
In some embodiments, a composition disclosed herein comprises one or a plurality of rAAV constructs. In some embodiments, when more than one rAAV construct is included in the composition, the rAAV constructs are each different. In some embodiments, an rAAV construct comprises an anti-VEGF coding region, e.g., as described herein. In some embodiments, a composition comprises an rAAV particle comprising an AAV construct described herein. In some embodiments, the r AAV particle is encapsidated by an Anc80 capsid. In some embodiment, the Anc80 capsid comprises a polypeptide of SEQ ID NO: 44.
In some embodiments, a composition disclosed herein can be administered to a subject with a surgical procedure. In some embodiments, administration, e.g., via a surgical procedure, comprises injecting a composition disclosed herein via a delivery device as described herein into the inner ear. In some embodiments, a surgical procedure disclosed herein comprises performing a transcanal tympanotomy; performing a laser-assisted micro-stapedotomy; and injecting a composition disclosed herein via a delivery device as described herein into the inner ear.
In some embodiments, a surgical procedure comprises performing a transcanal tympanotomy; performing a laser-assisted micro-stapedotomy; injecting a composition disclosed herein via a delivery device as described herein into the inner ear; applying sealant around the round window and/or an oval window of the subject; and lowering a tympanomeatal flap of the subject to the anatomical position.
In some embodiments, a surgical procedure comprises performing a transcanal tympanotomy; preparing a round window of the subject; performing a laser-assisted micro-stapedotomy; preparing both a delivery device as described herein and a composition disclosed herein for delivery to the inner ear; injecting a composition disclosed herein via the delivery device into the inner ear; applying sealant around the round window and/or an oval window of the subject; and lowering a tympanomeatal flap of the subject to the anatomical position.
In some embodiments, performing a laser-assisted micro-stapedotomy includes using a KTP otologic laser and/or a CO2 otologic laser.
As another example, a composition disclosed herein is administered using a device and/or system specifically designed for intracochlear route of administration. In some embodiments, design elements of a device described herein may include: maintenance of sterility of injected fluid; minimization of air bubbles introduced to the inner ear; ability to precisely deliver small volumes at a controlled rate; delivery through the external auditory canal by the surgeon; minimization of damage to the round window membrane (RWM), or to inner ear, e.g., cochlear structures beyond the RWM; and/or minimization of injected fluid leaking back out through the RWM.
The devices, systems, and methods provided herein also describe the potential for delivering a composition safely and efficiently into the inner ear, in order to treat conditions and disorders that would benefit from delivery of a composition disclosed herein to the inner ear, including, but not limited to, hearing disorders, e.g., as described herein. As another example, by placing a vent in the stapes footplate and injecting through the RWM, a composition disclosed herein is dispersed throughout the cochlea with minimal dilution at the site of action. The development of the described devices allows the surgical administration procedure to be performed through the external auditory canal in humans. The described devices can be removed from the ear following infusion of an amount of fluid into the perilymph of the cochlea. In subjects, the device may be advanced through the external auditory canal, either under surgical microscopic control or along with an endoscope.
An exemplary device for use in any of the methods disclosed herein is described in
Referring still to
Evaluating Hearing Loss and Recovery
In some embodiments, hearing function is determined using auditory brainstem response measurements (ABR). In some embodiments, hearing is tested by measuring distortion product optoacoustic emissions (DPOAEs). In some such embodiments, measurements are taken from one or both ears of a subject. In some such embodiments, recordings are compared to prior recordings for the same subject and/or known thresholds on such response measurements used to define, e.g., hearing loss versus acceptable hearing ranges to be defined as normal hearing. In some embodiments, a subject has ABR and/or DPOAE measurements recorded prior to receiving any treatment. In some embodiments, a subject treated with one or more technologies described herein will have improvements on ABR and/or DPOAE measurements after treatment as compared to before treatment. In some embodiments, ABR and/or DPOAE measurements are taken after treatment is administered and at regular follow-up intervals post-treatment.
In some embodiments, hearing function is determined using speech pattern recognition or is determined by a speech therapist. In some embodiments, hearing function is determined by pure tone testing. In some embodiments, hearing function is determined by bone conduction testing. In some embodiments, hearing function is determined by acoustic reflex testing. In some embodiments hearing function is determined by tympanometry. In some embodiments, hearing function is determined by any combination of hearing analysis known in the art. In some such embodiments, measurements are taken holistically, and/or from one or both ears of a subject. In some such embodiments, recordings and/or professional analysis are compared to prior recordings and/or analysis for the same subject and/or known thresholds on such response measurements used to define, e.g., hearing loss versus acceptable hearing ranges to be defined as normal hearing. In some embodiments, a subject has speech pattern recognition, pure tone testing, bone conduction testing, acoustic reflex testing and/or tympanometry measurements and/or analysis conducted prior to receiving any treatment. In some embodiments a subject treated with one or more technologies described herein will have improvements on speech pattern recognition, pure tone testing, bone conduction testing, acoustic reflex testing and/or tympanometry measurements after treatment as compared to before treatment. In some embodiments, speech pattern recognition, pure tone testing, bone conduction testing, acoustic reflex testing and/or tympanometry measurements are taken after treatment is administered and at regular follow-up intervals post-treatment.
Methods of Characterizing
The term “mutation in a GJB2 gene” refers to a modification in a known consensus functional GJB2 gene that results in the production of a connexin 26 protein having one or more of: a deletion in one or more amino acids, one or more amino acid substitutions, and one or more amino acid insertions as compared to the consensus functional connexin 26 protein, and/or results in a decrease in the expressed level of the encoded connexin 26 protein in a mammalian cell as compared to the expressed level of the encoded connexin 26 protein in a mammalian cell not having a mutation. In some embodiments, a mutation can result in the production of a connexin 26 protein having a deletion in one or more amino acids (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 16, 17, 18, 19, 20, or more amino acids). In some embodiments, the mutation can result in a frameshift in the GJB2 gene. The term “frameshift” is known in the art to encompass any mutation in a coding sequence that results in a shift in the reading frame of the coding sequence. In some embodiments, a frameshift can result in a nonfunctional protein. In some embodiments, a point mutation can be a nonsense mutation (i.e., result in a premature stop codon in an exon of the gene). A nonsense mutation can result in the production of a truncated protein (as compared to a corresponding consensus functional protein) that may or may not be functional. In some embodiments, the mutation can result in the loss (or a decrease in the level) of expression of GJB2 mRNA or connexin 26 protein or both the mRNA and protein. In some embodiments, the mutation can result in the production of an altered connexin 26 protein having a loss or decrease in one or more biological activities (functions) as compared to a consensus functional connexin 26 protein.
In some embodiments, the mutation is an insertion of one or more nucleotides into a GJB2 gene. In some embodiments, the mutation is in a regulatory and/or control sequence of the connexin 26 gene, i.e., a portion of the gene that is not coding sequence. In some embodiments, a mutation in a regulatory and/or control sequence may be in a promoter or enhancer region and prevent or reduce the proper transcription of the GJB2 gene. In some embodiments, a mutation is in a known heterologous gene known to interact with a connexin 26 protein, or the GJB2 gene (e.g., GJB6, or other gap junction genes).
Methods of genotyping and/or detecting expression or activity of GJB2 mRNA and/or connexin 26 protein are known in the art (see e.g., Ito et al., World J Otorhinolaryngol. 2013 May 28; 3(2): 26-34, and Roesch et al., Int J Mol Sci. 2018 January; 19(1): 209, each of which is incorporated in its entirety herein by reference). In some embodiments, level of expression of GJB2 mRNA or connexin 26 protein may be detected directly (e.g., detecting connexin 26 protein, detecting GJB2 mRNA etc.). Non-limiting examples of techniques that can be used to detect expression and/or activity of GJB2 directly include, e.g., real-time PCR, quantitative real-time PCR, Western blotting, immunoprecipitation, immunohistochemistry, mass spectrometry, or immunofluorescence. In some embodiments, expression of GJB2 and/or connexin 26 protein can be detected indirectly (e.g., through functional hearing tests, ABRs, DPOAEs, etc.).
In some embodiments, tissue samples (e.g., comprising one or more inner ear cells, e.g., comprising one or more hair cells and/or one or more supporting cells) may be evaluated via morphological analysis to determine morphology of hair cells and/or support cells before and after administration of any agents (e.g., compositions, e.g., compositions comprising constructs, and/or particles, etc.) as described herein. In some such embodiments, standard immunohistochemical or histological analyses may be performed. In some embodiments, if cells are used in vitro or ex vivo, additional immunocytochemical or immunohistochemical analyses may be performed. In some embodiments, one or more assays of one or more proteins or transcripts (e.g., western blot, ELISA, polymerase chain reactions) may be performed on one or more samples from a subject or in vitro cell populations.
Production Methods
AAV systems are generally well known in the art (see, e.g., Kelleher and Vos, Biotechniques, 17(6):1110-17 (1994); Cotten et al., P.N.A.S. U.S.A., 89(13):6094-98 (1992); Curiel, Nat Immun, 13(2-3):141-64 (1994); Muzyczka, Curr Top Microbiol Immunol, 158:97-129 (1992); and Asokan A, et al., Mol. Ther., 20(4):699-708 (2012), each of which is incorporated in its entirety herein by reference). Methods for generating and using AAV constructs are described, for example, in U.S. Pat. Nos. 5,139,941, 4,797,368 and PCT filing application US2019/060328, each of which is incorporated in its entirety herein by reference.
Methods for obtaining viral constructs are known in the art. For example, to produce AAV constructs, the methods typically involve culturing a host cell which contains a nucleic acid sequence encoding an AAV capsid protein or fragment thereof, a functional rep gene; a recombinant AAV construct composed of AAV inverted terminal repeats (ITRs) and a coding sequence; and/or sufficient helper functions to permit packaging of the recombinant AAV construct into the AAV capsid proteins.
In some embodiments, components to be cultured in a host cell to package an AAV construct in an AAV capsid may be provided to the host cell in trans. Alternatively, any one or more components (e.g., recombinant AAV construct, rep sequences, cap sequences, and/or helper functions) may be provided by a stable host cell that has been engineered to contain one or more such components using methods known to those of skill in the art. In some embodiments, such a stable host cell contains such component(s) under the control of an inducible promoter. In some embodiments, such component(s) may be under the control of a constitutive promoter. In some embodiments, a selected stable host cell may contain selected component(s) under the control of a constitutive promoter and other selected component(s) under the control of one or more inducible promoters. For example, a stable host cell may be generated that is derived from HEK293 cells (which contain E1 helper functions under the control of a constitutive promoter), but that contain the rep and/or cap proteins under the control of inducible promoters. Other stable host cells may be generated by one of skill in the art using routine methods.
Recombinant AAV construct, rep sequences, cap sequences, and helper functions required for producing an AAV of the disclosure may be delivered to a packaging host cell using any appropriate genetic element (e.g., construct). A selected genetic element may be delivered by any suitable method known in the art, e.g., to those with skill in nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic techniques (see, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y., which is incorporated in its entirety herein by reference). Similarly, methods of generating AAV particles are well known and any suitable method can be used with the present disclosure (see, e.g., K. Fisher et al., J. Virol., 70:520-532 (1993) and U.S. Pat. No. 5,478,745, which are incorporated in their entirety herein by reference).
In some embodiments, recombinant AAVs may be produced using a triple transfection method (e.g., as described in U.S. Pat. No. 6,001,650, which is incorporated in its entirety herein by reference). In some embodiments, recombinant AAVs are produced by transfecting a host cell with a recombinant AAV construct (comprising a coding sequence) to be packaged into AAV particles, an AAV helper function construct, and an accessory function construct. An AAV helper function construct encodes “AAV helper function” sequences (i.e., rep and cap), which function in trans for productive AAV replication and encapsidation. In some embodiments, the AAV helper function construct supports efficient AAV construct production without generating any detectable wild-type AAV particles (i.e., AAV particles containing functional rep and cap genes). Non-limiting examples of constructs suitable for use with the present disclosure include pHLP19 (see, e.g., U.S. Pat. No. 6,001,650, which is incorporated in its entirety herein by reference) and pRep6cap6 construct (see, e.g., U.S. Pat. No. 6,156,303, which is incorporated in its entirety herein by reference). An accessory function construct encodes nucleotide sequences for non-AAV derived viral and/or cellular functions upon which AAV is dependent for replication (i.e., “accessory functions”). Accessory functions may include those functions required for AAV replication, including, without limitation, those moieties involved in activation of AAV gene transcription, stage specific AAV mRNA splicing, AAV DNA replication, synthesis of cap expression products, and AAV capsid assembly. Viral-based accessory functions can be derived from any known helper viruses such as adenovirus, herpesvirus (other than herpes simplex virus type-1), and vaccinia virus.
Additional methods for generating and isolating AAV viral constructs suitable for delivery to a subject are described in, e.g., U.S. Pat. Nos. 7,790,449; 7,282,199; WO 2003/042397; WO 2005/033321, WO 2006/110689; and U.S. Pat. No. 7,588,772, each of which is incorporated in its entirety herein by reference. In one system, a producer cell line is transiently transfected with a construct that encodes a coding sequence flanked by ITRs and a construct(s) that encodes rep and cap. In another system, a packaging cell line that stably supplies rep and cap is transiently transfected with a construct encoding a coding sequence flanked by ITRs. In each of these systems, AAV particles are produced in response to infection with helper adenovirus or herpesvirus, and AAVs are separated from contaminating virus. Other systems do not require infection with helper virus to recover the AAV—the helper functions (i.e., adenovirus E1, E2a, VA, and E4 or herpesvirus UL5, UL8, UL52, and UL29, and herpesvirus polymerase) are also supplied, in trans, by the system. In such systems, helper functions can be supplied by transient transfection of the cells with constructs that encode the helper functions, or the cells can be engineered to stably contain genes encoding the helper functions, the expression of which can be controlled at the transcriptional or posttranscriptional level.
In some embodiments, viral construct titers post-purification are determined. In some embodiments, titers are determined using quantitative PCR. In certain embodiments, a TaqMan probe specific to a construct is utilized to determine construct levels. In certain embodiments, the TaqMan probe is represented by SEQ ID NO: 58, while forward and reverse amplifying primers are exemplified by SEQ ID NO: 59 and 60 respectively.
Exemplary Forward qPCR Primer for Quantification of Constructs (SEQ ID NO: 59)
Exemplary Reverse qPCR Primer for Quantification of Constructs (SEQ ID NO: 60)
As described herein, in some embodiments, a viral construct of the present disclosure is an adeno-associated virus (AAV) construct. Several AAV serotypes have been characterized, including AAV1, AAV2, AAV3 (e.g., AAV3B), AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV Anc80, as well as variants thereof. In some embodiments, an AAV particle is an AAV2/6, AAV2/8, AAV2/9, or AAV2/Anc80 particle (e.g., with AAV6, AAV8, AAV9, or Anc80 capsid and construct with AAV2 ITR). Other AAV particles and constructs are described in, e.g., Sharma et al., Brain Res Bull. 2010 Feb. 15; 81(2-3): 273, which is incorporated in its entirety herein by reference. Generally, any AAV serotype may be used to deliver a coding sequence described herein. However, the serotypes have different tropisms, e.g., they preferentially infect different tissues. In some embodiments, an AAV construct is a self-complementary AAV construct.
The present disclosure provides, among other things, methods of making AAV-based constructs. In some embodiments, such methods include use of host cells. In some embodiments, a host cell is a mammalian cell. A host cell may be used as a recipient of an AAV helper construct, an AAV minigene plasmid, an accessory function construct, and/or other transfer DNA associated with the production of recombinant AAVs. The term includes the progeny of an original cell that has been transfected. Thus, a “host cell” as used herein may refer to a cell that has been transfected with an exogenous DNA sequence. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.
Additional methods for generating and isolating AAV particles suitable for delivery to a subject are described in, e.g., U.S. Pat. Nos. 7,790,449; 7,282,199; WO 2003/042397; WO 2005/033321, WO 2006/110689; and U.S. Pat. No. 7,588,772, each of which is incorporated in its entirety herein by reference. In one system, a producer cell line is transiently transfected with a construct that encodes a coding sequence flanked by ITRs and a construct(s) that encodes rep and cap. In another system, a packaging cell line that stably supplies rep and cap is transiently transfected with a construct encoding a coding sequence flanked by ITRs. In each of these systems, AAV particles are produced in response to infection with helper adenovirus or herpesvirus, and AAV particles are separated from contaminating virus. Other systems do not require infection with helper virus to recover the AAV particles—the helper functions (i.e., adenovirus E1, E2a, VA, and E4 or herpesvirus UL5, UL8, UL52, and UL29, and herpesvirus polymerase) are also supplied, in trans, by the system. In such systems, helper functions can be supplied by transient transfection of the cells with constructs that encode the helper functions, or the cells can be engineered to stably contain genes encoding the helper functions, the expression of which can be controlled at the transcriptional or posttranscriptional level.
In yet another system, a coding sequence flanked by ITRs and rep/cap genes are introduced into insect host cells by infection with baculovirus-based constructs. Such production systems are known in the art (see generally, e.g., Zhang et al., 2009, Human Gene Therapy 20:922-929, which is incorporated in its entirety herein by reference). Methods of making and using these and other AAV production systems are also described in U.S. Pat. Nos. 5,139,941; 5,741,683; 6,057,152; 6,204,059; 6,268,213; 6,491,907; 6,660,514; 6,951,753; 7,094,604; 7,172,893; 7,201,898; 7,229,823; and 7,439,065, each of which is incorporated in its entirety herein by reference.
The disclosure is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the disclosure should in no way be construed as being limited to the following examples, but rather should be construed to encompass any and all variations that become evident as a result of the teaching provided herein.
It is believed that one or ordinary skill in the art can, using the preceding description and following Examples, as well as what is known in the art, make and utilize technologies of the present disclosure.
This example provides a description of generating a viral construct as described herein. A recombinant AAV (rAAV) particle was generated by transfection with an adenovirus-free method as used by Xiao et al., J Virol. 73(5):3994-4003, 1999, which is incorporated in its entirety herein by reference. The cis plasmids with AAV ITRs, the trans plasmid with AAV Rep and Cap genes, and a helper plasmid with an essential region from an adenovirus genome were co-transfected in HEK293 cells. The rAAV construct expressed human connexin 26 under a single construct strategy using the constructs described. AAV Anc80 capsid was prepared to encapsulate a unique rAAV connexin 26 protein encoding construct.
Those of ordinary skill in the art will readily understand that similar constructs can be made in accordance with this example. For instance, rAAV constructs that express mammalian, primate, or human connexin 26 under single, dual, or multi construct strategies can be generated. AAV serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, rh8, rh10, rh39, rh43, and Anc80 can each be prepared to encapsulate four sets of connexin 26 constructs to test (i) a concatemerization-transplicing strategy, (ii) a hybrid intronic-homologous recombination-transplicing strategy, (iii) an exonic homologous recombination strategy, as summarized by Pryadkina et al., Meth. Clin. Devel. 2:15009, 2015, which is incorporated in its entirety herein by reference, and (iv) a single construct strategy. In some embodiments, a recombinant AAV (rAAV) particle is generated by transfection with an adenovirus-free method as used by Xiao et al., J Virol. 73(5):3994-4003, 1999, which is incorporated in its entirety herein by reference.
This example provides a description of purification of a viral construct. A recombinant AAV (rAAV) is produced using a triple transfection protocol and purified. The fractions are analyzed by dot blot to determine those containing rAAV genomes. The viral genome number (vg) of each preparation is determined by a quantitative real-time PCR-based titration method using primers and probe corresponding to the ITR region of the AAV construct genome (Bartoli et al., Gene. Ther. 13:20-28, 2006, which is incorporated in its entirety herein by reference).
In some embodiments of this example, a recombinant AAV (rAAV) was produced using a standard triple transfection protocol and purified by two sequential cesium chloride (CsCl) density gradients, as described by Pryadkina et al., Mol. Ther. 2:15009, 2015, which is incorporated in its entirety herein by reference. At the end of second centrifugation, 11 fractions of 500 μl were recovered from the CsCl density gradient tube and purified through dialysis in 1×PBS. The fractions were analyzed by dot blot to determine those containing rAAV genomes. The viral genome number (vg) of each preparation was determined by a quantitative real-time PCR-based titration method using primers and probe corresponding to the ITR region of the AAV construct genome (Bartoli et al., Gene. Ther. 13:20-28, 2006, which is incorporated in its entirety herein by reference).
Those of ordinary skill in the art will readily understand that similar production and purifying processes can be conducted in accordance with this example. For instance, rAAV particles may be purified using various column chromatography methods known in the art, and/or viral genomes may be quantified using alternative primer sets.
This example relates to the preparation of compositions comprising rAAV particles, and a physiologically acceptable solution. An rAAV particle was produced and purified to a titer of 1.2×1013 vg/mL and was then prepared at dilutions of 6×104, 1.3×105, 1.8×105, 4.5×109, and 1.3×1010, vg/mL in a physiologically acceptable solution (e.g., commercially available 1×PBS with pluronic acid F68, prepared to a final concentration of: 8.10 mM Sodium Phosphate Dibasic, 1.5 mM Monopotassium Phosphate, 2.7 mM Potassium Chloride, 172 mM Sodium Chloride, and 0.001% Pluronic Acid F68).
In alternative embodiments, an rAAV is produced and purified to a known concentration (e.g., a titer of approximately 1×103 vg/mL) and is then prepared at desired concentrations (e.g., dilutions of 6×104, 1.3×105, 1.8×105, 4.5×109, and 1.3×1010, vg/mL) in a physiologically acceptable buffer (e.g., commercially available 1×PBS with pluronic acid F68, prepared to a final concentration of: 8.10 mM Sodium Phosphate Dibasic, 1.5 mM Monopotassium Phosphate, 2.7 mM Potassium Chloride, 172 mM Sodium Chloride, and 0.001% Pluronic Acid F68; or e.g., artificial perilymph comprising NaCl, 120 mM; KCl, 3.5 mM; CaCl2), 1.5 mM; glucose, 5.5 mM; HEPES, 20 mM. which is titrated with NaOH to adjust its pH to 7.5 (total Na+ concentration of 130 mM) as described in Chen et al., J Controlled Rel. 110:1-19, 2005, which is incorporated in its entirety herein by reference). Those of ordinary skill in the art will readily understand that alternative formulations can be prepared in accordance with this example. For instance, rAAV particles may be purified to an alternative titer, prepared at alternative dilutions, and suspended in alternative suitable solutions.
This example relates to a device suitable for the delivery of rAAV particles to the inner ear. A composition comprising rAAV particles is delivered to the cochlea of a subject using a specialized microcatheter designed for consistent and safe penetration of the round window membrane (RWM). The microcatheter is shaped such that the surgeon performing the delivery procedure can enter the middle ear cavity via the external auditory canal and contact the end of the microcatheter with the RWM. The distal end of the microcatheter may include at least one microneedle with a diameter from about 10 microns to about 1,000 microns, which produces perforations in the RWM that are sufficient to allow a construct as described (e.g., an rAAV construct) to enter the cochlear perilymph of the scala tympani at a rate which does not damage the inner ear (e.g., a physiologically acceptable rate, e.g., a rate of approximately 30 μL/min to approximately 90 L/min), but small enough to heal without surgical repair. The remaining portion of the microcatheter, proximal to the microneedle(s), is loaded with the rAAV/artificial perilymph formulation at a defined titer (e.g., approximately 1×1012 to 5×103 vg/mL). The proximal end of the microcatheter is connected to a micromanipulator that allows for precise, low volume infusions of approximately 30 μL to approximately 100 μL.
This example relates to the introduction, regulation, and expression analysis of rAAV constructs expressing a hGJB2 gene in mammalian cells grown in vitro or ex vivo. Mock rAAV particles, rAAV constructs, or rAAV particles comprising rAAV constructs (as represented by
For RNA expression analysis. RNA was extracted using RNeasy Mini Kit (Qiagen). Relative mRNA expression levels were determined using quantitative real-time PCR with hGJB2 specific primers and TaqMan probe (SEQ ID NO: 58-60) and a human GAPDH TaqMan probe as control (Life Technologies). Robust and dose dependent GJB2 mRNA production was observed (
Additionally, experiments were conducted to determine mRNA expression levels from rAAV constructs transduced into wild type explants (ex vivo). Mock rAAV particles or rAAV particles comprising rAAV constructs (as represented by
Further, experiments were conducted to demonstrate mRNA expression regulation from rAAV constructs transfected into HEK293FT cells. rAAV constructs comprising hGJB2.FLAG (CAG.5UTR.hGJB2.FLAG.3UTR; SEQ ID NO: 82) and optional miRNA regulatory target sites (miRTS) located in the 3′UTR (CAG.5UTR.hGJB2.FLAG.miRTS.3UTR;
Those of ordinary skill in the art will readily understand that there are alternative methods of conducting the experiments associated with the current example, for instance, alternative viral titers, MOIs, cell concentrations, time to cellular harvest, reagents utilized for cellular harvesting or mRNA or protein analysis, AAV serotypes, and/or standard modifications to a construct comprising an SLC26A4 gene are practical and expected alterations of the current example.
This example relates to the introduction, and expression analysis of rAAV constructs overexpressing a GJB2 gene in neonatal cochlear explants. Mock rAAV particles or rAAV particles comprising rAAV constructs (
rAAV Anc80 particles comprising rAAV constructs driven by CAG, CMVe-GJB2p, or smCBA promoter/enhancer combinations were prepared and transduced into mouse neonate (P2) cochlear explants at a known MOI (approximately 5.8×109, 1.4×1010, or 1.8×1010 vg/per cochlea respectively). Explants were grown to levels appropriate for harvest (e.g., for 72 hours post transduction), and were then prepared for immunofluorescence staining/imaging through fixation using 4% PFA. Explants were then DAPI stained (presented in blue) and immunostained using anti-FLAG antibodies (presented in green), and hair cell specific anti-Myo7a antibodies (presented in red), explants were subsequently imaged (exemplary data presented in
The current example relates to the introduction of constructs described herein to the inner ear of aged mice. rAAV particles comprising an AAV capsid and a construct encoding a connexin 26 protein or characteristic functional portion thereof are prepared in formulation buffer (e.g., artificial perilymph or 1×PBS with pluronic acid F68) and then administered to the scala tympani in mice as described by Shu et al., Human Gene Therapy, 27(9):687-699, 2016, which is incorporated in its entirety herein by reference). Male and female mice older than P15 are anesthetized using an intraperitoneal injection of xylazine (e.g., approximately 5-10 mg/kg) and ketamine (e.g., approximately 90-120 mg/kg). Body temperature is maintained at 37° C. using an electric heating pad. An incision is made from the right post-auricular region and the tympanic bulla and posterior semicircular canal are exposed. The bulla is perforated with a surgical needle and the small hole is expanded to provide access to the cochlea. The bone of the cochlear lateral wall of the scala tympani is thinned with a dental drill so that the membranous lateral wall is left intact. A small hole is then drilled in the posterior semicircular canal (PSCC). Patency of the canalostomy is confirmed by visualization of a slow leak of perilymph. A Nanoliter Microinjection System in conjunction with glass micropipette is used to deliver a total of approximately 1 μL of construct containing buffer (e.g., rAAV constructs described herein at approximately 4.5×109 to 5×1010 vg/per cochlea in artificial perilymph or 1×PBS with pluronic acid F68) to the scala tympani at a rate of approximately 2 nL/second. The glass micropipette is left in place for 5 minutes post-injection. Following cochleostomy and injection, the opening in the tympanic bulla and the PSCC are sealed with small pieces of fat, and the muscle and skin are sutured. The mice are allowed to awaken from anesthesia and their pain is controlled with 0.15 mg/kg buprenorphine hydrochloride for 3 days.
This example relates to the transgenic expression and analysis of transgenic connexin 26 protein in wild-type mice. Wild-type mice were administered AAVAnc80 particles (1.2×1010 vg/cochlea) comprising CAG.hGJB2.F.GFP (schematic provided in schematic provided in
This example relates to the transgenic expression and analysis of transgenic connexin 26 protein in adult mice. Suitable mutant GJB2 mice can be generated following temporally controlled tamoxifen induced knockout in Sox10-CreER×Cx26flox lines, or CAG-CreER×Cx26flox lines. Control and Mutant GJB2 mice aged are raised in accordance with animal welfare guidelines and approved by the Institutional Animal Care and Use Committee (IACUC), and surgical methods according to Example 7 are performed. Concurrent sham surgeries are performed as above with Anc80L65-GFP virus or vehicle as a negative control. At defined time points (e.g., 1 month, 2 month, 6 month, and 12 months post-surgery), mice are harvested for immunofluorescence staining/imaging. All harvested control and GJB2 mutant mice cochlear slices or whole-mount preparations are imaged using DAPI for nuclear expression, anti-Connexin 26 antibody, and anti-Myo7 or anti-phalloidin antibody.
This example relates to the transgenic expression and analysis of transgenic connexin 26 protein in neonatal mice. Suitable mutant GJB2 mice can be generated following temporally controlled tamoxifen induced knockout in Sox10-CreER×Cx26flox lines, or CAG-CreER×Cx26flox lines. Neonatal wild type or GJB2 mutant mice aged P0 to P4 are anesthetized (e.g., by hyperthermia on ice) to prepare for introduction of compositions described herein. Mock rAAV particles or rAAV constructs (as represented by
The present example pertains to a phenotypic analysis of hearing in mice which are transgenically expressing GJB2 mRNA and connexin 26 protein in the inner ear. Suitable mutant GJB2 mice can be generated following temporally controlled tamoxifen induced knockout in Sox10-CreER×Cx26flox lines, or CAG-CreER×Cx26flox lines. Neonatal control and Mutant GJB2 mice aged P0 to P4 are anesthetized by hyperthermia on ice to prepare for introduction of compositions described herein. Vehicle controls, mock rAAV particles or rAAV constructs (as represented by
At defined test time points (e.g., 1 month, 2 month, 6 month, and 12 months post-surgery), control and mutant GJB2 mice which had undergone unilateral composition injection are anesthetized with sodium pentobarbital (e.g., approximately 35 mg/kg) delivered intraperitoneally. Mice are then placed and maintained in a head-holder within a grounded and acoustically and electrically insulated test room. An evoked potential detection system (e.g., Smart EP 3.90, Intelligent Hearing Systems, Miami, Fla., USA) is used to measure the thresholds of the auditory brainstem response (ABR) in mice. Click sounds as well as 8, 16, and 32 kHz tone bursts at varying intensity (from 10 to 130 dB SPL) are used to evoke ABRs in test mice. The response signals are recorded with a subcutaneous needle electrode inserted ventrolaterally into the ears of the mice. Sham injected mice act as a negative control while the mock-injected ear may act as an internal control for ABR tests, improvements in ABR performance is observed in test ears when compared to control ears and/or animals.
This example relates to a phenotypic analysis of hearing in adult mice that are transgenically expressing connexin 26 protein. Suitable mutant GJB2 mice can be generated following temporally controlled tamoxifen induced knockout in Sox10-CreER×Cx26flox lines, or CAG-CreER×Cx26flox lines. Control and Mutant GJB2 mice are raised in accordance with animal welfare guidelines approved by the Institutional Animal Care and Use Committee (IACUC), and once of suitable age, surgical methods according to Example 7 are performed. Concurrent sham surgeries are performed as above with either vehicle formulation buffer or Anc80L65-GFP as a negative control. At defined time points (e.g., 1 month, 2 month, 6 month, and 12 months post-surgery), mice are anesthetized (e.g., with sodium pentobarbital at approximately 35 mg/kg or with xylazine at approximately 5-10 mg/kg and ketamine at approximately 90-120 mg/kg) delivered intraperitoneally. Mice are then placed and maintained in a head-holder within a grounded and acoustically and electrically insulated test room. An evoked potential detection system (Smart EP 3.90, Intelligent Hearing Systems, Miami, Fla., USA) is used to measure the thresholds of the auditory brainstem response (ABR) in mice. Click sounds as well as 8, 16, and 32 kHz tone bursts at varying intensity (from 10 to 130 dB SPL) are used to evoke ABRs in test mice. Response signals are recorded with a subcutaneous needle electrode inserted ventrolaterally into the ears of the mice. Improvements in hearing function are observed in exemplary results from aged GJB2 mutant mice which are unilaterally injected with compositions as described herein. Sham injected mice act as a negative control while the mock-injected ear may act as a control for ABR tests, improvements in ABR performance is observed in test ears when compared to control ears and/or animals.
This example relates to the testing of maternal blood to determine an offspring's GJB2 genotype prior to birth to facilitate swift and efficacious therapeutic intervention. Maternal blood samples (20-40 mL) are collected into Cell-free DNA (cfDNA) tubes. At least 7 mL of plasma is isolated from each sample via a double centrifugation protocol of 2,000 g for 20 minutes, followed by 3,220 g for 30 minutes, with supernatant transfer following the first spin. cfDNA is isolated from 7-20 mL plasma using a QIAGEN QIAmp Circulating Nuclei Acid kit and eluted in 45 μL TE buffer. Pure maternal genomic DNA is isolated from the buffy coat obtained following the first centrifugation.
By combining thermodynamic modeling of the assays to select probes with minimized likelihood of probe-probe interaction with amplification approaches described previously (Stiller et al., 2009 Genome Res 19(10):1843-1848, which is incorporated in its entirety herein by reference), multiplexing of 11,000 assays can be achieved. Maternal cfDNA and maternal genomic DNA samples are pre-amplified for 15 cycles using 11,000 target-specific assays and an aliquot is transferred to a second PCR reaction of 15 cycles using nested primers. Samples are prepared for sequencing by adding barcoded tags in a third 12-cycle round of PCR. The targets include SNPs corresponding to the greater than 200 mutations in GJB2 known to lead DFNB1, DFNA3, Bart-Pumphrey syndrome, hystrix-like ichthyosis with deafness (HID), palmoplantar keratoderma with deafness, keratitis-ichthyosis-deafness (KID) syndrome, or Vohwinkel syndrome, and/or sequences that cover all exons of GJB2, in order to detect any presently unknown but potentially pathogenic variant. Optionally, sequences corresponding to other connexin genes which are amplified to identify possible heterologous digenic cases of DFNB1, DFNA3, Bart-Pumphrey syndrome, hystrix-like ichthyosis with deafness (HID), palmoplantar keratoderma with deafness, keratitis-ichthyosis-deafness (KID) syndrome, or Vohwinkel syndrome. The amplicons are then sequenced using an Illumina HiSeq sequencer. Genome sequence alignment is performed using commercially available software.
This application claims the benefit of U.S. Provisional Application No. 63,024/468, filed May 13, 2020 and U.S. Provisional Application No. 63/152,835, filed Feb. 23, 2021, which are incorporated herein by reference in their entirety. The content of the electronically submitted sequence listing in ASCII text file (Name: 4833_006PC02_Seqlisting_ST25.txt; Size: 227,027 bytes; and Date of Creation: May 13, 2021) filed with the application is incorporated herein by reference in its entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US21/32354 | 5/13/2021 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63152835 | Feb 2021 | US | |
| 63024468 | May 2020 | US |
